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INTRODUCTION 
 
 
Preface 
Emerging, and potentially emerging, diseases have become a subject of major interest for 
scientists worldwide. 
Climate change, international transport of humans and goods, socio-economic changes, man-
made or natural modifications of environment, development and commercialization of new 
diagnostic methods associated to an increased awareness and pro-active approach, have lead 
to the discovery of new pathogens and new clinical illnesses in Europe.  
Infections transmitted by vectors are of predominant interest as distribution of known, or 
potential, vectors and hosts are in expansion. The dynamics of such diseases are in constant 
evolution allowing adaptation of pathogens to new epidemiological niches and conditions. 
This phenomenon can lead to the emergence of disease in an area previously non-infected. 
The pathogenic causal agent finds itself in a naïve population of animals or humans leading to 
potentially severe clinical manifestations and disastrous medical and economical 
consequences. Furthermore, many illnesses at risk of emerging in animals are zoonoses and 
several of them have currently become a severe threat to public health. Indeed, it is essential 
to promote early detection of emerging diseases in the veterinary field as well as in the 
medical field. The “One world, one health” concept is of major importance in these 
circumstances. 
Clinical epidemiology applied to animal emerging diseases consists in the study of infectious 
and parasitic diseases. Its aim is to determine risk factors for emergence, development and 
maintenance of new pathogens in a new environment. As mentioned above, early detection of 
emerging animal diseases is essential. However, emerging diseases are usually very poorly 
known or understood in the countries concerned, rendering diagnosis very difficult. In this 
context, communication between countries and centralization of information is essential. In 
this study, several epidemiological methods have been developed to facilitate diagnosis by 
veterinarians. However clinical epidemiology has its limitations and laboratory analyses or 
complementary examinations with more sophisticated equipment are sometimes unavoidable.  
Widely used and very fashionable in the recent years, the definition of an emerging disease 
can lead to controversy. In this work, we will use the definition of the World Health 
Organization (WHO) that defines an emerging disease as “a pathogen that is newly 
recognized or newly evolved, or that has occurred previously but shows an increase in 
incidence or expansion in geographical, host, or vector range” 
(www.who.int/zoonoses/emerging_zoonoses/en).  
At the beginning of emergence of a disease, clinical cases and their diagnoses are rare events. 
Prevalence of infection is very low. A certain lap of time is necessary for the transmission of 
the pathogen and, consequently, for infection of a larger proportion of the population. During 
this process the prevalence of disease increases gradually. The causal agent and its natural 
cycle must adapt to the new conditions present. With the gradual increase in number of 
immune individuals through the natural spread of disease or through large scale preventive 
vaccination programs, the prevalence of new infections and of clinical illness diminishes with 
time. Once completely abolished, the population or species or area is once more considered 
free from the disease. Further emergence of the same disease can however take place in new 
naïve populations.  
Emerging zoonoses can either be symptomatic in 100% of cases, asymptomatic in a majority 
of cases, or seemingly completely asymptomatic in their reservoir host. Seroprevalence 
indicates circulation of the pathogen in the population and potential zoonotic risk.  
 
 
This study was based on three different diseases:  
‐ one considered 100% symptomatic (as long as the animal doesn’t die from an 
independent cause beforehand): equine vegetative endocarditis 
‐ one with only 10% of cases being symptomatic: West Nile fever in horses 
‐ one with, to our knowledge, no clinical expression reported in western Europe (0% 
symptomatic): Q fever in western European horses, felines, pigs and wild boars 
% expression 
clinique
Disease
Equine, feline, porcine Q fever
Equine West Nile Fever
Equine endocarditis
100
0
10
 
Vegetative endocarditis is a very rare condition in equids. Its prevalence is very low 
worldwide. As mentioned previously, an emerging disease initially has a very low 
prevalence. Equids with endocarditis generally develop associated clinical signs during 
their life span, except in cases where the animal dies as a consequent of an independent 
pathology (e.g., colic) with the endocarditis lesion being a fortuitous postmortem finding. 
In this study, vegetative endocarditis in equids was used as a model for the development 
of an epidemiological methodology for early clinical diagnosis of rare diseases, including 
future emerging diseases with a high rate of clinical expression. 
West Nile Fever (WNF) is an example of emerging zoonosis in Europe. The aim of this 
section was to perform a direct application of the methodology developed for a disease with 
clinical expression (equine endocarditis) to a disease with a high percentage of asymptomatic 
infections. In this way, WNF emphasizes the limitations of clinical diagnoses and introduces 
the importance of laboratory testing in cases of emerging diseases implicating asymptomatic 
infections.  
Previously an undiagnosed zoonosis, Q fever is currently an emerging public health problem. 
To our knowledge, no data concerning its prevalence and its potential clinical signs in western 
European equids, felines, pigs and wild boars is available. Seropositivity in equids, felines, 
pigs and wild boars would signify that the Q fever causes asymptomatic infections in these 
species. In infected ruminant herds, asymptomatic infections and chronic carriers are common 
and cause a problem for clinical diagnosis and control of the disease. The lack of clinical 
expression render laboratory testing essential to determine prevalence of infection.  
 
 
 
 
 
 
 
 
1. Introduction to the diseases studied 
 
1.1. Equine vegetative endocarditis 
 
1.1.1. Definition and epidemiology 
 
Bacterial endocarditis, also called vegetative or infective endocarditis, is a rare heart condition 
in horses (Figure 1). Because of the rareness of this disease, large scale epidemiological 
studies are lacking in this species. The few reported cases suggest that males could to be more 
frequently affected than females (Buergelt et al. 1985; Sage and Worth, 1999) and that young 
horses (under four years of age) could be predisposed to the development of endocarditis 
(Buergelt et al., 1985; Maxson and Reef, 1997). A later study by Maxson and Reef (1997) on 
a number of 10 horses concluded that no breed or sex predilection was obvious. Although this 
condition remains rare, its various forms of clinical expression make it an important element 
in the differential diagnosis of horses presented with vague clinical signs (such as weight loss, 
poor performance, fever of unknown origin, shifting lameness, etc.), or presented with signs 
suggestive of heart disease (Dedrick et al., 1988; Travers and Van den Berg, 1995; Patterson, 
1996; Bonagura and Reef, 1998; Smith, 2002). 
1.1.2. Clinical signs 
 
Two different forms of vegetative endocarditis can be distinguished: an acute form and a 
subacute or chronic form. Signs characterizing the acute form are high fever, depression, 
reluctance to move due to thoracic discomfort or lameness, and the rapid development of 
signs of cardiac insufficiency (edema, increased jugular filling, etc.). In the subacute or 
chronic form, which is much more common, horses may show intermittent fever spikes, 
weight loss, shifting lameness, poor performance, lethargy/depression, and/or a significant 
heart murmur lasting for weeks or months. Signs of cardiac failure usually occur only as a 
terminal event (Travers and Van den Berg, 1995). Over a period of 10 years from 1982 to 
1992 at the New York State College of Veterinary Medicine, 19 horses suffering from 
vegetative endocarditis were observed (Ball and Weldon, 1992). All these horses exhibited 
lesions of endocarditis at necropsy, but only five of them (thus only 26%) presented with 
clinical signs related to the disease. The fourteen other horses (74%) presented with a variety 
of primary problems. 
Although endocarditis is frequently associated with the presence of a heart murmur, this is not 
always the case. In humans, 10% of patients affected by the disease don’t exhibit a heart 
murmur upon clinical examination (Weldon, 1992). The type of heart murmur obviously 
depends on the location and size of the lesion, which can lead to valvular insufficiency or 
valvular obstruction (Hillyer et al., 1990). Changes in the quality of a heart murmur can also 
be compatible with bacterial endocarditis (Dedrick et al., 1988; Hillyer et al., 1990). 
The most commonly affected valve in equids appears to be the aortic valve, followed by the 
mitral valve. The tricuspid valve is the third most frequently affected valve. The pulmonary 
valve is rarely concerned in this species (Ball and Weldon, 1992). Mural atrial vegetative 
lesions have also been reported in horses (Collatos et al., 1990). 
Vegetative endocarditis can be associated with cardiac arrhythmias on clinical examination 
and electrocardiogram. The reported arrhythmias include atrial fibrillation, atrial or 
ventricular premature beats and ventricular tachycardia (Buergelt et al., 1985; Roby and Reef, 
1986; Dedrick et al., 1988; Collatos et al. 1990). Ventricular premature contractions and atrial 
fibrillations are the most common arrhythmias encountered in horses with bacterial 
endocarditis (Karzenski et al., 1997). 
 
  
 
Figure 1. Vegetative endocarditis lesion on the mitral valve in a 3 year old cart horse 
(Liège University, 8/12/2006) 
 
1.1.3. Pathogenesis 
 
Each form of bacterial endocarditis (i.e. acute and subacute or chronic) is characterized by a 
specific pathway of valve infection (Figure 2).  
The acute form of endocarditis consists of the infection by a primary pathogen attaching 
directly to the endothelium of the heart valves (Travers and Van den Berg, 1995). The only 
predisposing factor necessary is systemic infection with an organism capable of binding 
directly to the endothelium (Ball and Weldon, 1992). The most common organisms associated 
with this type of endocarditis are Staphylococcus aureus and some Streptococcus spp..  
In the subacute or chronic form, an opportunistic pathogen colonizes the valve after the 
occurrence of certain predisposing events (Travers and Van den Berg, 1995). Indeed, under 
normal circumstances, vascular endothelium is resistant to infection by opportunistic bacteria. 
Therefore, the first step to valve infection is damage to the valve itself (Freedman, 1987). This 
Endocarditis lesion  Cardiac valve
Chordae 
tendineae 
often occurs due to what is called the venturi or jet effect, during which turbulent blood flow 
traumatizes the endothelium (Travers and Van den Berg, 1995). This induces a lesion 
composed principally of platelets and fibrin forming a non-bacterial thrombotic vegetation. 
The next step is the discharge of microorganisms into the general circulation (bacteremia) 
from a peripheral site (Freedman, 1987). This bacteremia is usually of a transient nature. The 
inflammation focus source of infection can be a foot abscess, septic laminitis, phlebitis, etc. 
(Ball and Weldon, 1992). However, the primary source of infection is often not found 
(Travers and Van den Berg, 1995). The microorganisms become adherent to the non-bacterial 
thrombotic vegetation covering the damaged endothelium with subsequent deposition of 
additional fibrin and platelets, thereby covering the infecting agent (Freedman, 1987). In this 
way, the microorganisms are protected from circulating cellular immune system and can 
multiply within the platelet-fibrin vegetation. It also appears that the presence of a high 
agglutinating antibody titre toward the infecting organism is necessary to induce the 
endocarditis lesion. It has been shown experimentally that without a high antibody titre the 
development of the disease is impossible (Travers and Van den Berg, 1995). Clumping of free 
bacteria by antibodies in the blood could form a larger inoculum that could more readily be 
deposited on the platelet-fibrin thrombus. Moreover, antibody-antigen complexes formed are 
probably also responsible for the skin manifestations of infective endocarditis (e.g., petechiae, 
Osler and Janeway lesions), as well as associated arthritis and glomerulonephritis. Immune-
complexes may be detected as cryoprecipitates and stimulate the formation of antiglobulin 
(rheumatoid factor) (Freedman, 1987).Once the infection is established, the bacteria can slip 
back into the circulation though little pores in the covering of fibrin and platelets, causing a 
new burst of bacteremia. The dislodgement of fragments of infected vegetation into the 
general circulation can produce peripheral emboli. These embolic showers cause either 
infarctions or metastatic infections of distant organs, causing secondary organ dysfunction 
(Ball and Weldon, 1992; Travers and Van den Berg, 1995). Lesions on the right side of the 
heart most frequently cause embolic pneumonia (Travers and Van den Berg, 1995). Left sided 
heart lesions cause mainly renal and spleen involvement (Ball and Weldon, 1992; Travers and 
Van den Berg, 1995). Another after-effect of infective endocarditis is the development of 
congestive heart failure due to valvular insufficiency secondary to valvular damage. Non-
septic arthritis can be associated with endocarditis (Freedman, 1987; Travers and Van den 
Berg, 1995). When arthritis is observed in association with endocarditis, three possibilities 
must be considered (Ball and Weldon, 1992): (1) the focus of the initial infection was a septic 
joint causing septicemia, then secondary infection of other joints and the development of 
infective endocarditis; (2) the infective endocarditis caused a bacteremia that has been at the 
origin of the development of septic arthritis; (3) the arthritis observed is the consequence of an 
immune-complex disposition in the synovial basement membrane. Glomerulonephritis, as 
mentioned above, could also be due to the disposition of immune-complexes on the basement 
membrane as has been shown in humans suffering from vegetative endocarditis. Myocardial 
infarcts also sometimes occur as a consequence of endocarditis (Ball and Weldon, 1992). 
They are more likely to occur in horses with left sided endocarditis and may contribute to the 
development of congestive heart failure (Maxson and Reef, 1997). 
 
Valve lesion Focus of infection
Non‐bacterial thrombotic vegetation        
Bacteremia
Bacterial thrombotic vegetation= endocarditis lesion
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Figure 2. Pathogenesis of vegetative endocarditis 
Legend: 
Pathway surrounded in blue: pathogenesis of subacute/chronic endocarditis only; predisposing factor for 
endocarditis 
Pathway surrounded in green: pathogenesis for acute AND subacute/chronic endocarditis  
 
The organisms found in subacute or chronic equine endocarditis lesions vary considerably. 
The most commonly reported, even if it represents only a few cases, are Streptococcus 
zooepidermicus and Actinobacillus equuli (Hatfield et al., 1987; Travers and Van den Berg, 
1995; Ramzan, 2000). Many other organisms have been reported, such as Pseudomonas 
aeruginosa (Travers and Van den Berg, 1995), Erysipelothrix rhusiopathiae (McCormick, 
1985), Escherichia coli, Candida parapsilosis (Buergelt et al., 1985), Pasteurella spp. 
(Church et al., 1998), Serratia marcescens (Ewart et al., 1992), Shigella equirulis (Ball and 
Weldon, 1992) , Mycobacterium tuberculosis (Person, 1987), Pseudomonas cepacia (Travers 
and Van den Berg, 1995) and other Streptococci (Buergelt et al., 1985; Dowres, 1985; Robey 
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Echocardiography remains the most specific, but not highly sensitive, modality for the 
diagnosis of endocarditis (Karzenski et al., 1997). Echocardiographic diagnosis of valvular 
endocarditis was first reported in man by Dillon et al. in 1973. Six years later, this method of 
diagnosis was used in a horse suffering from vegetative endocarditis by Pipes et al. (1979).  
Two dimensional (2D) mode and M-mode echocardiography should be used systematically. 
The affected valve usually appears thickened or with an increased echogenicity. It may also 
appear shaggy or ragged or as parallel linear or irregular echoes. Increased echogenicity can 
be observed when calcification of the valve occurs. In domestic animals, valve calcification is 
usually secondary to bacterial endocarditis (Bonagura and Pipers, 1983). Vegetations should 
be differentiated from ruptured chordae tendineae, flail valvular leaflets or nodular thickening 
(Verdegaal and Sloet van Oldruitenborgh-Oosterbaan, 2006). If an endocarditis lesion is 
detected, Doppler echocardiography should be performed to examine the severity of valvular 
regurgitation. Active lesions can usually be differentiated from healing or old lesions by their 
echographic appearance. Decrease in size, smoothing, and increased echogenicity of the 
vegetative lesion is consistent with control of infection. On the other hand, enlargement of the 
valvular lesion indicates failure of treatment (Maxson and Reef, 1997). Moreover, serial 
echocardiography allows follow-up of the development or progress of heart failure. An 
indication of prognosis is based on the degree of enlargement of the cardiac chambers, 
severity of regurgitation and extent of the myocardial dysfunction. Observation of initial signs 
of congestive heart failure (increased size of cardiac cavities, shortening fraction decreased, 
etc.) worsens the vital prognosis for the patient (Maxson and Reef, 1997).  
Electrocardiography can be employed to characterize arrhythmias resulting from myocardial 
damage (Karzenski et al., 1997).  
 
Blood culture  
Blood sample cultures and antibiograms are useful to identify the infecting pathogen and 
determine the choice of antibiotic if treatment is attempted (Ewart et al., 1992; Travers and 
Van den Berg, 1995; Karzenski et al., 1997; Maxson and Reef, 1997; Verdegaal and Sloet van 
Oldruitenborgh-Oosterbaan, 2006). It is thought that blood samples taken during a fever 
episode increases the likelihood of a positive blood culture. In practice, the phlebotomy site 
should be prepared aseptically. The samples are aseptically collected in a commercial broth 
media for blood culture. At least 3 samples should be collected from a different venipuncture 
over a two hour period. Moreover, the blood sampling should be done before any 
administration of antibiotic treatment or, if not possible, at least 24 hours after the last 
antibiotic treatment (Ball and Weldon, 1992).  
Blood analyses and biochemistry results 
Most commonly reported laboratory findings associated with endocarditis are 
hyperproteinemia, hyperfibrinogenemia, anemia, leukocytosis with mature neutrophilia, 
hypoalbuminemia and hyperglobulinemia associated to hypergammaglobulinemia (Hatfield et 
al., 1987; Dedrick et al., 1988; Kasari and Roussel, 1989; Hillyer et al., 1990; Ball and 
Weldon, 1992; Travers and Van Den Berg, 1995; Maxson and Reef, 1997). Those changes are 
indicative of a severe chronic inflammatory process (Van Lierde, 1988). 
Other diagnostic aids 
Other complementary examinations such as synovial fluid sampling, X-rays, urinalysis, 
broncho-alveolar lavages, etc. may be useful in cases showing metastatic manifestations of 
the disease. 
 
1.1.5. Treatment 
 
If a treatment is attempted, it should be instituted as early as possible in the course of the 
disease. However, due to the non-specific signs associated with endocarditis, early detection 
of the disease is often difficult. 
Vegetative endocarditis being an infection of the valvular endothelium by a specific 
microorganism, treatment logically consists of a high dose of bactericidal antibiotic based on 
the results of the antibiogram for a minimum period of 4 to 6 weeks (Hillyer et al., 1980; 
Dedrick et al., 1988; Collatos et al., 1990). Ideally, the antibiotics should be administered 
intravenously. Good tissue penetration is necessary because the valvular vegetations consist 
of walled-off layers of avascular fibrous tissue with ennested organisms (Ball and Weldon, 
1992; Travers and Van den Berg, 1995). Blood culture described above should be performed 
for directing an appropriate antibiotic therapy. While awaiting the results of the bacterial 
culture, a broad spectrum antibiotherapy should be initiated (Travers and Van den Berg, 
1995). Indeed, early initiation of aggressive therapy seems to greatly affect the final outcome. 
The result of blood culture can be negative and thus, in such cases, broad spectrum antibiotics 
are the only option. On the contrary, when blood culture is positive, the antibiotherapy should 
be altered upon receipt of the antibiogram results and if initial clinical response is not 
favorable. The initial antibiotic therapy of choice is soluble penicillin G associated with 
gentamycin because of its broad spectrum and good penetration (Travers and Van den Berg, 
1995). It is important to consider that poor penetration of antimicrobials into vegetations, high 
numbers of bacteria at the site of infection (inoculum effect) and slow growth of deep-seated 
bacterial colonies all hinder the effectiveness of antimicrobial treatment and complicate the 
interpretation of in vitro susceptibilities (Collatos et al., 1990). Therefore, when choosing a 
drug, one must consider not only the blood culture and antibiogram results, but also the 
spectrum of activity, penetrability into the affected tissue, ability to maintain high tissue 
concentrations, bactericidal versus bacteriostatic effects, and potential for drug-induced 
toxicity during prolonged use (Karzenski et al., 1997). Antibiotic dosages should provide 
serum concentrations at least 4 times greater than the concentration needed to kill the 
organism in vitro (Dedrick et al., 1988). 
Treatment of congestive heart failure secondary to vegetative endocarditis is occasionally 
necessary though it is rarely rewarding because in those cases, the extent of valvular damage 
is usually already large (Travers and Van den Berg, 1995; Karzenski et al., 1997). Valvular 
insufficiency may remain even if appropriate antibiotic therapy is instituted; in some cases, it 
may even increase as the valve lesion becomes fibrotic, resulting in unmanageable congestive 
heart failure (Ball and Weldon, 1992). Intermittent ventricular premature contractions and 
atrial fibrillation often resolve spontaneously once the underlying disease process is treated. If 
this is not the case, anti-arrhythmic drugs can be necessary (Karzenski et al., 1997). 
Non-steroidal anti-inflammatory drugs can also be used for the treatment of endocarditis. 
Their anti-pyretic and anti-inflammatory effects improve the horse’s demeanor and thus 
improve appetite and attitude (Collatos, 1992; Karzenski et al., 1997). Risks of nephrotoxicity 
and gastrointestinal ulceration should be considered with prolonged use. Concerning this later 
point, ketofen has been proven to be less toxic than phenylbutazon and flunixin meglumin 
(Karzenski et al., 1997). Flunixin meglumin is particularly useful to counteract the 
prostaglandins released in response to endotoxemia associated with Gram negative bacteria. 
The use of aspirin may also diminish further platelet aggregation on the vegetative lesion 
(Patteson, 1996). 
Resolution of clinical signs, echocardiographic findings and reduction in leukocytosis and 
hyperfibrinogenemia should be used to evaluate the response and determine the duration of 
therapy (Maxson and Reef, 1997). The monitoring of plasma fibrinogen levels is a good guide 
to follow the inflammatory process. It is advisable to maintain antibiotherapy for 
approximately two additional weeks after fibrinogen levels became normal and clinical signs 
resolved. It is wise to repeat this assay after cessation of the antibiotic treatment to be able to 
act at an early stage in case of reappearance of the complaint (Patteson, 1996). 
1.1.6. Prognosis 
 
In all cases of infective endocarditis, the prognosis is poor. As mentioned above, valvular 
insufficiency may remain despite reduction of the size and sterilization of the lesion. In 
addition, infarctions, metastatic infections and financial limitations may also complicate 
treatment and affect prognosis. Mortality rates have been calculated for dogs (80%) and cattle 
(70%) but not for horses, due to the rarity of this pathology (Ball and Weldon, 1992). The 
mortality rate is however considered to be very similar to the values calculated for dogs and 
cattle. 
Marked cardiac chamber enlargement, severe deformation of the valve leaflets, severe 
valvular regurgitation and signs of congestive heart failure are grave prognosis indicators 
(Maxson and Reef, 1997). Pulmonary valve involvement may also carry a poor prognosis as a 
result of pulmonary stenosis and risks of development of a secondary cor pulmonale (Nilsfors 
et al., 1991). 
Sudden death may occur even after an apparent clinical cure and is likely to be the result of a 
cardiac arrhythmia or myocardial dysfunction (Collatos et al., 1990; Maxson and Reef, 1997). 
 
 
 
1.2. West Nile Fever 
1.2.1. Definition and epidemiology 
 
West Nile fever virus (WNV) was initially isolated from the blood of a mildly febrile woman 
in the West Nile district of Uganda in 1937 (Smithburn et al., 1940). Previously, WNV was 
rarely associated with disease in either humans or horses (Castillo-Olivares and Wood, 2004; 
Dauphin and Zientara, 2007). The only exception was the outbreak in Camargue (southern 
France) in 1962 and 1963 where at least 80 horses with ataxia and weakness were reported 
with a mortality rate of 25 to 30%. Since then, sporadic and major outbreaks mainly in 
humans but also in horses have occurred in Africa, Middle East and Europe (Murgue et al., 
2001; Castillo-Olivares and Wood, 2004). Only recently has West Nile fever (WNF) become 
a major public health and veterinarian concern (Dauphin et al., 2004; Zeller and 
Schuffenecker, 2004). Indeed, in the last decades (mainly since the mid 1990’s), WNV has re-
emerged as an important pathogen for humans and horses (Autorino et al., 2002; Weese et al., 
2003; Castillo-Olivares and Wood, 2004; Zeller and Schuffenecker, 2004; Dauphin and 
Zientara, 2007; Leblond et al., 2007a; Blitvich, 2008). An increased frequency of occurrence 
with, in parallel, an increased proportion of neurological cases (encephalitis, meningitis, 
meningoencephalitis) was been reported. During the USA outbreak in 2000, the number of 
severe human cases, increase in the severity of the neurological disease observed in infected 
horses, and high bird mortality (three elements present at the time) gave a whole new 
importance to this disease previously considered of minor consequences (Petersen and 
Roehrig, 2001; Sardelis et al., 2001; Castillo-Olivares and Wood, 2004; Dauphin and 
Zientara, 2007; Blitvich, 2008).  
WNF is a viral zoonotic infection caused by a mosquito-borne flavivirus of the Flaviviridae 
family (Petersen and Roehrig, 2001; Autorino et al., 2002), within the Japanese encephalitis 
(JE) antigenic complex. The JE complex includes 4 related viruses that cause infections of the 
central nervous system (CNS): JE virus in Asia, St Louis encephalitis virus in North and 
South America, Kunijn (considered a subtype of WNV) and Murray Valley encephalitis 
viruses in Australia (Marfin and Gubler, 2001). The mature virion consists of an icosahedral 
nucleocapsid enveloped in a lipid bilayer with a diameter of approximately 50nm (Figure 4). 
Envelope (E) proteins present in the lipid bilayer mediate cellular attachment and membrane 
fusion and are the major viral immunogen during infection (Chambers et al., 1998; Hobson-
Peters et al., 2008). WNV’s genome is a single positive–stranded linear message-sense RNA 
of approximately 11 Kb that encodes for a single open reading frame, which is flanked by a 5’ 
(7-methylguanosine) cap and no polyadenylation at the 3’end. The resulting single 
polyprotein is post-translationally cleaved by host and viral proteases to produce 3 structural 
(capsid protein, premembrane (PrM), and E proteins) and 7 nonstructural proteins (NS1, 
NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (Chambers et al., 1998; Rossi et al., 2010). Five 
major genetic lineages of WNV have been distinguished: lineage 1 is found in North America, 
North Africa, Europe and Australia and includes most of the epidemic strains isolated since 
1996 (Marfin and Gulber, 2001); lineage 2 in sub-Saharan Africa and Madagascar and 
includes many enzootic strains (Marfin and Gulber, 2001; Burt et al., 2002; Lanciotti et al., 
1999); lineages 3 and 4 in central and eastern Europe (Lvov et al., 2004; Bakonyi et al., 2005) 
and lineage 5 in India (Bondre et al., 2007).  
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virus to replicate (intrinsic phase). A viremia of at least 105 pfu/ml is generally considered 
necessary for an infected vertebrate to serve as a reservoir (amplification) host (Turell, 2000; 
Sardelis, 2001). For transmission to proceed, vectors must feed on competent hosts during the 
viremic period. The virus is ingested during the bloodmeal and enters the vector’s digestive 
tract. Next, the virus must replicate and enter the salivary glands. This “within the vector” 
cycle phase is called the extrinsic phase and is known to be temperature and humidity 
dependant (Epstein, 2001; Petersen and Roehrig, 2001; Castillo-Olivares and Wood, 2004; 
Blitvich, 2008). The cycle is completed once the competent vector infects a host through a 
new bloodmeal (Figure 5). At least 198 bird species are known to be implicated in the viral 
cycle, each with various amplifying role and susceptibility (Dauphin and Zientara, 2007). The 
house sparrow is considered to be a major reservoir in Europe and the USA because of its 
abundance in these regions. Migratory birds may introduce WNV into new areas (Cantile et 
al., 2000; Ostlund et al., 2000; Autorino et al., 2002; Mumcuoglu et al., 2005). The virus has 
been isolated in 60 species of mosquitoes but less than 10 are considered to be principal 
vectors (Ostlund et al., 2000; Dauphin and Zientara, 2007). Virus isolations have occasionally 
been reported from hematophagus arthropods (ticks) (Hubalek and Halouzka, 1999; Cantile et 
al., 2000; Ostlund et al., 2000; Dauphin et al., 2004; Mumcuoglu et al., 2005; Zeller and 
Schuffenecker, 2005; Blitvich, 2008), mites and hippoboscid flies (Hubalek and Halouzka, 
1999; Farajollahi et al., 2005; Mumcuoglu et al., 2005; Blitvich, 2008). Some mosquito 
species are exclusively ornithophilic, thus are exclusively implicated in the enzootic, also 
called natural, cycle. Other species, known as bridging vectors, have more general feeding 
habits and can transmit WNV to humans, horses and other non-avian vertebrates after feeding 
upon viremic birds (Sardelis et al., 2001). Shifts in mosquito host selection have been 
documented. One study indicated that Culex pipiens mosquitoes in the northeastern USA shift 
their feeding behavior from highly competent American robins to mammals and humans in 
the late summer to early fall, coinciding with the emigration of this avian species (Kilpatrick 
et al., 2006). A better knowledge of mosquitoes’ feeding preferences would allow a better 
understanding of WNV ecology and hereafter the development of more efficient control 
strategies (Dauphin and Zientara, 2007). During warm periods, the extrinsic phase can take as 
little as two weeks (Castillo-Olivares and Wood, 2004). Mosquito reproduction and longevity 
are also dependent on environmental factors such as temperature, humidity and rainfall. As a 
result of this climatic dependence, a highly seasonal variation in WNV transmission and in 
disease outbreak is observed (Castillo-Olivares and Wood, 2004; Ward, 2005). Indeed, in 
most temperate regions such as Europe, Canada, Northern States of the USA, most clinical 
WNF cases occur in late summer or autumn when insect numbers and temperatures are high 
(Hubalek and Halouzka, 1999; Murgue et al., 2001; Castillo-Olivares and Wood, 2004; Zeller 
and Schuffenecker, 2004). However, in Europe, WNV outbreaks remain erratic and spatially 
and temporary limited phenomena, occurring quite unpredictably, even if all conditions 
appear to be present in a definite place (Dauphin et al., 2004; Zeller and Schuffenecker, 
2004). For WNV’s enzootic transmission cycle to be maintained in a location, a sufficient 
number of infected mosquitoes having completed the extrinsic phase must feed on a sufficient 
number of competent amplification hosts (Castillo-Olivares and Wood, 2004). Mammalian 
species including both horses and humans are thought to rarely develop titers sufficient to 
infect mosquito species and viremia is of short duration (Cantile et al., 2000). Thus, 
mammalian species are very unlikely to be able to sustain infectivity cycles. These species are 
called incidental (Joubert et al., 1971; Cantile et al., 2000; Cantile et al., 2001) or “dead end” 
host (Ostlund et al., 2000; Cantile et al., 2001; Murgue et al., 2001; Autorino et al., 2002; 
Weese et al., 2003; Dauphin et al., 2004; Zeller and Schuffenecker, 2004; Dauphin and 
Zientara, 2007; Epp et al., 2007; Blitvich, 2008; Castillo-Olivares and Wood, 2008). On the 
contrary to horses and humans, reptiles might be potential amplification hosts as they are 
known to develop a viremia of long duration and can overwinter (Dauphin et al., 2004; Zeller 
and Schuffenecker, 2004). Direct bird to bird transmission has been documented 
experimentally (Weese et al., 2003) but remains to be proven in natural conditions. Moreover, 
WNV transmission through infected blood products and organs and from mother to child 
through breast feeding has been reported (Shireley et al., 2002; Campbell et al., 2002). 
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Figure 5. West Nile Virus cycle 
Legend:  
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WNF is maintained in an area by its enzootic cycle between reservoir birds and competent mosquitoes. The 
mosquito gets infected during a bloodmeal on a viremic bird. The virus replicates in the mosquito during the 
extrinsic phase (humidity and temperature dependent). After viral replication, WNV enters the mosquito’s 
salivary glands. The mosquito infects a bird during a bloodmeal through its saliva. Birds are competent host. A 
second replication phase takes place. This phase is the intrinsic phase (in the reservoir host). Birds develop a 
high viremia allowing infection of new mosquitoes during subsequent bloodmeals.  
Mosquitoes can also feed on dead end hosts, also called incidental hosts. Dead end hosts do not permit sufficient 
amplification of WNV. Viremia remains insufficient for infection of mosquitoes during subsequent bloodmeals. 
The cycle is thus aborted. Humans and horses are dead end host. 
 
It has been demonstrated that a higher proportion of dry bushes, open water, and woodlands in 
the vicinity of animals were risk factors for WNF cases. These biotopes are indeed favorable 
for the presence of birds and could represent areas of a higher contact rate among mosquitoes, 
reservoirs, and accidental hosts (Leblond et al., 2007b). A high WNV circulation level may be 
due to an enzootic status of the virus in that particular area or due to a reintroduction of the 
virus by other means (animal circulation, migratory birds). In Europe, bird mortality is rare 
(Murgue et al., 2001; Dauphin et al., 2004; Zeller and Schuffenecker, 2004; Dauphin and 
Zientara, 2007; Leblond et al., 2007a). 
Individual factors of receptivity to the virus seem of major importance for the evolution and 
clinical expression of WNF (Joubert et al., 1971; Beasley et al., 2002). Indeed, Glass et al. 
(2005), Brault et al. (2007), and Lim et al. (2009) demonstrated that variations in certain loci 
influenced susceptibility to and clinical presentation of WN infection. The study by Glass et 
al. (2005) demonstrated that the locus CCR5, coding for CCR5 chemokine receptor, was an 
essential resistance factor against neuroinvasive infections. Indeed, the CCR5 deficient mice 
used in the study had increased viral titers in the CNS system and a higher mortality rate 
(Glass et al., 2005). Moreover, a genetic risk factor for initial WN infection found by Lim et 
al. in 2009 was the presence of a single point mutation in the gene OAS1, a member of an 
IFN-regulated gene family involved in degradation of viral RNA. Homozygotes for the OAS1 
“A” allele at SNP rs10774671 were significantly more numerous among WN-positive 
individuals independently of the infection’s clinical presentation. Furthermore, primary 
lymphoid tissue originating from human homozygotes was cultured in the ex-vivo model by 
Lim et al. (2009) and increased levels of WNV replication were observed. Later, Lim et al. 
(2010) studied the effect of a mutation named CCR5∆32 in humans. Their study found that 
CCR5∆32 mutation did not influence susceptibility to infection but did have a significant 
effect on early clinical presentation. Indeed, the symptoms retained by Lim et al. (2010) were 
more frequently reported in homozygous CCR5∆32 individuals than in heterozygous and 
wild-type CCR5 individuals. Moreover, the total number of symptoms reported per individual 
was superior in the WN-infected homozygous CCR5∆32 group (Lim et al., 2010). The 
presence of antibodies against other flaviviruses is also thought to play a role in determining 
clinical presentation in some certain areas (e.g., Africa) (Beasley et al., 2002). Furthermore, 
clinical expression of a viral disease can vary depending on the pathogenicity of the isolate 
circulating within the population at that specific time and place. Indeed, a recent study by 
Vazquez et al. (2010) reported the circulation of two different WNV strains in Spain after 
genomic analyses: one avirulent strain and one pathogenic strain. Several scientific studies 
support the hypothesis that clinical differences are due to differences in viral strains, each 
viral strain potentially having a different pathogenicity (Cecilia and Gould, 1991; Havely et 
al., 1994; Chambers et al., 1998). Previous studies have suggested that N-linked glycosylation 
was implicated in attenuation of viral neuroinvasiveness and neurovirulence (Cecilia and 
Gould, 1991; Halevy et al., 1994). Chambers et al. (1998) studied the nucleotide sequence 
coding for the E protein of WNV strains with different virulence proprieties. Six different 
strains were sequenced by polymerase chain reaction (PCR) and analyzed. Differences in N-
linked glycolsylations of the E protein were observed, as well as genomic sequence 
modifications at nucleotide and amino acid levels. The viral attenuation process could thus be 
more complicated than previously thought (Chambers et al., 1998). In a mouse model, 
Beasley et al. (2002) isolated groups of viruses in lineage 1 and lineage 2 with variable 
neuroinvasive potentials. According to the authors, their neuroinvasive potential was found 
not to be influenced by the source of the virus (mosquito, mammal, bird) or by its passage 
history. Venter et al. (2009) demonstrated that highly neuroinvasive lineage 1 and lineage 2 
genotypes could be isolated from infected horses.  
In a study during the 1999 WNV epizootic in New York on 25 symptomatic equine WNF 
cases, no breed, gender or age predilection for the development of the clinical disease was 
observed. Moreover, no consistent abnormalities on hematologic examination or in blood 
chemistry profile were reported in these horses (Ostlund et al., 2000).  
1.2.2. Clinical signs 
 
As mentioned previously, the major onset of clinical cases occurs during August and 
September (Marfin and Gulber, 2001).  
In humans, after an incubation period of 3 to 15 days, WNF either remains asymptomatic or 
causes a mild febrile illness (Murgue et al., 2001; Autorino et al., 2002; Zeller and 
Schuffenecker, 2004; Epp et al., 2007). Commonly, infected patients suffer from 3 to 6 days 
of fever, headaches, backaches, myalgia, anorexia, and generalized lymphadenopathy. In 50% 
of cases a roseolar or maculopapular rash is observed (Marfin and Gulber, 2001). However, in 
a minority of cases, meningitis, meningoencephalitis, myelitis, optic neuritis or polyradiculitis 
occur (Murgue et al., 2001; Autorino et al., 2002; Kelley et al., 2003; Weese et al., 2003; Epp 
et al., 2007). Typically, neurologically affected patients suffer from fever and weakness 
during the prodromic phase followed by an acute onset of severe flaccid paralysis (Kelley et 
al., 2003). Despite maintenance of extremity reflexes and touch sensation, mental status can 
be modified due to involvement of the cerebral cortex (Asnis et al., 2001; Kelley et al., 2003). 
Furthermore, gastrointestinal complaints, pharyngitis, and conjunctivitis have been reported in 
several cases (Asnis et al, 2001). Factors disrupting the blood-brain barrier (BBB) (e.g., 
hypertension) and a less efficient immunity (elderly) are thought to enhance progression of 
CNS infections (Hayes, 1989). Indeed, older people have a significantly higher risk of severe 
neurological illness and death (Asnis et al., 2001; Marfin and Gulber, 2001). Severe 
neurological cases can also occur in children but are less common than in the elderly (Asnis et 
al., 2001). Global fatality rates vary depending on the epidemic but remain low: 4.3% during 
the 1996 epidemic in Romania; 12% during the 1999 epidemic in the northeastern USA; and 
6.7% during the 2000 epidemic in Israel (Marfin and Gubler, 20001). 
In horses, WNF is usually asymptomatic (Cantile et al., 2000; Cantile et al., 2001; Castillo-
Olivares and Wood, 2004; Zeller and Schuffenecker, 2004; Dauphin and Zientara, 2007; Epp 
et al., 2007; Blitvich, 2008; Sebastian et al., 2008). If clinical signs occur, they are non 
specific (Weese et al., 2003; Dauphin and Zientara, 2007). Except for fever, clinical signs are 
almost exclusively of a neurological nature and reflect the CNS pathology (Ostlund et al., 
2000; Murgue et al., 2001; Castillo-Olivares and Wood, 2004; Zeller and Schuffenecker, 
2004; Leblond et al., 2007a; Blitvich, 2008). Horses seem to be particularly sensitive to WNV 
with approximately 10% of infected animals presenting neurological disorders, as compared 
to 1% of humans (Petersen and Roehrig, 2001). West Nile (WN) infections may involve both 
central and peripheral nervous systems. A transitory febrile phase may occasionally be 
observed before the neurological clinical signs but this is not always the case (Murgue et al., 
2001; Castillo-Olivares and Wood, 2004; Zeller and Schuffenecker, 2004). The clinical signs 
most commonly observed are ataxia, paresis, limb paralysis which can affect one, or two 
(usually the hindlimbs), or all four limbs, the latter cases usually progressing into recumbency 
(Cantile et al., 2000; Ostlund et al., 2000; Murgue et al., 2001; Castillo-Olivares and Wood, 
2004; Zeller and Schuffenecker, 2004; Dauphin and Zientara, 2007; Leblond et al., 2007a). 
Other clinical signs reported are skin fasciculations, muscle tremors (Murgue, 2001), and 
muscle rigidity (Cantile et al., 2000; Ostlund et al., 2000; Castillo-Olivares and Wood, 2004; 
Dauphin and Zientara, 2007). A proportion of horses never recover from infection and die 
naturally or are euthanized (Cantile et al., 2000; Ostlund et al., 2000; Murgue et al., 2001; 
Weese et al., 2003; Castillo-Olivares and Wood, 2004; Leblond et al., 2007a). In clinically 
affected horses, the fatality rate has been estimated of 43 to 45% (Cantile et al., 2001).  
1.2.3. Pathogenesis 
 
Infected mosquitoes transmit the virus to humans and horses in saliva during subsequent bites. 
After local viral replication in tissues and lymph nodes, WNV is transported via lymphatics to 
blood. Viremia peaks between 4 and 8 days post-inoculation but viral concentration usually 
remains low (103pfu/ml) (Peiris and Amerasinghe, 1994; Hubalek and Halouzka, 1999). The 
mechanisms of viral infection of the CNS still remain uncertain. Currently, breakdown of the 
BBB is not thought to be necessary for CNS invasion and it is preferentially suggested that 
endothelial or axonal transport is the mean of infection (Rossi et al., 2010). Once in the neural 
cells, a second phase of viral replication occurs, causing severe inflammation and a cytotoxic 
immune response towards infected neural cells. Studies on mice suggested that host immune 
response could facilitate viral CNS infection by increasing BBB permeability and capillary 
leakage (Diamond and Klein, 2004; Wang et al., 2004; Arjona et al., 2007; Gracia-Tapia et 
al., 2007). Moreover, Samuel and Diamond (2005) found that in experimentally infected 
mice, high viremia easily lead to infection of the brain in the presence of a disrupted BBB. In 
their study, high viremia was correlated with severity of infection (Samuel and Diamond, 
2005). Further research is required to highlight the means of CNS infection in humans and 
horses. In addition, the role of host immune response and of viral concentration in the host’s 
blood has not yet been determined in these species. 
1.2.4. Diagnostic methods 
 
Clinically WNF cannot be distinguished from other CNS infections. Moreover, the majority 
of human encephalitis cases (75%) are not diagnosed accurately (Asnis et al., 2001). 
Differential diagnosis of human WNF includes encephalitides viruses (mainly enteroviruses 
and other arboviruses) and bacterial meningitis (Asnis et al., 2001; Rossi et al., 2010). 
Differential diagnosis of equine WNF in France and Belgium includes equine herpesvirus-1, 
Borna disease, rabies, equine protozoal myeloencephalitis, trauma, moldy corn poisoning, 
hepatoencephalopathy, and cervical instability, also called Wobbler syndrome (Leblond et al., 
2007a). Elsewhere, depending on the geographical and epidemiological context, African horse 
sickness (for sudden death cases only), equine encephalosis, eastern equine encephalomyelitis 
(EEE), Venezuelan equine encephalomyelitis and western equine encephalomyelitis can also 
be included (Venter et al., 2009). Common laboratory findings in WNF cases are non specific: 
leukocytosis or leukopenia in blood, and lymphocytic pleocytosis in the cerebrospinal fluid 
(CSF) with counts of 10 to 100 cells/mm3, with elevated protein concentration (up to 900mg 
%) (Marfin and Gubler, 2001). Medical imaging can help localize the neurological 
inflammation. Magnetic resonance imaging (MRI) is the diagnostic method of choice for 
human encephalitis by visualization of acute meningeal enhancement (Marfin and Gulber, 
2001).  
Specific diagnosis of WNF is made by enzyme-linked immunosorbent assay (ELISA), 
immunohistochemical (IHC) staining, viral isolation, PCR or postmortem examination. 
 ELISA using the envelope protein E as the antigen of choice is the most commonly used 
serological assay (Hobson-Peters et al., 2008). Its sensitivity can approach 100% in 
appropriately timed CSF and serum samples (Tradei et al., 2000). A high level of WNV-
specific immunoglobulin (Ig) M antibodies in a single acute phase serum sample associated to 
neurological clinical signs strongly suggests WNF. However, several problems are associated 
with IgM ELISA. Indeed, WNV-specific IgM antibodies are generally not detectable before 
the end of viremia (8-10 days post-infection) (Hayes, 1989; Ostlund et al., 2000) and can 
remain detectable for several months (2 to 3 months) in sera from infected individuals (Tardei 
et al., 2000). Furthermore, cross-reactions can occur with other flaviviruses including yellow 
fever virus (YF), dengue virus, and members of the JE antigenic complex preventing 
definitive diagnosis. Currently commercial testing for WNV-specific antibodies is limited for 
this reason (CDC, 1997). Definitive diagnosis can only be obtained by means of plaque 
reduction neutralization test (PRNT) (Peris and Amerasinghe, 1994). In initial cases of an 
outbreak, PRNT comparing the antibody titers to WNV, St Louis encephalitis virus, and, 
when indicated, YF, dengue and JE should be used for serologic confirmation of infection 
(CDC, 1997). PRNT with an acute sample and a convalescent sample (collected at least 10 
days later) are compared to document a 4-fold rise in antibody titer. Indeed, according to the 
CDC (1997), a 4-fold change in neutralizing antibody titer should still be sought to provide a 
specific diagnosis of WNF infection. A single negative assay of a sample obtained early 
during the clinical course of illness does not exclude infection (CDC, 1997). While PRNT is 
still considered the gold standard for specific diagnosis, ELISA is routinely used as it is less 
laborious, cheaper and more suited to high-throughput screening. Currently, attempts have 
been made to improve the specificity of E protein-based antigens by focusing on using 
peptides or individual domains of the E protein (Beasley et al., 2004; Herrmann et al., 2007; 
Roberson et al., 2007; Hobson-Peters et al., 2008). However, distinguishing WNV strains and 
sensitivity of such ELISA remain a problem (Hobson-Peters et al., 2008). Anti-WNV IgG 
ELISA is of little use for acute diagnosis as seropositivity only indicates past exposure. 
Indeed, IgG are only detectable 2 or more weeks post-infection and can persist for up to 2 
years (Ostlund et al., 2000). Because IgM antibody does not cross the BBB, intrathecal IgM 
indicates intrathecal production (Asnis et al., 2001).  
Another diagnostic method is IHC staining. IHC is capable of detecting the presence of a 
flavivirus on a formalin-fixed biopsy or necropsy material (Peris and Amerasinghe, 1994). 
However, its lack of specificity and the necessity of confirmation by other diagnostic means 
limit its use. 
WNV isolation must be performed in a biosafety level 3 laboratory (Marfin and Gubler, 
2001). Virus can be isolated from human serum, blood, and CSF early in the febrile stage and 
from brain obtained during biopsy or autopsy (Peris and Amerasinghe, 1994). After sampling, 
virus growth is obtained by intracranial inoculation into suckling mice or on continuous cell 
lines of mosquito or mammalian origin (Peris and Amerasinghe, 1994). Hayes (1989) 
reported that in healthy humans the virus can be isolated from blood from two days before the 
onset of illness through the fourth day of illness. However, the rate of successful isolation 
drops rapidly after the first day of illness. In immunocompromised patients, viral isolation can 
be prolonged up to 22 to 28 days after infection. Not only is viral isolation difficult, but it also 
requires 3 weeks limiting its usefulness as a diagnostic method at the beginning of an 
epidemic (Johnson et al., 2003).  
PCR assays have been developed to diagnose WNF by detecting viral RNA. A single-stage 
real time (RT)-PCR can detect viral RNA in birds and mosquitoes but its sensitivity is low for 
infected equine brain samples (Johnson et al., 2001). Johnson et al. (2001) developed a RT-
nested PCR (RT-nPCR) for this purpose. A portion of the genomic region coding for the E 
protein was amplified during the assays. The results obtained by RT-nPCR were compared to 
results obtained by RT-PCR, viral isolation using cell cultures, and serology (IgM capture 
(MAC)-ELISA and PRNT). RT-nPCR was found to be 100,000-fold more sensitive than 
single-stage RT-PCR. Compared to viral isolation, RT-nPCR was also more sensitive. 
Moreover, RT-nPCR was completed in less than 24 hours. Specificity of RT-nPCR was also 
good compared to the other diagnostic assays. In conclusion, RT-nPCR is a reliable and rapid 
diagnostic assay for equine and avian samples. Furthermore, RT-nPCR can be standardized 
and performed on many samples at the same time. A nested multiplex RT-PCR that is capable 
of detecting and differentiating WNV and EEE virus has also been developed (Johnson et al., 
2003).  
Finally, postmortem examination can be useful in cases where WNF is suspected. Chronic 
inflammatory infiltrates of variable density can be visualized in the CNS. Lymphocytes are 
the predominant cells present. Gliosis, scattered microglial nodules, focal perivascular 
cuffing, and infiltrating macrophages can be observed in the most affected area (Asnis et al., 
2001; Kelley et al., 2003). Small hemorrhages and extensive neuronal degeneration have also 
been reported (Shieh et al., 2000; Sampson et al., 2000). The brainstem, anterior horn of the 
spinal cord and cerebrum appear to be preferentially involved (Kelley et al., 2003).   
1.2.5. Treatment 
 
In human and veterinary medicine, no specific treatment against WNF exists. To this day, 
supportive care remains essential. Respiratory support, management of cerebral edema, and 
prevention of secondary bacterial infections are the key to patient survival.  
Makhoul et al. (2009) suggested administration of intravenous immunoglobulin G (IVIG) 
with a high concentration in anti-WNV antibodies, to prevent possible neuronal destruction 
and future disabilities. The IVIG used in their study was obtained from pooled healthy human 
sera and was administered at a dose of 0.4g/kg for 5 days. The authors found that early IVIG 
treatment associated with supportive care improved outcome.  
1.2.6. Prognosis 
 
If adequate supportive care is provided, recovery in humans is usually complete and rapid, 
despite being slower in adults than in children (Hubalek and Halouzka, 1999; Marfin and 
Gulber, 2001). Neutralizing antibodies directed against specific epitopes on the E protein 
appear to provide long-lived protection against reinfection (Marfin and Gubler, 2001). Non-
neurological complications of infection such as myocarditis, pancreatitis, and fulminant 
hepatitis can occur but remain rare (Marfin and Gulber, 2001). However, more recent studies 
on WNF and its short- and long-term effects have found that long-term physical, functional, 
and cognitive problems after acute WNF were not as uncommon as previously thought 
(Sejvar, 2007). Previously, permanent sequelae and long-term effects of WNV infection were 
not recorded, and were thus considered absent or of negligible importance (Hubalek and 
Halouzka, 1999). Extreme fatigue is the most frequently reported long-term complaint 
(Gottfried et al., 2005; Ou et al., 2005; Carson et al., 2006). Indeed, in the study by Watson et 
al. (2004), 96% of the 98 patients with otherwise uncomplicated WNF suffered from 
persistent fatigue for a median of 36 days. Weakness, concentration and memory difficulties 
several months after infection are also frequently reported (Ou et al., 2005; Carson et al., 
2006; Haaland et al., 2006). Furthermore, an association between WNF and Parkinson disease 
is suspected. The study by Carson et al. (2006) on a total of 49 patients (11 with 
neuroinvasive and 38 with non-neuroinvasive WNF), post-illness, found that results at motor 
speed and manual dexterity tests were the most significantly abnormal. Parkinsonism 
associated with WNV infection is usually transient and self limited, but in this study, 
Parkinsonism was found to persist in some patients for more than 1.5 years following acute 
illness. Moreover, persistent tremor was observed or reported in 20% of the 49 patients. 
Myalgia, arthralgia and headaches can also occur despite apparent complete recovery from 
acute infection (Patnaik et al., 2006). A post-WNF syndrome similar to the post-poliovirus 
infection syndrome, with development of delayed onset or recurrence of limb weakness is 
considered possible or even likely (Sejvar, 2007). Persistence of WNV in the CNS has been 
suggested during experimental infections in monkeys but remains to be clarified and is 
hypothetical in humans (Perelman and Stern, 1974; Pogodina et al., 1983; Nash et al., 2001). 
Younger age is more predictive of eventual functional recovery than is severity of initial 
illness (Klee et al., 2004).  
The most frequent cause of death in patients infected by WNV is cerebral edema after 
neuronal death and degeneration (Marfin and Gulber, 2001). Concerning WN encephalitis, in-
hospital case-fatality rate is estimated to be approximately of 20%. Acute mortality appears to 
be due to acute respiratory failure or sudden cardiac complications (Pepperell et al., 2003; 
Sejvar et al., 2005; Bode et al., 2006). Moreover, following hospitalization patients frequently 
require placement in rehabilitation centers (Bode et al., 2006). Physical, occupational or 
speech therapy may also be necessary (Klee et al., 2004). In addition, Green et al. (2005) 
reported that patients affected by WN encephalitis have a higher long-term mortality rate than 
the general population, with a 1-year post-infection mortality comparable to those of patients 
with chronic non-infectious diseases.  
In equine cases, the severity of initial clinical signs has been reported not to necessarily hinder 
the ability to recover if appropriate supportive care is provided (Ostlund et al., 2000). 
However, studies on long-term effects of WNV infection are lacking at present. Late 
diagnosis in equids compared to humans, due to non specific clinical signs and cost of 
diagnostic methods, associated with the difficulty and cost of supportive treatment could 
explain the significantly higher fatality rate in this species (approximately 40% versus 
approximately 10%) (Cantile et al., 2001). 
1.2.7. Preventive measures 
 
Vaccination 
Several strategies have been pursued for the WNV vaccine development. Inactivated, also 
called killed vaccines have been obtained by inactivation of WNV with formalin. In the past 
decade, plasmid DNA vaccines and live vectored vaccines have been developed. DNA 
vaccination consists in WNV structural antigens (PrM and E) being expressed from DNA 
plasmids (Davis et al., 2001). Recombinant vaccines use a heterologous virus backbone to 
produce WNV antigens. The vectors used are canarypox (e.g., RecombitekTM), YF virus (e.g., 
ChimerivaxTM) and Dengue 4 (e.g., WNV-DEB4) (Rossi et al., 2010). The recombinant WNV 
canarypox vector ALVAC-WNV vaccine has been developed recently (Minke et al., 2004; 
Siger et al., 2004). Canarypox virus vectors undergo an abortive replication cycle in 
mammalian cells during which the inserted gene product (transgene) is expressed which 
results in the stimulation of both humoral and cell-mediated immune responses in a manner 
similar to natural infection (Berencsi et al., 2001; El Garch et al., 2008). The study by El 
Garch et al. (2008) showed that immunity against WNV persisted for 9 months following a 
primary course of two injections and 5 months following the first booster vaccination with 
recombinant ALVAC-WNV vaccine. Furthermore, canarypox virus vectors allow for a strong 
immunogenicity of the recombinant antigen and appear to be free of inhibitory effects of 
vector immunity even after multiple injections (Franchini et al. 2004; El Garch et al., 2008). 
Another recent vaccine is a live-attenuated chimeric WN/YF vaccine, ChimerVax WN02, that 
comprises WNV NY 99 PrM and modified E sequences inserted into the backbone of the YF 
17D vaccine genome (Smith et al., 2011). The PrM and E genes of the YF-17D vaccine strain 
were exchanged for those of the WNV NY 99 strain 385-399. Three attenuating mutations 
were introduced into the WNV E codon: E170 (leucine to phenylalanine), E336 (alanine to 
valine), and E440 (lysine to arginine). Smith et al (2011) found E430 specific CD8+ T cells 
through the first year following vaccination with chimeric WN/YF virus. It is thus a very 
promising vaccine. Finally vaccination by inoculation of purified viral proteins has been 
attempted (Quiao et al., 2004). 
Currently there is no Food and Drug Administration (FDA)-licensed vaccine to prevent WN 
infection in humans but effective, licensed vaccines are available for horses (Rossi et al., 
2010). Indeed, inactivated vaccines and RecombitekTM has been licensed for use in horses. 
Mosquito control 
In a study by Epp et al. (2007) mosquito control methods were found to be significant 
protection factors against WNV infection. Indeed, in this study, horses in herds without any 
mosquito control methods were 8.2 times more at risk of WN infection. When mosquito 
control methods (fans in barn, sealing at night, or both; smudges, insecticides) were compared 
the use of fans in barns housing the animals was the strongest protective factor. 
 
1.3. Q fever 
1.3.1.  Definition and epidemiology 
Q fever was first described in 1937 by E.H. Derrick in Queensland, Australia (Derrick, 1937). 
It was previously classified as a “Category “B” critical biological agent” by the Centre for 
Disease Control and Prevention (CDC) and is considered a potential weapon for bioterrorism 
(Alibek, 1999). Q fever is a public health concern throughout the world (Rousset et al., 
2009a). However, it is rarely a notifiable disease and its surveillance is frequently severely 
neglected (Maurin and Raoult, 1999). Q fever is a zoonotic bacterial disease caused by 
Coxiella burnetii, an obligate intracellular Gram negative bacterium of the Legionellales order 
(Komiya  et al., 2003; Berri  et al., 2007; Rousset  et al., 2007a; Hartzell  et al., 2008; 
Frangoulidis  et al., 2009). Domestic ruminants are considered the main reservoir for the 
pathogen but Q fever is known to infect a large variety of hosts, mammals (humans, caprids, 
bovids, ovids, small rodents, dogs, cats), as well as birds, fish, reptiles and arthropods 
(Marmion and Stoker, 1950; Davoli and Signorini, 1951; Slavin, 1952; Marmion  et al., 1954; 
Stocker and Marmion, 1955; Blanc and Bruneau, 1956; Evans, 1956; Syrucek and Raska, 
1956; Fiset, 1957; Hirai et To, 1998). It is a highly infectious disease (Benenson and Tigertt, 
1956; Ormsbee et al., 1978). Infected mammals shed bacteria in milk, feces, urine, vaginal 
mucous and very importantly in birth products (Figure 6). 
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1.3.2. Clinical signs 
 
The main characteristic of Q fever is its clinical polymorphism (Kuroiwa et al., 2007; Hartzell 
et al., 2008; Million et al., 2009; Pape et al., 2009). After an incubation period of 1 to 3 weeks 
(Maurin and Raoult, 1999; Watanabe and Takahashi, 2008), Q fever can cause either an acute 
or a chronic disease. Q fever infections remain poorly understood (Rousset et al., 2007a; Pape 
et al., 2009) and their prevalence and importance have been underestimated for many years 
(Rousset et al., 2007a). Estimating the level of infection in animals remains problematic 
(Rousset et al., 2007a).  
Complementary information on epidemiology, clinical signs, as well as the development of Q 
fever pathogenesis, diagnostic methods, treatment, and prognosis are available in the two 
reviews inserted hereby. 
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A B S T R A C T
As neglected zoonosis for many years, Q fever is now ubiquitous in Japan. Similarly to
elsewhere in the world, domestic animals are considered to be important reservoirs of the
causal agent, Coxiella burnetii, a resistant intracellular bacterium. Infected animals shed
bacteria in milk, feces, urine, vaginal mucous and birth products. Inhalation of bacteria
present in the environment is the main route of animal and human infection. Shedding of
C. burnetii in milk by domestic ruminants has a very limited impact as raw milk is seldom
ingested by the Japanese population. The clinical expression of Q fever in Japan is similar to
its clinical expression elsewhere. However clinical cases in children are more frequently
reported in this country. Moreover, C. burnetii is speciﬁed as one of the causative
organisms of atypical pneumonia in the Japanese Respiratory Society Guideline for the
management of community-acquired pneumonia. In Japan, C. burnetii isolates are
associated with acute illness and are mainly of moderate to low virulence. Cats are
considered a signiﬁcant source of C. burnetii responsible for human outbreaks in
association with the presence of infected parturient cats. Since its recognition as a
reportable disease in 1999, 7–46 clinical cases of Q fever have been reported by year. The
epidemiology of Q fever in Japan remains to be elucidated and the exact modes of
transmission are still unproven. Important further research is necessary to improve
knowledge of the disease itself, the endogenous hosts and reservoirs, and the
epidemiological cycle of coxiellosis in Japan.
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. Introduction
Q fever was ﬁrst described in 1937 (Derrick, 1937). Q
ver is a ubiquitous neglected zoonosis caused by a
esistant intracellular bacterium, Coxiella burnetii (Derrick,
937; Mitscherlich and Marth, 1984; Babudieri, 1959;
aurin and Raoult, 1999; Rousset et al., 2009). Ignored for
any years, Q fever is now thought to be ubiquitous in
pan since the reservoirs are present throughout the
ountry (Hirai and To, 1998). Similarly to elsewhere in the
orld, domestic animals are considered to be important
eservoirs of C. burnetii (Hirai and To, 1998). However Q
ver is known to infect not only a large variety of hosts,
ammals (humans, caprids, bovids, ovids, small rodents,
ogs, and cats) but also birds, ﬁsh, reptiles and arthropods
irai and To, 1998;Maurin and Raoult, 1999; Bildfell et al.,
000; Berri et al., 2007; Rousset et al., 2007; Okimoto et al.,
007; Hartzell et al., 2008). It is a highly infectious disease
rmsbee et al., 1978). Infected mammals shed bacteria in
ilk, feces, urine, vaginal mucous and very importantly in
irth products. Inhalation of resistant bacteria present in
e environment is the main route of animal and human
fection. The main characteristic of Q fever is its clinical
olymorphism (Kuroiwa et al., 2007; Hartzell et al., 2008;
illion et al., 2009; Pape et al., 2009). After an incubation
eriod of 1–3 weeks (Maurin and Raoult, 1999; Watanabe
nd Takahashi, 2008), Q fever can cause either an acute or a
hronic disease.
This review describes the epidemiological situation of
fever in Japan. The authors’ choice of country was
ased ﬁrstly on the peculiar role of cats and additionally
f wild birds in the epidemiology of Q fever in Japan and
econdly the limited epidemiological investigation and
wareness of Q fever in Japan incited further research on
he subject.
. Clinical expression
.1. In humans
Since April 1999, the management of infection control
nd prevention in Japan has changed drastically and Q
ver was designated as a national reportable disease. Q
ver occurs almost all over the country. Under the revised
urveillance system, clinical cases of Q fever have been
eported 7–46 cases since 1999 for a total of 127 million
habitants (Mahara, 2006). The clinical expression of Q
ver in Japan is similar to its clinical expression elsewhere
jercito et al., 1993; Htwe et al., 1993). In the acute form,
fections can be totally asymptomatic or can lead to self-
et al., 1998b; Sampere et al., 2003; Setiyono et al., 2005;
Berri et al., 2007; Kuroiwa et al., 2007; Delsing and
Kullberg, 2008; Hartzell et al., 2008; Schimmer et al., 2008;
Frangoulidis et al., 2009; Million et al., 2009; Pape et al.,
2009; Ughetto et al., 2009). Pneumonia is typically mild
but progression to acute distress syndrome can occur
(Hartzell et al., 2008; Watanabe and Takahashi, 2008).
Indeed a study found Q fever to be involved in 2.5% of
patients with an acute infection/exacerbation of a chronic
lower respiratory tract disease state (Okimoto et al., 2007).
In Japan, pneumonia is a common clinical presentation of
acute Q fever. The prevalence of C. burnetii infection as
causative agent for atypical pneumonia differs between
different countries. Indeed, To et al. (1996) found that
39.7% of Japanese patients with atypical pneumonia were
infected by C. burnetii. On the other hand, in the rural areas
of Nova Scotia, a province of Canada, only 20% of patients
admitted to hospital with atypical pneumonia were
infected by Q fever (Marrie, 1990). In France, Tissot
Dupont et al. (1992) reported a prevalence of atypical
pneumonia caused by C. burnetii of 45.8%. The variability in
prevalence between countries is most probably due to
differences in incidence of Q fever in domestic ruminants
(goats, sheep, and cattle). On the other hand, variability in
occurrence of clinical illness could be explained by
differences between local strains and their respective
virulence, and/or by physiological differences in the host
(To et al., 1996). Alimentary habits could also play a role. In
France, for example, farmers and stock breeders are known
to drink unpasteurized milk. Moreover, 61.9% of French
patients infected by Q fever presented clinical signs of
hepatitis (Tissot Dupont et al., 1992; Maurin and Raoult,
1999). However, currently, bacterial genotype and not
route of infection is thought to determine clinical
presentation. Furthermore transmission of infection by
oral route remains a matter of debate (Marmoin and
Stoker, 1958; Benson et al., 1963; Krumbiegel and
Wisniewski, 1970; AFSSA, 2004; Dorko et al., 2008; Natale
et al., 2009).
In Japan, C. burnetii isolates are mainly associated with
acute illness and are ofmoderate to low virulence (Oda and
Yoshiie, 1989; Hirai and To, 1998). C. burnetii is speciﬁed as
one of the causative organisms of atypical pneumonia in
the Japanese Respiratory Society Guideline for the
management of community-acquired pneumonia (Oki-
moto et al., 2004; Watanabe and Takahashi, 2008).
In Japan, on the contrary to other countries, clinical
expression of the disease has frequently been observed in
children (Hirai and To, 1998) (Table 1). The study by To
et al. (1996) suggested that Q fever was an important cause
f atypical pneumonia in Japanese children. Cases ofmiting ‘inﬂuenza-like’ illness, pneumonia or hepatitis (To o
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tal (Kuroiwa et al., 2007). The difference in prevalence of
fection in Japanese children compared to children from
her countries could be due to: (1) a more frequent
nical expression (as mentioned here above) due to a
fferent virulence of the bacterial strain or to a greater
sensitivity of the host, increasing the probability of
diagnosis; (2) to a greater awareness of physicians of
the possibility of Q fever infection in atypical and/or non-
speciﬁc clinical cases.
In pregnant women, clinical expression of Q fever,
initially asymptomatic, results in abortions, intrauterine
ble 1
roprevalence and isolation of Coxiella in animals and humans from Japan, through 1990–2008.
arameter Kingdom Species Number of
samples
% of positive Reference
eroprevalence Animal Healthy cattle 329 29.2 Yoshiie et al. (1991)
562 46.6 Htwe et al. (1992)
1501 25.4 Htwe et al. (1992)
619 16.9 Nguyen et al. (1997)
Reproductive disorder cattle 102 84.3 Htwe et al. (1992)
166 78.9 To et al. (1995)
207 60.4 To et al. (1996)
Sheep 256 28.1 Htwe et al. (1992)
Goat 85 23.5 Htwe et al. (1992)
Dog 635 15 Htwe et al. (1992)
589 10.2 Nguyen et al. (1997)
81 9.9 Nagaoka et al. (1996)
301 16.6 Hirai (1999)
Cat 274 0 Htwe et al. (1992)
100 16 Morita et al. (1994)
150 15.3 Nguyen et al. (1997)
101 6.7 Nagaoka et al. (1996)
304 18.8 Hirai (1999)
Pig 396 0 Htwe et al. (1992)
Chicken 1589 2 To et al. (1996)
Quail 174 2.9 To et al. (1996)
Duck 158 2.2 To et al. (1996)
Bear 36 77.8 Ejercito et al. (1993)
Deer 133 61.7 Ejercito et al. (1993)
Hare 8 62.5 Ejercito et al. (1993)
Monkey 54 27.7 Ejercito et al. (1993)
Nutria 32 12.5 Ejercito et al. (1993)
Wild rodent 129 24.1 Hirai and To (1998)
Crow 431 36 To et al. (1996)
Rock Dove 201 6 To et al. (1996)
Human Veterinarians 9 22.2 Yoshiie et al. (1991)
Healthy humans (adults) 60 3.3 Htwe et al. (1992)
275 22.2 Htwe et al. (1992)
Meat-processing workers 107 11.2 Htwe et al. (1992)
Adults with respiratory disorders (in general) 184 15.2 Htwe et al. (1992)
Adults with atypical pneumonia 284 1.4 Okimoto et al. (2004)
120 4.17 Watanabe and Takahashi (2008)
Children with ﬂu-like symptoms 55 32.7 Nagaoka et al. (1996)
Children with atypical pneumonia 56 35.7 To et al. (1996)
58 46.55 Maurin and Raoult (1999)
Hospitalized patients (adults) 3000 5.2 Nguyen et al. (1997)
Veterinary students 275 35.64 Htwe et al. (1993)
Adults with acute exacerbation of chronic
respiratory disease
80 2.5 Okimoto et al. (2007)
Adults with acute exacerbation of COPDa 240 0.4 Lieberman et al. (2001)
solation Animal Cattle with reproductive disorder (raw milk) 207 24.6 To et al. (1995)
Healthy cattle (raw milk) 47 36.3 Nagaoka et al. (1996)
Healthy cattle (fetus) 4 50.0 To et al. (1995)
Tick (Ixodes spp.) 15 26.7 To et al. (1995)
Dogs (sera) 5 100 To et al. (1996)
Cat (sera, uterus swabs) 5 100 To et al. (1996)
Human Acute Q fever (adults) 1 100 Oda and Yoshiie (1989)
Atypical pneumonia (children) 58 36.2 To et al. (1996)
Hospitalized patients (adults) 17 76.5 Hirai (1997)
Chronic Q fever endocarditis (adults)b 56 7.1 Yuasa et al. (1996)
m Hirai and To (1998), Hirai (1999), Nagaoka et al. (1998) and various sources.
COPD: chronic obstructive pulmonary disease.
Light microscopic observation.
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remature delivery (Peter et al., 1987; Numazaki et al.,
000; Delsing and Kullberg, 2008; Hartzell et al., 2008;
chimmer et al., 2008; Vaidya et al., 2008b; Frangoulidis
t al., 2009). Sporadically other clinical signs have been
eported (such as osteomyelitis, septic arthritis, pericarditis,
yocarditis, arteritis, hemolytic anemia, granulomatous
epatitis, lymphadenopathy, Guillain-Barre´, optic neuritis,
aralysis of the oculomotor nerve, meningitis, encephalitis,
olyradiculonevritis, peripheral neuropathy, cranial nerve
eﬁciency, and exanthema) (Hirai and To, 1998; Frangou-
dis et al., 2009; Million et al., 2009; Pape et al., 2009).
In Japan, such as other countries, chronic infection leads
ommonly to endocarditis (Yuasa et al., 1996). Chronic
epatitis, osteomyelitis, septic arthritis, interstitial lung
isease (Berri et al., 2007), and infection of aneurysm and
ascular grafts (Delsing and Kullberg, 2008; Ughetto et al.,
009) have also been reported in chronic cases of Q fever
rangoulidis et al., 2009; Pape et al., 2009). Individuals
ith underlying valvulopathy or other cardiovascular
bnormalities are predisposed to the development of
ndocarditis (Maurin and Raoult, 1999; Kuroiwa et al.,
007; Delsing and Kullberg, 2008; Hartzell et al., 2008;
illion et al., 2009; Pape et al., 2009; Ughetto et al., 2009).
urthermore, chronic fatigue syndrome has been diag-
osed in previously infected individuals (Berri et al., 2007;
illion et al., 2009).
.2. In farm animals
C. burnetii is widespread among cattle population in
pan (4.4 millions of heads). Bovine coxiellosis is rarely an
vert disease, except for reproductive disorders (such as
bortion, infertility, metritis and mastitis) in females
kewise to other parts of the world (To et al., 1995,
998a; Vaidya et al., 2008a). Although high rates of
bortions are rarely observed in cattle (Palmer et al., 1983),
hedding of large quantities of germs remains a reality in
e absence of any clinical sign. A retrospective study by
ildfell et al. (2000) demonstrated that C.burnetii only
poradically leads to abortion in cattle, but was signiﬁ-
antly associated with placentitis. Some studies have
eported an increase in seroprevalence of Q fever in
panese cattle in recent years (Hirai and To, 1998). Cattle
lay an important role in maintaining infection and in
ispersing the organism in the environment (Beaudeau
t al., 2006; Guatteo et al., 2006; Rodolakis et al., 2007).
hey are one of the major reservoirs of C. burnetii in Japan
o et al., 1998a). The controversy associated to transmis-
ion of Q fever through milk ingestion is of minor
portance for the Japanese population. Indeed shedding
f C. burnetii in milk has a very limited impact as raw milk
seldom ingested by the native population (Okimoto
t al., 2004). Rawmilk is commonly pasteurized at 63 8C for
0min or more therefore no problem is expected
atanabe and Takahashi, 2008).
The rarity of sheep (10,000 heads) and goats (32,000
eads) populations renders these animals non signiﬁcant
r the spread of the disease (Hirai and To, 1998). Q fever
as not been reported in pigs as yet but available data
2.3. In pet animals
Dogs and cats have been found to be positive for C.
burnetii by serology and bacteriology throughout the
Japanese territory (Hirai and To, 1998; Komiya et al.,
2003). Nagaoka et al. (1998) isolated C. burnetii in swabs of
feline vaginal mucosa and suggested that the organism
could be associated with reproductive disorders or
abortions in the feline species. Further epidemiological
study about the relationship between feline disorders and
C. burnetii infection are suggested by the authors (Nagaoka
et al., 1998). Small human outbreaks of coxiellosis
associated with the presence of infected parturient cats
have been reported in several studies (Marrie et al.,
1988a,b, 1989; Pinsky et al., 1991). Cats are thus
considered as a potential source for human infections in
this country. However premature conclusions must not be
made and supplementary evidence of feline to human
transmission of Q fever is necessary with special attention
to potential confounding factors. Outbreaks associated to
infected dogs have not yet been reported to our knowledge.
The dogs’ role as reservoir of the pathogen remains poorly
explored.
3. Epidemiological data
The epidemiology of Q fever in Japan remains to be
elucidated and the exact modes of transmission are still
unproven (Hirai and To, 1998). The review by Hirai and To
(1998) attempted to explain the epidemiology of Q fever in
Japan. Fig. 1 illustrates their hypotheses. Environment and
ticks would be responsible for infection of domestic
animals; infected domestic animals hereafter leading to
human infections. Transmission directly from infected
wild animals to humanswould also be possible. Ticks could
play a role in transmission of disease from the environ-
ment to domestic animals. Tick transmission from
domestic and wild animals to humans (Hirai and To,
1998) is considered minor.
Humans
Crows
Pigeons
Ducks
Dogs
Cats
Cattle
Sheep
Goats
Deers
Bears
Mice
Environment
Ticks
Ticks
Aerosol Aerosol Aerosol Aerosol
Ticks
Wild birds Wild animals
(Milk and dairy
products)
Ticks
Aerosols
Ticks
Aerosols
Environment
TicksFig. 1. Epidemiology of Q fever in Japan.From Hirai and To (1998).emains scarce (Hirai and To, 1998).
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Hirai and To (1998) reported the seroprevalence of Q
ver in domestic and wild animals present in Japan
able 1). Several authors contributed to these estima-
ns. In domestic animals, cattle with reproductive
sorders had the highest percentage of seroprevalence
coxiellosis. A signiﬁcant level of seropositivity was
tected in wild animals but the results must be
terpreted with care as the sample size is often limited.
ows (seroprevalence of 36%) could be involved in
nsmission of C. burnetii from infected areas to non
fected areas.
In a study performed by To et al. (1998b) many wild
rds were found to be seropositive against C. burnetii by
onoclonal antibody assay (MA). The polymerase chain
action (PCR) also used in this study conﬁrmed the
rological results by detecting the bacterial DNA.
rthermore areas where infected livestock was present
ere associated with a higher seroprevalence of Q fever
birds. The authors suggested that wild birds could be
ed as indicators of foci of infection (To et al., 1996).
mestic birds were also found to be seropositive for Q
ver and capable of infecting humans (Hirai and To,
98) rendering additional investigation necessary,
pecially to determine the eventual role as natural
servoir of C. burnetii (dejection and soil). In 2006,
icken products were highly suspected as responsible
r Q fever infections in humans (Muramatsu et al.,
06). C. burnetii was detected in market eggs and
ayonnaise (Tatsumi et al., 2006). Initially the prob-
ility that the bacteria were alive was considered high
atsumi et al., 2006). However, the results of further
vestigations remain non precise and incomplete. PCR-
sed detection of C. burnetii DNA in dead bacterial
gments was reported but there are no reports
monstrating contamination with viable bacteria
atanabe and Takahashi, 2008). No data is available
ncerning the extent of transmission of C. burnetii from
ild animals and birds to humans and domestic animals
irai and To, 1998). Its epidemiological importance,
wever, is considered minor (Hirai and To, 1998). A
evious study reported that four out of 11 Japanese
ild species had a prevalence of infection higher to 50%,
two had a prevalence of infection lesser to 50%, and ﬁve
species were free from infection (Ejercito et al., 1993).
Three hypotheses could explain absence of infection in
the ﬁve species: the species were either isolated in a area
free from Q fever, or they had an innate resistance to
infection, or were false negative animals due to a lack of
sensitivity of the laboratory diagnostic method (Ejercito
et al., 1993). Further epidemiological studies are
necessary to explain this apparent or real resistance to
infection.
To et al. (1998a) studied the seropositivity rate in
herds of dairy cattle with reproductive disorders in
Japan. The three main reproductive problems studied
were infertility, metritis and mastitis. The rates of
positivity were assessed by indirect immunoﬂuores-
cence assay (IFA) (with a distinction for phase 1
antibodies and phase 2 antibodies), by PCR (in sera
and milk samples) and by isolation (in milk samples).
Phase 2 antibodies and phase 1 antibodies are associated
with acute and with chronic infections, respectively. The
study showed that 60.4% of the cows considered were
seropositive by IFA towards phase 2 bacteria. In addition,
3.9% and 24.6% were seropositive by PCR on sera and
milk respectively. All PCR-positive samples were con-
ﬁrmed by isolation. Whatever be the laboratory
method, a positive result was always obtained. This
study by To et al. (1998a) demonstrated that in herds
with reproductive disorders the prevalence of Q fever
was far from nil.
In studies on feline seroprevalence, stray cats were
found to have a higher incidence of infection than
domestic cats (Nagaoka et al., 1998; Komiya et al.,
2003) (Table 1). In this species it is suspected that Q
fever could be responsible for breeding disorders
(Nagaoka et al., 1998).
3.2. Prevalence of Q fever in the Japanese population
Table 1 reports the seroprevalence in humans in Japan
(Hirai and To, 1998). It is interesting to notice that many
healthy humans are seropositive to Q fever. In this study,
the seroprevalence of infection was relatively high in
children with respiratory disorders, ﬂu-like
symptoms, atypical pneumonia and in adults with
ble 2
idence of Q fever as a cause of community-acquired pneumonia in Japan, Europe, Asia, Africa and America from Watanabe and Takahashi (2003),
atanabe and Takahashi (2008) and varied sources.
rea Report year No. of patients No. of Q fever cases Incidence (%) Reference
frica 1997 65 6 9.2 Koulla-Shiro et al. (1997)
merica (USA) 1996 149 4 2.7 Marrie et al. (1996)
2001 170 4 2.4 Bochud et al. (2001)
sia 1997 346 20 5.8 Lieberman et al. (1996)
urope 1991 225 18 8.0 Albornoz et al. (1991)
1996 124 3 2.4 Torres et al. (1996)
1997 106 19 17.9 Zalacain et al. (1997)
1998 173 4 2.3 Sopena et al. (1998)
1999 395 11 2.8 Ruiz et al. (1999)
apan 2000 232 2 0.9 Saito et al. (2006)
2004 284 4 1.4 Okimoto et al. (2004)2004 400 10 2.5 Takahashi et al. (2004)
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ize is a problem for interpretation in certain categories
f human beings. Table 2 reports the estimated number
f cases of community-acquired pneumonia in different
ountries from 1989 to 2001. In Japan, the incidence rate
f Q fever has signiﬁcantly increased between 2000 and
004. However, Q fever had been underdiagnosed for
any years in Japan and increased awareness and
ecognition of the illness might be responsible for the
creased observation in this study (Watanabe and
akahashi, 2008).
.3. Isolation of C. burnetii from animals and humans
Hirai and To (1998) reported the isolation rates of C.
urnetii in different animals present in Japan (Table 1).
etuses of healthy cattle had a high content in
acteria. Ticks of the Ixodes order were signiﬁcantly
fected by C. burnetii. Indeed 75% of the sampled Ixodes
icks in the Toyama prefecture were infected by the
acteria.
As mentioned previously, cats are considered a
igniﬁcant source of C. burnetii in Japan (Marrie et al.,
988a; Marrie et al., 1988b; Marrie et al., 1989; Pinsky
t al., 1991). In the study by Nagaoka et al. (1998) bacteria
ere isolated from vaginal swabs of asymptomatic cats as
ell as of cats with respiratory disorders, with fever or
ith fever and abortion. The bacteria were also isolated in
ats with atypical clinical manifestations (compared to
uman clinical manifestations) such as peritonitis and
ammary tumors.
Table 1 reports the isolation ratesofC. burnetii inhumans
ith various clinical signs (Hirai and To, 1998). The rate of
olation in children is particularly high compared to those
bserved in other parts of the world (To et al., 1996;Maurin
and Raoult, 1999). Positive serologies, occasionally asso-
ciated to bacterium isolation, were a relative frequent
ﬁnding in adults with fever of unknown origin (Knockaert
et al., 2003; Arnow and Flaherty, 1997; Hirschman, 1997;
Lozanoet al., 1996). In consequence, Q fever serology should
be included in the standard work-up of fever of unknown
origin in Japan. To conﬁrm these results a second studywith
larger samples of humans would be necessary.
4. Diagnosis of Q fever and vaccination
Q fever is rarely mentioned in Japanese medical text
books and many physicians are unaware of its existence
(Watanabe and Takahashi, 2008). Similarly, Japanese
veterinarians are insufﬁciently informed about the risks
associated to manipulations of infected animals or
infected biological matter (Abe et al., 2001). Thus the
recognition of Q fever infections remains limited through-
out the country (Watanabe and Takahashi, 2008).
Reported clinical cases are rare with the ﬁrst clinical case
reported dating from 1989 (Watanabe and Takahashi,
2008). Increasing the physicians’ awareness of the
possibility of Q fever infections is essential as rapid
diagnosis is known to improve prognosis (To et al., 1996).
Table 3 reports the different aspects of the illness to
facilitate diagnosis by a clinician (Watanabe and Takaha-
shi, 2008). To reach deﬁnite diagnosis IFA, complement
ﬁxation test (CFT), enzyme linked immunoassay (ELISA)
and PCR are available (e.g., Field et al., 2000; Ughetto et al.,
2009). Imported IFA and ELISA kits present problems
when used on Japanese individuals. Indeed, it has been
observed that the increase in IgM antibodies in many
Japanese patients infected in Japan is slow; whereas the
increase in IgM antibodies is very rapid in Japanese
patients infected abroad. This suggests that Coxiella
able 3
iagnostic points of acute Q fever from Watanabe and Takahashi (2008).
Area Criteria Key points
Clinical viewpoint Opportunities for contact with animals It should be noted that even slight contact may lead to an infection
The risk of mass exposure is high around an animal after delivery
An epidemic outbreak is possible at home or in an ofﬁce
Subjective and objective symptoms Systemic symptoms such as high fever, arthralgia, and malaise are
signiﬁcant
Inﬂuenza-like symptoms in the ‘‘off-season’’
Responsiveness to antimicrobial drugs ß-Lactam antibiotics are basically ineffective (spontaneous remission
during treatment is possible)
Tetracyclines, macrolides and quinolones are effective
Etiological diagnosis Measurement of antibody titers to
phase II Coxiella
It is often impossible to evaluate antibody titers based only on acute
phase serum samples
It may take a few months for antibody titers to increase
It is important to monitor antibody titers even after recovery from
the disease
PCR-based detection of the Coxiella gene It is often necessary to use a nested PCR technique
Detection is also possible in various samples from outside the
respiratory system
For suspected cases, acute phase samples should be kept in a freezer
At present PCR should be considered as an adjunct diagnostic technique
Overall evaluation The clinical picture changes in antibody titers and PCR results should
be integrated into the evaluation
It is necessary to differentiate the pathogen from Mycoplasma,Chlamydia, and Legionella
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kahashi, 2008). Moreover, the Japanese population
ight have a different physiological response to infection
mpared to Caucasians. Currently, results obtained with
ported IFA and ELISA kits remain difﬁcult to interpret.
rthermore, ELISA kits require a retest with the standard
A before evaluating a patient (Watanabe and Takahashi,
08). In conclusion, new rapid diagnostic tests speciﬁ-
lly using the Japanese strain of C. burnetii are indis-
nsable. In addition, a larger number of Japanese
stitutions and laboratories should be equipped with
e diagnostic tests (Watanabe and Takahashi, 2008).
ccination is uncommon in Japan because of the limited
cognition of the disease (Watanabe and
kahashi, 2008).
Conclusion and perspectives
Q fever is a newly discovered disease in Japan.
eviously it was considered completely absent. Knowl-
ge of the illness is thus limited. Available epidemiolo-
cal data consists frequently of small samples of animals
humans rendering the interpretation poorly accurate.
e lack of knowledge of the epidemiological and
ographical situation in certain areas of the country also
uses problems. The estimation of the prevalence or
cidence of Q fever is difﬁcult due to the recent awareness
the illness, to the absence of previous data and to
roprevalences estimated on sampled individuals that are
t necessarily representative of the endogenous popula-
n. Recently differential diagnoses are including Q fever
d cases are being diagnosed and reported. Important
rther research is however necessary to improve knowl-
ge of the disease itself, of the endogenous hosts and
servoirs (e.g., the role of domestic birds should be more
vestigated), and of the epidemiological cycle of cox-
losis in this country. Diagnostic tests must be improved
increase their sensitivity and avoid the necessity of
testing. They must be adapted to the Japanese strain of
cteria and to the Japanese conditions. The multi-
sciplinary approach neededwould involve a large variety
scientists. To this day, Q fever remains a challenge for the
terinary and medical profession.
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ABSTRACT  
Q fever is an ubiquitous neglected zoonosis caused by an extremely resistant intracellular 
bacterium, Coxiella burnetii. Knowledge of C. burnetii remains limited to this day. Its 
resistant (intracellular and environmental) and infectious proprieties have been poorly 
investigated. Understanding of the infected host’s immune response remains vague and 
essentially hypothetical. Domestic ruminants are considered the main reservoir of bacteria but 
a large number of species can be infected. Infected animals shed the highly infectious 
organisms in milk, feces, urine, vaginal mucus and very importantly, in birth products. 
Inhalation is the main route of infection. Clinically Q fever is extremely polymorphic 
rendering its diagnosis difficult. Frequently asymptomatic in animals and humans, Q fever 
can cause acute or chronic infections. Consequences of infection can be dramatic and, at herd 
level, can lead to significant financial losses. Vaccination with inactive whole cell bacteria has 
been performed and proved effective in humans and animals. However inactive whole cell 
vaccines present several defects. Recombinant vaccines have been developed in experimental 
conditions and have great potential for the future. Q fever has become a severe public health 
problem and awareness of the disease must be promoted worldwide. Q fever is a challenging 
disease for scientists as significant further investigations are necessary. Great research 
opportunities are available to reach a better understanding and thus a better prevention and 
control of the infection.  
Keywords: Q fever, zoonosis, Coxiella burnetii, reproductive disorders, atypical pneumonia 
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1. INTRODUCTION 
Q fever was first described in 1937 by E. H. Derrick in Queensland, Australia (Derrick, 
1944). It was previously classified as a “Category “B” critical biological agent” by the Centre 
for Diseases Control and Prevention and is considered a potential weapon for bioterrorism 
(Alibek, 1999). Q fever is a public health concern throughout the world (Rousset et al., 2009). 
However it is rarely a notifiable disease and its surveillance is frequently severely neglected.  
Q fever is a zoonotic bacterial disease. Domestic ruminants are considered the main reservoir 
for the pathogen but Q fever is known to infect a large variety of hosts, mammals (humans, 
caprids, bovids, ovids, small rodents, dogs, cats) but also birds, fish, reptiles and arthropods 
(Marmion and Stoker, 1950; Davoli and Signorini, 1951; Slavin, 1952; Marmion et al., 1954; 
Blanc and Bruneau, 1956; Evans, 1956; Fiset, 1957; Syrucek and Raska, 1956; Stocker and 
Marmion, 1955; Hirai et To, 1998). It is a highly infectious disease (Benenson and Tigertt, 
1956; Ormsbee et al., 1978). Q fever infections remain poorly understood (Rousset et al., 
2007a; Pape et al., 2009) and their prevalence and importance have been underestimated for 
many years (Rousset et al., 2007a). Estimating the level of infection in animals remains 
problematic (Rousset et al., 2007a).  
2. CAUSAL AGENT  
The causal agent of Q fever is Coxiella burnetii, an obligate intracellular Gram negative 
bacterium of the Legionellales order (Mitscherlich and Marth, 1984; Ransom and Huebner, 
1951; Babudieri, 1959). Its predilected target cells are the macrophages situated in body 
tissues (lymph nodes, spleen, lungs and liver, e.g.) and the monocytes circulating in the blood 
stream (Baca et al., 1983).  
Two different antigenic forms of C. burnetii can be distinguished (Baca and Paretsky, 1983). 
The difference between phase I and phase II bacterial forms resides in the variation of the 
Introduction 
 
52 
 
surface lipopolysaccharide (LPS) (Amano and Williams, 1984). Only phase I bacteria have a 
complete LPS on their surface and are virulent bacteria (Moos and Hackstadt, 1987). Phase I 
bacteria can be isolated from a naturally infected individual or from animals infected in a 
laboratory (Krt, 2003; Setiyono et al., 2005). On the other hand, phase II bacteria have an 
incomplete LPS due to a spontaneous genetic deletion of 25,992 bp (Thompson et al., 2003) 
and are non virulent (Setiyono et al., 2005). Phase II bacteria occur during serial passage in an 
immunologically incompetent host, such as cell cultures or fertilized eggs (Krt, 2003; 
Thompson et al., 2003; Setiyono et al., 2005). The deleted chromosomal region comprises a 
high number of genes that are predicted to function in LPS or lipooligosaccharide 
biosynthesis, as well as in general carbohydrate and sulfur metabolism (Hoover et al., 2002). 
However, in Australia, the study by Thompson et al. (2003) on the genome of phase II human 
strains by polymerase chain reaction (PCR) reported the absence of truncated genes or of 
deletions. The Institute for Genomic Research has suggested that at least two other 
chromosomal regions are implicated in phase transition (Thompson et al., 2003). Antigenic 
variation of C. burnetii is important for serological diagnosis. Indeed, serologically, anti-
phase II antibodies (IgG and IgM) are found at high levels in acute Q fever, whereas anti-
phase I antibodies (IgG and IgA) are found at high levels only during the chronic infection 
(Setiyono et al., 2005).  
Several genetic studies have been performed on C. burnetii. The genome of the American 
Nine Mile strain was sequenced completely in 2003 (Seshadri et al., 2003). The chromosome 
is circular and varies in size from 1.5 to 2.4 106 base pairs. Occasionally a 33- to 42-kb 
plasmid can be observed in the intracellular media but its function remains to be determined 
(Maurin and Raoult, 1999). Bacterial isolates can be identified by a probe to 16S ribosomal 
RNA (rRNA), which is highly conserved (Masuzawa et al., 1997a). Genetic heterogeneity of 
C. burnetii is limited with approximately 30 distinct variants (Million et al., 2009). According 
Introduction 
 
53 
 
to experimental studies, bacterial strains vary in their pathogenic effect (Stoenner and 
Lackman, 1960; Oda and Yoshiie, 1989; Kazr et al., 1993; To et al., 1995). Masuzawa et al. 
(1997b) studied the macrophage infectivity potentiator gene (Cbmip of 654-base DNA) and 
the sensor-like protein gene (qrsA of 1227-base DNA) sequences between eleven strains. 
Their results demonstrated that Cbmip and qrsA sequences were highly conserved (>99%) 
and didn’t explain differences in pathogenicity (Masuzawa et al., 1997b). Furthermore, three 
different plasmids have been identified in Coxiella variants (Frazier et al., 1990): QpH1, 
QpRS and QpDG (Samuel et al., 1983; Mallavia, 1991). Another plasmid (QpDV) has been 
isolated in a strain from a human case of endocarditis (Valkova and Kazar, 1995). Plasmids 
differ by size and genomic sequence. However, several identical genomic sequences are 
present in all plasmids. In bacteria without plasmids, these sequences are found on the 
chromosome (Frazier et al., 1990). Generally, plasmids are of little interest for identification 
of microorganisms because they are not critical for survival and can infect a large variety of 
organisms (Frazier et al., 1990). However, C. burnetii plasmids have proven to be useful 
because different strains contain different plasmids. In fact, QpH1, QpRS and QpDV were 
present in different genotypes and were associated with difference in pathogenicity in the 
study by Frazier et al. (1990). Moreover, Savinelli et al. (1990) reported that in human 
patients, the QpH1 and the QpRS plasmids (or plasmidless strains containing QpRS-related 
plasmid sequences) were associated with acute and chronic infection, respectively. However, 
later studies by genomic restriction fragment length polymorphism analysis, plasmid typing or 
lipopolyssacharride analysis, on a larger number of strains did not confirm their results. 
Indeed, recent data shows that genetic variation has an apparent closer connection with the 
geographical source of the isolate than with clinical presentation (Maurin and Raoult, 1999; 
Glazunova et al., 2005). Moreover, host factors seem to be more important than genomic 
variation for development of acute or chronic infection (Yu and Raoult, 1994; La Scola et al., 
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1998). According to the recent report by the OIE (2005), no specific genotype is associated to 
acute or chronic infection, to a particular clinical outcome, or to a specific host.  
3. PATHOGENESIS 
 The first step of infection is entry of the bacterium into the host’s cells by passive entry, 
followed by internalization in phagosomes. Phagolysosomes are formed after the fusion of 
phagosomes with cellular acidic lysosomes. The multiple intracellular phagolysosomes 
eventually fuse together leading to the formation of a large unique vacuole. C. burnetii has 
adapted to the phagolysosomes of eukaryotic cells and is capable of multiplying in the acidic 
vacuoles (Hackstadt et al., 1981). In fact, acidity is necessary for nutrients assimilation and 
for its metabolism, including synthesis of nucleic acids and amino acids (Thompson et al., 
1990). Multiplication of C. burnetii can be stopped by raising the phagolysosomal pH using 
lysosomotropic agents such as chloroquine (Akporiaye et al., 1983; Raoult et al., 1990). The 
mechanisms of C. burnetii survival in phagolysosomes are still under study. Mo et al. (1995) 
and Akporiaye and Baca (1983) identified three proteins involved in intracellular survival: 
superoxide dismutase, catalase and a macrophage infectivity potentiator (Cbmip). Redd and 
Thompson (1995) found that secretion and export of Cbmip was triggered by an acid pH in 
vitro. Later, studies by Zamboni and Rabonovitch (2003) and by Brennan et al. (2004) 
demonstrated that growth of C. burnetii was reduced by reactive oxygen intermediates (ROI) 
and reactive nitrogen intermediates. Hill and Samuel (2011) analyzed C. burnetii’s genome 
and identified 2 acid phosphatase enzymes. They demonstrated experimentally that both a 
recombinant acid phosphatase (rACP) enzyme and C. burnetii extracts had a pH-dependent 
acid phosphatase activity. Moreover, rACP and bacterial extracts were capable of inhibiting 
ROI response by PMN despite their exogenous stimulation by a strong PMN stimulant. 
Inhibition of the assembly of the NADPH oxidase complex was found to be the mechanism 
involved (Hill and Samuel, 2011). The intracellular cycle of C. burnetii leads to the formation 
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of two development stages of the bacterium known as “small-cell variant”(SCV) and “large-
cell variant” (LCV) (McCaul and Williams, 1981; McCaul et al., 1981; McCaul et al., 1991; 
Samuel et al., 2000). SCV is the extracellular form of the bacterium. Typically rod-shaped, 
SCV are compact measuring from 0.2 to 0.5 μm with an electron-dense core (McCaul and 
Williams, 1981). SCVs are metabolically inactive and are capable of resisting to extreme 
conditions such as heat, desiccation, high or low pH, disinfectants, chemical products, 
osmotic pressure and UV rays (Babudieri, 1950; Ransom and Huebner, 1951; McCaul et al., 
1981; Mitscherlich and Marth, 1984; Samuel et al., 2000). Their extreme resistance in the 
environment (pseudo-spores) enables the bacteria to survive for long periods of time in the 
absence of a suitable host. This resistant form of C. burnetii is reversible (Rousset et al., 
2007a). Indeed, once inhaled or ingested the SCV attaches itself to a cell membrane and is 
internalized. After phagolysosomal fusion, the acidity of the newly formed vacuole induces 
activation of SCV’s metabolism and its development into LCV. During the morphogenesis 
from SCV to LCV no increase in bacterial number is reported (Coleman et al., 2004). LCV is 
the metabolically active intracellular form of C. burnetii. They are more pleomorphic than 
SCV. Their cell wall is thinner and they have a more dispersed filamentous nucleoid region. 
They can exceed 1μm in length (McCaul and Williams, 1981). Intracellular growth is 
relatively slow with a doubling time of approximately 8 to 12 hours (Baca and Paretsky, 
1983). LCVs can differentiate into spore-like bacteria by binary asymmetrical division. The 
endogenous spore-like forms can undergo further development and metabolic changes until 
finally reaching the SCV form. Finally cell lysis, or possibly exocytosis, releases the resistant 
bacteria into the extracellular media (Khavkin, 1977). Apoptosis of the infected cell can be 
induced by the intracellular bacterium itself leading to the destruction of the dead cell by other 
macrophages. This process permits C. burnetii to infect new cells and to continue its slow 
multiplication (Rousset et al., 2007a). The physical and biological factors responsible for the 
sporulation-like process remain unknown. Most natural infections by C. burnetii are probably 
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due to its resistant form (SCV or pseudo-spore) present in the environment. Decreasing the 
prevalence of Q fever infections using hygienic preventive measures requires a strict 
limitation of the environmental population of Coxiella pseudo-spores (Rousset et al., 2007a). 
During chronic infection the bacteria multiply at a slower rate (approximately 20h for one 
doubling), which is similar to the rate of the host cells mitosis. This phenomenon would allow 
persistence of the bacteria in the cell without causing cellular damage (Roman et al., 1986).  
Studies on the immune reaction in naturally or experimentally infected individuals have 
suggested that cellular immunity and the synthesis of IFNγ are essential for control of C. 
burnetii infection (Izzo and Marmion, 1993; Helbig et al., 2003; Shannon et al., 2009).  
Helbig et al. (2003) demonstrated the predominant role of IFNγ, its level of production 
determining the outcome of infection. Indeed, IFNγ has been successfully tested to treat Q 
fever in patients not responding to antibiotic treatment (Morisawa et al., 2001; Maltezou and 
Raoult, 2002). A study by Shannon et al. (2009) reported that the development of protective 
antibody-mediated immunity in vivo was found to be independent of the cellular Fc receptors 
and of the complement (Shannon et al., 2009). The major part of vaccine-derived humoral 
response consists of IgG antibodies directed against proteins (Novak et al., 1992; Vigil et al., 
2010). Several studies report that natural humoral response to C. burnetii is directed against 
both protein and glycolipid fractions (Hendrix et al., 1990; Zhang et al., 2003; Zhang et al., 
2004; Zhang et al., 2005). Chen et al. (2011) identified 8 new CD4+ T cell epitopes. 
However, all the CD4+ T cell epitopes didn’t lead to B cell stimulation and specific antibody 
production. Koster et al. (1985a) reported that in chronic infections, peripheral blood 
lymphocytes do not proliferate when exposed to C. burnetii antigens despite proliferating 
when exposed to other antigens or mitogens. This was not observed in acute infection (Koster 
et al., 1985b). In addition, Shannon et al. (2005) observed that C. burnetii phase I cells 
appeared almost invisible to dendritic cells.  
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Further research is more than necessary to fully understand the complex processes developed 
by C. burnetii to enter and infect a specific host’s cell, to resist in the intracellular and 
extracellular environment, and its ability to cause illness. Moreover, a better understanding of 
the immune system’s reaction to infection would give an insight into the processes developed 
by the bacterium and by the host that determine the final outcome of disease (asymptomatic, 
acute or chronic). 
4. EPIDEMIOLOGICAL AND CLINICAL ASPECTS 
4.1. Routes of infection 
Inhalation is the most common route of infection in both animals and human (Welsh et al., 
1957; Tissot-Dupont et al., 1999; Russell-Lodrigue et al., 2006). Inhalation of a small number 
of bacteria is sufficient for the development of an infection in a new host (Ormsbee et al., 
1978). As mentioned above, domestic animals are considered the main reservoir for the 
pathogen (Lang, 1990; Guatteo et al., 2007; Vaidya et al., 2010). Infected animals 
contaminate the environment by shedding C. burnetii in milk, feces, urine, saliva (Hirai et To, 
1998; Guatteo et al., 2006) and very importantly in vaginal secretions, placenta, amniotic 
fluids and other products of conception (To et al., 1996; Hirai et To, 1998; To et al., 1998a; 
Hatchette et al., 2002; Kim et al., 2005; Guatteo et al., 2006; Rodolakis et al., 2007; Berri et 
al., 2007; Rousset et al., 2009a). C. burnetii also spreads by wind causing infections at a 
distance from the initial source of bacteria (Marrie and Raoult, 1997; To et al., 1996; Okimoto 
et al., 2004).  
In domestic ruminants, milk is the most frequent route of pathogen shedding (Rodolakis et al., 
2007). Currently, controversy remains concerning the possibility of infection by oral route 
(AFSSA, 2004). Results of previous studies on the subject are considered inconclusive 
(Marmion et al., 1954; Marmion and Stoker, 1956; Benson et al., 1963; Krumbiegel and 
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Wisniewki, 1970; Dorko et al., 2008). OIE advises not to drink raw milk originating from 
infected farms (OIE, 2005). Further research is required to clarify the probability of infection 
by oral route. If infection by oral route is proven to be efficient, the sufficient number of 
pathogens capable of causing Q fever should be determined (Rousset et al., 2006).  
Human-to-human transmission does not usually occur (OIE, 2005; Watanabe and Takahashi, 
2008), although it has been described following contact with parturient women (Deutch and 
Peterson, 1950; Raoult and Stein, 1994). Currently, risk of transmission through blood 
transfusion is considered negligible (Anonymous, 1977; Desling and Kullberg, 2008). 
Transplacental transmission, intradermal inoculation and postmortem examinations have been 
associated to sporadic cases of Q fever (Harman, 1949; Gerth et al., 1982; Stein and Raoult, 
1998; Anonymous, 1950). In addition, cases of sexual transmission of Q fever have been 
reported (Kruszewska et al., 1996; Milazzo et al., 2001; Miceli et al., 2010). 
 4.2. Q fever in domestic animals and wildlife 
Cattle 
Q fever is widespread in livestock and its seroprevalence is thought to have increased in 
recent years (Maurin and Raoult, 1999). Often neglected in the differential diagnosis, Q fever 
can persist in a herd causing great financial losses on the long term (To et al., 1998a).  
In ruminants, well-known manifestations of Q fever are abortion, stillbirth, premature 
delivery and delivery of weak offspring (Rousset et al., 2009a). However these dramatic 
clinical manifestations are generally only expressed in sheep and goats. In bovids, Q fever is 
frequently asymptomatic. Clinical infected cows develop infertility, metritis and mastitis (To 
et al., 1998a). A retrospective study by Bildfell et al. (2000) found that C.burnetii was 
significantly associated with placentitis. Placental necrosis and fetal bronchopneumonia were 
also significantly associated with the presence of C. burnetii in the trophoblastes (Bildfell et 
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al., 2000). Unlike humans and cows infected experimentally (Plommet et al., 1973), naturally 
infected ruminant rarely present respiratory or cardiac signs. Beaudeau et al. (2006) and 
Guatteo et al. (2006) performed respective studies on shedding of C. burnetii by infected 
cows. In the study by Guatteo et al. (2006) the apparent proportion of shedders among the 
cows sampled was 45.5%.  Milk was the most frequent positive sample for the bacterium 
compared to feces and vaginal mucus samples. The percentage of positive samples of each 
type was 24.4, 20.7 and 19% respectively. 65.4% of sampled cows excreted by one shedding 
route only, whereas 6.4% shed bacteria in the vaginal mucus, feces and milk simultaneously. 
A combined shedding in vaginal mucus and in feces was observed in 14.6% of cases. 
Unfortunately no value is available for the rate of combination of shedding in milk and 
vaginal mucus in this study (Guatteo et al., 2006). The study by Beaudeau et al. (2006) 
reported that 85% of their infected cows excreted by one shedding route only. In their study, 
only 2% of the infected cows shed bacteria in the vaginal mucus, feces and milk 
simultaneously. When combined shedding occurred, the combination of shedding in vaginal 
mucus and milk was the most frequently observed. The results of these two French studies are 
very similar and the differences observed could be due to differences in the sampled 
population of cattle. Differences in the diagnostic laboratory methods could also be an 
influential factor. Furthermore, different areas can have variable prevalence of Q fever and, 
not only is shedding in milk intermittent and its outset not associated with parturition, it also 
differs from one herd to another despite species being identical (Rodolakis et al., 2007). Milk 
being such a major shedding route, bulk tank milk (BTM) samples are useful for investigation 
of the sanitary grade of bovine (Czaplicki et al., 2009) and caprine herds (Dubuc-Forfait et al., 
2009). Indeed, polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay 
(ELISA) performed on BTM samples, in addition to the analysis of serum samples of at least 
10% of the animals in the herd, give rapid, economical and valuable information on the herd’s 
status (Rodokalis et al., 2007). In cows’ milk, Marrie (1990) identified C. burnetii for up to 32 
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months postpartum. Vaginal and fecal bacterial discharges seem to have a major impact on 
environmental contamination as a result of practices at kidding and effluent management 
(Rodolakis et al., 2007; Rousset et al., 2009a). Indeed, the incidence of Q fever has been 
observed to increase significantly during the lambing period (winter and early spring) (Evans, 
1956). A seasonal correlation with spread of goat manure was reported in the Netherlands 
during the outbreaks of 2007-2008 (Desling and Kullberg, 2008).  
Epidemiological data has shown that cows are more frequently chronically infected with 
persistent shedding of bacteria as a result (Lang, 1990). The sites of chronic C. burnetii 
infection are the uterus and mammary glands of females (Babudieri, 1959; Baca and Paretsky, 
1983). 
Goats  
Numerous studies have suggested that epizootics of Q fever in goats are related to outbreaks 
in humans (Desling and Kullberg, 2008; Schimmer et al., 2008; Klassen et al., 2009; Rousset 
et al., 2009a). Indeed in many countries, goats are the most common source of human 
infection due to their extensive raising and close contact with humans (Berri et al., 2007).  
Q fever in goats can induce pneumonia, abortions, stillbirth and delivery of weak kids; the 
latter two clinical signs being the most frequently observed (Berri et al., 2007; Vaidya et al., 
2008; Rousset et al., 2009a). Abortions occur principally nearing the end of the pregnancy 
(Rousset et al., 2009a). The frequency of occurrence of Q fever abortions in goats is more 
important than in sheep with up to 90% of females being affected (Berri et al., 2007). 
Moreover, a study by Berri et al. (2007) reported that successive abortions at two kidding 
seasons can be observed. Similarly to cattle, pregnant animals are more susceptible to 
infection than non pregnant animals (Berri et al., 2007). These animals also frequently 
develop chronic infections with persistence of the bacteria in the uterus and mammary glands 
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(Sanchez et al., 2006). Hormonal changes during pregnancy cause immunomodulation in the 
female body causing reactivation of the organism. This immunomodulation has been 
advanced as an explanation for the increased multiplication of the organism in the placenta 
(Polydourou, 1981). Shedding of C. burnetii by infected goats is discontinuous (Arricau-
Bouvery et al., 2003; Arricau-Bouvery et al., 2005; Berri et al., 2005; Berri et al., 2007; 
Rousset et al., 2009a). In naturally infected goats, shedding seemed to be limited to the 
kidding season following infection (Hatchette et al., 2003). However, an experimental study 
performed by Berri et al. (2007) reported that infected animals can shed Coxiella during two 
successive kidding seasons in vaginal mucus and milk. Moreover, shedding in milk can be 
maintained for a long period (Berri et al., 2005; Berri et al., 2007). Milk has been considered 
the major route of bacteria excretion for this species by several authors (Rodokalis et al., 
2007).  
Sheep 
Sheep have a predisposition for abortion similarly to goats (Hirai et To, 1998; Berri et al., 
2007). However, Q fever in sheep seldom causes chronic infections (Hirai et To, 1998; 
Rousset et al., 2007a; Vaidya et al., 2008). Infected sheep, like goats, shed C. burnetii in 
vaginal secretions, urine and feces and to a lesser extent in milk (Rodokalis et al., 2007). In 
naturally infected sheep, the bacterium has been isolated in vaginal discharges long after 
abortion (Berri et al., 2001) and can be shed at subsequent pregnancies (Berri et al., 2002). In 
the study by Rodokalis et al. (2007), no ewe was found to shed bacteria constantly in milk. 
Some sheep have been found to shed C. burnetii during 11 to 18 days postpartum in feces 
(Marrie, 1990). Most ewe shed bacteria by at least two routes, mainly in feces and vaginal 
mucus (Rodokalis et al., 2007). Rodokalis et al. (2007) reported a flock where no ewe ever 
shed by a single route (no exclusive shedding in milk or feces or vaginal mucus).  
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In certain areas (e.g. Basque country), sheep are an important source of human infections. 
Garcia-Pérez et al. (2009) studied the presence of C. burnetii DNA in BTM and its association 
with seroprevalence. The authors reported a lower seroprevalence in lambs and yearlings 
compared to older ewes. Herds with a history of abortion had a higher seroprevalence than 
other herds but the difference observed was not significant. Flocks with a level of 
seropositivity superior to 30% were more frequently positive on BTM-PCR analysis. 
However flocks with a low number of seropositive animals but with a positive result at BTM-
PCR analysis were also observed in this study (Gracia-Pérez et al., 2009). In France, two 
cases of human Q fever were associated with the use of ovine manure as garden fertilizer. The 
flock of sheep that had provided the manure did not present any clinical signs, despite the 
presence of seropositive animals and excretion of bacteria in feces (Berri et al., 2003). The Q 
fever outbreak that occurred in Bulgaria in 2004 was also associated to infected sheep and 
goats (Panaiotov et al., 2009).  
Pigs 
Natural susceptibility has been demonstrated by the presence of antibodies to C. burnetii in 
their serum (Marmion and Stoker, 1958). However the role played by pigs in the 
epidemiology of Q fever remains unknown (Hirai et To, 1998). 
Cats and dogs 
Cats and dogs can be infected by Q fever and have been associated with human infections in 
rural and urban areas (Mantovani and Benazzi, 1953; Kosatsky, 1984; Marrie et al., 1985; 
Buhariwalla et al., 1996; Marrie et al., 1988a; Marrie et al., 1988b; Marrie et al., 1988c; 
Marrie et al., 1989; Higgins and Marrie, 1990; Pinsky et al., 1991; Mattewman et al., 1997). 
In 1952, Gillepsie and Baker performed successful feline experimental infections by 
subcutaneous inoculation, feeding infected yolk sacs and by contact with infected cats. 
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Despite the presence of pathogen in blood, urine and a serological response, clinical signs 
were not observed in all infected cats. In felines, Q fever is, seemingly, frequently 
asymptomatic and remains undiagnosed. However, infected cats excrete bacteria in the 
environment and become a potential source of human infections. In Japan, cats are widely 
considered to be one of the most important reservoirs of C. burnetii (Komiya et al., 2003). 
The study by Komiya et al. (2003) found that seroprevalence was significantly higher in stray 
cats than in domestic cats. Thus the felines’ environment seems to influence the probability of 
Coxiella infection (Komiya et al., 2003). 
The potential importance of dogs for the transmission of Q fever to humans is rarely 
mentioned. Dogs are however as close, if not closer, to humans as cats. Like other species, 
dogs can potentially be infected by inhalation, tick bites, consumption of placentas or milk 
from infected cows. Buhariwalla et al. (1996) reported three human cases of Q fever 
associated to an infected parturient dog. The puppies all died within 24 hours of birth. Indeed, 
Q fever in parturient dogs has previously been associated with early death of puppies 
(Mantovani and Benazzi, 1953). Similarily to cats, a previous study on dogs in California 
reported a higher prevalence of infection in stray than in domestic dogs (Willeberg et al., 
1980).  
Currently, the effect of infection and its clinical presentation remain poorly investigated in 
felines and canines.  
Horses 
In previous studies, horses have been found to be seropositive toward Q fever (Willeberg et 
al., 1980). Indeed, the study by Willeberg et al. (1980) reported a seroprevalence of 26% 
(31/121) in horses in California. To our knowledge no human case of Q fever has been 
associated with equids. Moreover, Q fever is not investigated routinely in cases of infertility 
or obstetric complications in this species.  
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Wild animals 
At present, wildlife is considered of minor importance for Q fever epidemiology. Many wild 
mammals and birds have been found to be hosts to the infectious organism (Enright et al., 
1971; Riemann et al., 1978; Webster et al., 1995; Hirai and To, 1998; Ruiz-Fons et al., 2008; 
Astobiza et al., 2011). A few cases of transmission of C. burnetii from wild animals to 
humans have been reported but merit further experimental research (Syrucek and Raska, 
1956; Hirai et To, 1998). 
Ticks and other potential vectors 
Among ectoparasites, ticks are considered to be the natural primary reservoir of C. burnetii. 
Over 40 tick species are naturally infected (Cox, 1938; Parker and Davis, 1938; Davis, 1939; 
Cox, 1940; Smith, 1940; Smith and Derrick, 1940; Smith, 1941; Mantovani and Benazzi, 
1953; Pope et al., 1960; To et al., 1995; Ruiz-Fons et al., 2008). Experimental infections have 
been obtained in guinea pigs with Ixodes holocyclus, Haemaphysalis bispinosa, 
Rhipicephalus sanguineus and Dermacentor andersoni. In Europe, Ixodes ricinus is the most 
common tick. Rhipicephalus sanguineus ticks are frequent on dogs (Smith, 1940; Smith, 
1941; AFSSA, 2004). Thus, both these species of ticks could be (or become) reservoirs of C. 
burnetii in Europe. 
Ticks excrete bacteria in saliva and feces. After multiplying in the cells of the midgut and 
stomach of an infected tick, extremely infectious bacteria are deposited onto the animal’s skin 
during fecal excretion. The feces are extremely rich in bacteria and may reach a concentration 
of 1012 organisms per gram (Babudieri, 1959; Lang, 1990). Furthermore, transovarial 
transmission is suspected as bacteria have been isolated in the ovaries of infected ticks 
(Babudieri, 1959). However, despite all these factors, ticks are not thought to contribute to the 
maintenance of coxiellosis in endemic areas (Hirai and To, 1998; Rousset et al., 2007a). 
Indeed, in the study by Astobiza et al. (2011) none of the ticks analyzed were positive when 
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tested by PCR despite the area being endemic for Q fever. Furthermore, in an endemic area in 
Germany, only 3% of Dermacentor spp. were found to be infected (Pluta et al., 2010). 
Nevertheless ticks are suspected of having a significant role in the transmission of C. burnetii 
among wild vertebrates, especially rodents, lagomorphs and wild birds (Babudieri, 1959; 
Lang, 1990; Marie et al., 1986). In addition, Hirai and To (1998) hypothesized that they could 
play a role for transmission of Coxiella from infected wild animals to domestic naïve animals. 
Human infections through tick bites are rarely reported. Sporadic isolations of C. burnetii in 
chiggers, lice and flies have been reported (Cox, 1938; Philip, 1948; Giroud and Jardin, 
1954).  
4.3. Q fever in humans 
The main characteristic of Q fever is its clinical polymorphism (Derrick, 1937; Benenson and 
Tigertt, 1956; Babudieri, 1959). Q fever is therefore considerably underdiagnosed and 
underreported (Gidding et al., 2009). After an incubation period of 1 to 3 weeks (Maurin and 
Raoult, 1999; Watanabe and Takahashi, 2008), Q fever can cause either an acute or a chronic 
disease. Size of the inoculum, geographical area, route and time of infection, as well as host 
factors influence the duration of the incubation period (Benenson and Tiggert, 1956; 
Williams; 1991; Marrie et al., 1996) and may contribute to the clinical expression of acute or 
chronic infection (Babudieri, 1959; Marrie, 1990).  
Acute Q fever 
In the acute form, infections can be totally asymptomatic in 50 to 60% of cases or cause a 
self-limiting illness associated with fever, fatigue, headache and myalgia (influenza-like 
syndrome). When clinically expressed, acute fever is frequently accompanied by atypical 
pneumonia and/or hepatitis.  Pneumonia is an important manifestation of Q fever in humans 
(Derrick, 1937; Benenson and Tigertt, 1956; Babudieri, 1959). It is uncommon in Australia 
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and some parts of Russia, whereas in North America and Europe it is the major manifestation 
of infection (To et al., 1996; Okimoto et al., 2004). Pneumonia is typically mild but 
progression to acute distress syndrome can occur (Hartzell et al., 2007; Okimoto et al., 2007; 
Watanabe and Takahashi, 2008). Endocarditis can exceptionally be associated to acute 
infection in 0.76 % of cases (Fenollar et al., 2001; Fenollar et al., 2006). In pregnant women, 
Q fever can lead to spontaneous abortion, intrauterine fetal death (IUFD), premature delivery 
or intrauterine growth retardation. Transplacental infection of the fetus in utero has also been 
reported (Raoult and Stein, 1994; Kaplan et al., 1995; Raoult et al., 2002). Moreover, 
Carcopino et al. (2007) found that Q fever was significantly associated with oligoamnios, 
which is a recognized cause of neonatal morbidity and mortality (Barss et al., 1984; Moore et 
al., 1989). One case of endocarditis has been reported in a pregnant women with a 
bioprosthetic aortic valve and lead to maternofetal death at 27 weeks’ gestation (Carcopino et 
al., 2007). Infection during the first trimester of the pregnancy is particularly associated with a 
negative outcome (Carcopino et al., 2007; Raoult et al., 2002). After infection, breast feeding 
is of course contraindicated (Raoult et al., 2002).  
Mortality rate of acute Q fever is estimated of 1 to 2% (Tissot-Dupont et al., 1992; Delsing 
and Kullberg, 2008; Watanabe and Takahashi, 2008). Myocarditis, occurring in less than 1% 
of cases, is the first cause of death (Fournier et al., 2001). As yet, myocarditis has not been 
reported in pregnant women (Carcopino et al., 2009). 
Chronic Q fever 
Chronic Q fever consists in the persistence of infection for more than 6 months. Chronic Q 
fever concerns 5% of infected individuals (Fournier et al., 1998). Most commonly, 
endocarditis is observed in 60-70% of cases of chronic infections (Fenollar et al., 2004), but 
chronic hepatitis, osteomyelitis, septic arthritis, interstitial lung disease, and infection of 
aneurysm or vascular grafts can also occur (Derrick, 1937; Benenson and Tigertt, 1956; 
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Babudieri, 1959). Q fever-associated endocarditis has been estimated to be responsible for 3 
to 5 % of all cases of human endocarditis (Fenollar et al., 2001; Parker et al., 2006). 
Individuals with underlying valvulopathy or other cardiovascular abnormalities are 
predisposed to the development of endocarditis (Fenollar et al., 2001; Fenollar et al., 2006). 
Over recent years the occurrence of rare clinical manifestations such as osteomyelitis, optic 
neuritis, pericarditis, lymphadenopathy and Guillan-Barre has significantly increased. 
Meningitis, encephalitis, polyradiculonevritis, peripheral neuropathy, cranial nerve 
deficiency, optic neuritis and paralysis of the oculomotor nerve have been reported in 3.5% of 
infected patients. The main clinical signs in neurological cases are headaches, behavioral 
problems, cognitive deficiency or confusion. Convulsions and even epileptic fits and aphasia 
are possible (Schuil et al., 1985; Shaked et al., 1989; Bernit et al., 2002). In pregnant women, 
chronic Q fever can lead to spontaneous abortions in future pregnancies (Raoult and Stein, 
1994; Stein and Raoult, 1998; Langley et al., 2003). The prognosis of chronic infections is 
less favorable than for acute infections (Watanabe and Takahashi, 2008). Antibiotic treatment 
is less effective and the disease is usually long with mortality rates that can reach more than 
50% (Watanabe and Takahashi, 2008).  
Q fever in children 
In children Q fever is thought to be rare. This could be explained by frequent asymptomatic or 
nonspecific presentations of infection leading to undiagnosed cases of Coxiella infection. 
Cases of hepatitis and pneumonia have however been reported in children and can be fatal (To 
et al., 1996; Kuroiwa et al., 2007). In Northern Ireland, McCaughey et al. (2008) reported a 
seropositivity rate inferior to 10% in children. The seropositivity rate increased markedly 
during the late teenage years and especially in young adults (McCaughey et al., 2008). 
Increased exposure with age is a plausible hypothesis to explain this phenomenon. 
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Post-illness follow-up 
The study by Limonard et al. (2010) on follow-up of patients after the Q fever outbreak in the 
Netherlands, reported fatigue in 52% of patients 6 months post-illness and in 26% one year 
post-illness. They reported very high level of anti-phase I and anti-phase II antibodies up to 3 
months after onset of disease, then a gradual decrease in the following 9 months. Post-Q fever 
chronic fatigue syndrome is also reported (Hickie et al., 2006; Delsing and Kullberg, 2008; 
Marmion et al., 2009). This syndrome has been attributed to dysregulation of cytokine 
production, induced by persistent antigens including LPS and proteins, rather than persistent 
latent Coxiella (Marmion et al., 2009). 
5. ANIMAL MODELS FOR HUMAN Q FEVER 
Animal models for human infection are commonly laboratory mice and guinea pig models. 
Guinea pigs are regarded as a model of acute Q fever in humans (La Scola et al., 1997). On 
the contrary to guinea pigs, mice develop a chronic infection, although endocarditis doesn’t 
occur in normal adult mice. They remain chronically infected for months and excrete bacteria 
in feces and urine. Their susceptibility to infection varies in function of the mouse strain 
(Scott et al., 1987). Gonder et al. (1979) and Waag et al. (1999) reported a successful 
infection by aerosol route in cynomolgus and rhesus macaques. Post-infection, the macaques 
developed fever and pneumonia after 4 to 7 days. Their clinical expression of Q fever is thus 
unsurprisingly the closest to human clinical expression.    
6. PREDISPOSITIONS  
Recent experimental data indicates that host factors rather than specific genetic bacterial 
determinants are the main factors influencing the clinical course of C. burnetii infection (Yu 
and Raoult, 1994; La Scola et al., 1998; Raoult et al., 2005; Parker et al., 2006).  
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In humans, Q fever is mainly considered an occupational hazard. A study by Whitney et al. 
(2009) on 508 American veterinarians reported a prevalence rate (22.2%) far superior to the 
prevalence rate in the general adult US population. Veterinarians from a mixed or large 
animal practice were significantly more likely to be seropositive than veterinarians from a 
small animal practice. Furthermore, living on a farm, in the past or present, increased the 
probability of being seropositive for coxiellosis. Absence of protective clothing or mask, 
occupational risks (accidental cuts, needle sticks), and routine contact with water were also 
demonstrated as significant risk factors for infection (Whitney et al., 2009). Mc Quinston and 
Childs (2002) reported a seroprevalence of 7.8% among American veterinarians, farmers, 
slaughterhouse workers, and tannery workers. Furthermore, a Northern Irish study reported a 
seropositivity rate significantly higher among farmers than in the general population 
(P<0.001) (McCaughey et al., 2008).  
On the contrary to countries where cats are the main reservoir of C. burnetii where no sex 
predisposition is reported, men between 30 and 70 years of age are the most frequently 
affected by clinical Q fever in countries where cattle are considered the main reservoir 
(Davies et al., 1997; Montejo et al., 1985; Tellez et al., 1988; Sanzo et al., 1993; Spelman, 
1982; Thomas et al., 1994; Thomas et al., 1995). The study by Raoult et al. (2005) reported 
that being a male and over the age of 15 increased the risk of symptomatic disease. In 
Australia and France, males are 5-fold and 2.5-fold more likely than females to develop 
disease, respectively (Parker et al., 2006). In Northern Ireland, McCaughey et al. (2008) also 
reported a significantly higher seroprevalence in males than in females (P=0.023). 
Endocarditis is more frequently observed in men over 40 years of age (Brouqui et al., 1993). 
Although the precise reason for this difference remains unknown, it has been suggested that 
sex hormones play a role (Raoult et al., 2005; Parker et al., 2006). Indeed, Leone et al. (2004) 
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reported a protective role of 17beta-oestradiol towards Q fever infection rendering females 
more resistant.  
Immunocompromised hosts, pregnant women, people with heart valve lesions, vascular 
abnormalities, liver cirrhosis and cancer are more susceptible to developing chronic Q fever 
(Raoult et al., 2000; Fenollar et al., 2006). In the study by Carcopino et al. (2007), 52.8% of 
the pregnant women with acute Q fever developed chronic serologic profiles. However, 
suprisingly, in a comparative study on clinical expression and outcome of Q fever after the 
outbreak in Chamonix Valley in France, pregnant women were found to be significantly less 
frequently symptomatic than other women and other patients (9.1% women were 
symptomatic versus 90.6% of men, 75% women and 33.3% children) (Tissot-Dupont et al., 
2007).  
7. TREATMENT 
In non-pregnant women and other patients with acute Q fever, treatment consists in a daily 
dose of 200 mg doxycycline for 14 to 21 days. Hydroxychloroquine can be associated to 
doxycycline. Hydroxychloroquine increases the pH of the phagolysosomes and its association 
with doxycycline has a bacteriocidal effect (Maurin et al., 1992; Raoult et al., 1999). 
Rifampin, erythromycin, clarithromycin and roxithromycin can also be used as an alternative 
treatment (Gikas et al., 2001; Tissot-Dupont and Raoult, 2007). Fluoroquinolones are 
recommended in cases of meningoencephalitis as their penetration into the central nervous 
system is better compared to doxycycline. Mentioned previously, treatment with IFNγ has 
proven effective in certain cases (Morisawa et al., 2001; Maltezou and Raoult, 2002).  
Treatment of chronically infected patients consists in a daily dose of 200mg of doxycycline 
associated with 600mg of hydroxychloroquine for duration of 18 to 36 months. The dosage of 
hydroxychloroquine is adjusted three months after initiation of treatment to obtain a plasmatic 
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level of 1±0.2mg/l (Maurin et al., 1992). During the treatment, an ophthalmologic follow-up 
is recommended every 6 months to detect accumulation of hydroxychloroquine in the retina. 
Rolain et al. (2003) advised a plasmatic concentration of 5mg/l of doxycycline for effective 
treatment. Minimal Inhibition Concentration (MIC) for doxycyline against C. burnetii varies 
from 1 to 4 μg/ml (Raoult et al., 1999). Bacterial resistance to doxycycline has been observed 
by Rolain et al. (2005a,b) in a patient with endocarditis. Thus, serological testing on a regular 
basis to evaluate response to treatment is advised. It is considered that an anti-phase I IgG titer 
inferior to 200 is predictive of a clinical cure (Karakpusis et al., 2006). A decrease of 2 
dilutions in antibody titers in one year at the minimum signifies successful evolution (Raoult 
et al., 1999). 
In infected pregnant women, administration of long-term cotrimoxazole (320 mg 
trimethoprim and 1600 mg sulfamethoxazole for at least 5 weeks), a bacteriostatic antibiotic, 
is advised (Carcopino et al., 2007). After delivery, a daily treatment with 200 mg of 
doxycycline associated with 600 mg of hydroxychloroquine for 1 year minimum is advised 
for chronically infected women. The study by Carcopino et al. (2007) reported that long-term 
cotrimoxazole therapy significantly reduced the number of obstetric complications, the 
frequency of placentits, and the development of a chronic serological profile. In their study, 
no IUFD was observed in treated women (0% versus 27% of IUFD in non treated women). 
The only complications reported were intrauterin growth retardation and premature delivery. 
No spontaneous abortions and no oligoamnios occurred (Carcopino et al., 2007). 
 8. DIAGNOSTIC METHODS  
8.1. Direct diagnosis 
Direct diagnostic methods identify the presence of the bacterium or of one of its components. 
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Coloration and direct visualization 
Direct visualization of C. burnetii on smears or frozen tissue is a method of Q fever diagnosis. 
Smears are taken from the placenta of aborted ruminants, from the fetus’s stomach content or 
from other body tissues. C. burnetii doesn’t stain reliably with Gram stain and Gimenez stain 
is preferentially used (Gimenez, 1964). A Stamp-Macchiavello coloration, commonly called 
Macc staining, or routine Giemsa stain can also be performed. The specificity and sensitivity 
of direct visualization by bacterioscopic examination is poor, due to possible confusion with 
other pathogens such as Brucella spp., Chlamydophila spp. or Chlamydia spp. (Fournier et al., 
2003).  
Immunohistochemistry (IHC) 
IHC has been performed for the diagnosis of chronic cases of Q fever. It can be utilized for 
detection of C. burnetii in tissues fixed in paraffin or acetone smears (Raoult et al., 1994). 
Dilbeck and McElwain (1994) developed an avidin-biotin-peroxidase complex IHC staining 
method for diagnosis and routine screening of ovine and caprine placental tissues after 
abortion. This technique is rapid and does not necessitate live bacteria or fresh tissues for 
diagnosis. Furthermore, it renders retrospective studies on stored samples possible.  
Bacterial culture 
In vitro cell culture of the bacteria is the gold standard for diagnosis of bacterial infections. C. 
burnetii can be cultured efficiently in the yolk sac of chicken embryos  but also on diverse 
specimens, such as human embryonic lung fibroblasts, blood, cerebrospinal fluid, bone 
marrow, milk, etc. (Baca and Paretsky, 1983). However, technically, culture of C. burnetii 
remains a difficult process and sensitivity of this diagnostic method is low. Recently, C. 
burnetii can be grown outside a host cell in a cell-free laboratory medium (Omsland et al., 
2009). This finding is revolutionary and will permit further studies on C. burnetii. Another 
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practical limitation to bacterial isolation is that it requires a Biosafety Laboratory 3 because of 
its high infectivity. As a result, culture is rarely performed, especially in veterinary medicine 
(Fournier et al., 1998).  
Polymerase Chain Reaction (PCR) 
PCR offers substantial benefits for the identification of C. burnetii compared to other 
laboratory techniques, especially in the early clinical stages of the illness (Fournier and 
Raoult, 2003; Frangoulidis et al., 2009). It has been successful in detecting C. burnetii DNA 
in various samples, including cell cultures, biopsy samples, blood, arthropods and serum 
samples (Fenollar et al., 2004; Ughetto et al., 2009). Its sensitivity and specificity are high. 
However, the usefulness of conventional PCR is limited by its inability to quantify the 
bacteria present. The development of Real Time Quantitative PCR (RTq PCR) not only 
renders PCR a rapid diagnostic tool but also provides quantifiable information. RTq PCR can 
be automated and thus can be used in large scale studies. The qualities of PCR make it very 
useful for early diagnosis of infection during the period when antibodies are not yet present 
(Fournier and Raoult, 2003). Several primers are available for diagnosis (Stein and Raoult, 
1992; Willems et al., 1994; Frangoulidis et al., 2009; Schneeberger et al., 2009). A primer 
originating from the frequently repeated DNA sequence IS1111 (7 to 120 copies per genome) 
is commonly used and has proven to allow very sensitive testing (Frangoulidis et al., 2009; 
Schneeberger et al., 2009). In a study by Schneeberger et al. (2009), C. burnetii DNA was 
detected in 98% of seronegative acute Q fever patients and in 90% of anti-phase 2 IgM 
seropositive patients. PCR became progressively negative as the serological response 
developed (Schneeberger et al., 2009). Hou et al. (2011) noticed a significant association 
between the absence of IgM antibodies and a positive PCR result. Negative serology was 
most frequent in Q fever cases where sampling had been performed within the two weeks of 
illness. In such cases, the authors recommend routine PCR testing as well as serology. When 
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PCR was included in the diagnostic procedure primarily based on serology, a marked increase 
of sensitivity was observed (78% versus 29% when serology was used as unique diagnostic 
method) (Hou et al., 2011). PCR and RTq PCR are considered methods of choice for DNA 
detection in diverse samples (Beaudeau et al., 2006). However, they are currently only 
available in a limited number of laboratories (Fournier and Raoult, 2003). Furthermore, PCR 
and RTq PCR are incapable of distinguishing bacterial DNA from live and/or dead bacteria 
(Kramer et al., 2009). The advantage is that sampled tissues can be frozen, put into formalin 
or fixed with paraffin (Fournier and Raoult, 2003). The disadvantage is that interpretation of 
positive results in fresh samples can be difficult (Tatsumi et al., 2006; Watanabe and 
Takahashi, 2008). PCR kits are gradually becoming available (Arricau-Bouvery and 
Rodokalis, 2005).  
8.2. Indirect diagnosis 
Indirect diagnostic methods identify specific humoral or cellular immunity in response to C. 
burnetii infection. The diagnostic methods available in human and veterinary medicine differ. 
Complement Fixation Test (CFT) 
In veterinary medicine, CFT was the method of reference for serological diagnosis according 
to OIE (Herr et al., 1985; Peter et al., 1985; AFSSA, 2004). CFT usually utilizes phase 2 
antigens only (Krt, 2003; AFSSA, 2004). It is capable of detecting approximately 65% of 
infected subjects during the second week after initial clinical signs and 90% during the fourth 
week (OIE, 2005). CFT is more laborious, less specific and less sensitive than indirect 
immunofluorescence assay (IFA) (Fournier et al., 1996) or ELISA (described hereafter) 
(Fournier et al., 1998). A study by Rousset et al. (2007b) on goats originating from different 
herds reported that CFT results obtained on sera of aborting goats and of non-aborting goats 
were not significantly different and confirmed the lack of sensitivity of CFT compared to 
Introduction 
 
75 
 
ELISA. CFT, on the contrary to ELISA, is incapable of detecting all IgG subclasses. In 
ruminants, only IgG1 fix the complement and can thus be detected by CFT. Moreover, IgG2, 
IgM and anti-complement substances potentially present in sera are capable of interfering 
with fixation of IgG1 to the complement lowering the titer of IgG1 detected by CFT. Rousset 
et al. (2007b) advised not to use CFT for serological animal screening because of its low 
sensitivity.  
Enzyme-Linked Immunosorbent Assay (ELISA) 
Another method of diagnosis for human and animal cases is ELISA. This method is more 
sensitive, easier to perform and to standardize than CFT (Fournier et al., 1998). Moreover, a 
strong association was reported between strongly positive ELISA results and the occurrence 
of abortion in goats (Rousset et al., 2007b). As mentioned above, the higher sensitivity of 
ELISA compared to CFT could be due to the detection of the IgG2 subclass of antibodies, 
which are incapable of binding to the guinea pig complement (Krt, 2003). Commercially 
available human ELISA kits are frequently coated by phase 1 and phase 2 antigens. The 
antigens present are of two possible origins: antigens of the American Nine Mile strain of C. 
burnetii isolated from an endogenous tick, or antigens of a strain originating from infected 
European domestic ruminants. ELISA kits coated by the latter antigens are more sensitive and 
are advised for serological diagnosis (ACERSA, 2006). In France, the ELISAs available for 
veterinary diagnostic purposes do not differentiate anti-phase 1 and anti-phase 2 antibodies 
but detects total antibodies (AFSSA, 2004). ELISA tests can be automated which facilitates 
large scale studies (Rousset et al., 2007b).  
Immunofluorescence assay (IFA)  
In human medicine, IFA is commonly considered the reference diagnostic test and is the most 
frequently used worldwide (AFSSA, 2004). It is accurate, highly sensitive and specific 
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(Fournier et al., 1996). The study by Rousset et al. (2007b) on goats demonstrated an overall 
good agreement between IFA and ELISA results. The study also reported that IFA results 
obtained on sera of aborting goats and of non-aborting goats were significantly different and 
were associated with occurrence of abortion (Rousset et al., 2007b). Moreover, IFA is capable 
of detecting the two antigenic variants of C. burnetii (phase I and phase II). As mentioned 
previously, in acute infections the level of anti-phase II antibodies is higher than the level of 
anti-phase I antibodies. In chronic infections the reverse is observed (Fournier et al., 1998). 
As anti-phase II antibodies are present in all stages of infection, screening for epidemiological 
purposes is based on the detection of anti-phase II antibodies (Rousset et al., 2007b). Cross-
reactions with Legionella micdadei and Bartonella have been reported but do not cause any 
problem for the interpretation of quantitative results (Musso and Raoult, 1997; La Scola and 
Raoult, 1996). In human medicine, IFA distinguish IgG and IgM. Titers of anti-phase II IgG 
superior or equal to 200 and of anti-phase II IgM superior or equal to 50 correspond to an 
acute infection with a predictive value of 100%. An isolated high titer of IgM (≥ 50) can 
correspond to the beginning of an acute infection as long as the possibility of a false positive 
can be rejected. A chronic infection is characterized by a high titer in anti-phase I IgG (≥800) 
with a predictive value of 98% for a titer of 800 and a predictive value of 100% for a titer of 
1600 (Dupont et al., 1994). The preferential use of IFA instead of CFT in veterinary medicine 
would be advantageous for diagnosis and control of Q fever at animal level (AFSSA, 2004).  
Skin test 
A skin test method was proposed to investigate the cellular response and to improve detection 
of infected animals at herd level (Guatteo et al., 2008b). The skin test consists in an 
intradermal injection of extremely diluted inactivated vaccine (Coxevac®, CEVA-Santé 
animale, Libourne, France). The diluted vaccine induces an antigenic reaction. If the animal 
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has previously been infected by Q fever a nodule of variable size will appear at the site of 
injection. This test could easily be applied by rural practitioners.  
Negative aspects of indirect diagnostic methods 
The dependence of CFT, IFA and ELISA on the presence of antibodies limits their diagnostic 
value. Indeed, specific antibodies are often absent during the first 2 to 3 weeks of illness, 
making early diagnosis by serology difficult, if not impossible (Kuroiwa et al., 2007). In Q 
fever, phase II antibodies can be detected within two weeks of infection in most cases and 
within three weeks 90% are seropositive. AFSSA (2004) reports that a definitive diagnosis of 
human cases by IFA can only be confirmed one month and a half after the initial clinical 
signs. Cellular immunity also necessitates time before becoming detectable but the use of skin 
testing at herd level prevents it being a problem as different stages of infection are present 
simultaneously in the herd. None of these tests are capable of confirming an etiological 
diagnosis at an individual level. Moreover, in acute infections, rheumatic factor, anti-
mitochondrial antibodies, anti-nuclear antibodies, anti-smooth muscle antibodies, anti-
cardiolipin and lupus-anticoagulant and other autoantibodies often present a marked increase 
in their plasmatic levels and can interfere with diagnostic assays (Vardi et al., 2011). A high 
prevalence of IgM against Epstein-Barr virus, cytomegalovirus, parvcovirus, Bordetella 
pertussis and Mycoplasma pneumonia has also been detected. Vardi et al. (2011) concluded 
that diagnosis should not rely on a unique diagnostic approach. The global clinical and 
epidemiological context must be taken into account as well as the limitations of diagnostic 
assays. Bacteriological analyses are necessary to confirm or infirm any suspicion of Q fever 
(Rousset et al., 2007b). 
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8.3. Diagnosis by histopathology 
In acute cases of hepatitis, the presence of doughnut granulomas can be visualized in 
histopathology hepatic specimens but there are not pathognomonic of Q fever. However, in 
chronic infections, granulomas are less organized but bacteria can be detected in larges 
vacuoles (Fournier et al., 1998). As mentioned above, in bovids, placentitis was found to be 
significantly associated with C. burnetii infection (Bildfell et al., 2000). On microscopic 
examination, an increased number of mononuclear cells (macrophages, lymphocytes, plasma 
cells) can be identified in the chorionic stroma. Increased stromal collagen is also frequently 
observed. Furthermore, placental necrosis is significantly associated with the presence of C. 
burnetii. Chorionic epithelial cells and villus tips are the most frequently affected. Infected 
trophoblasts are distended and contain basophilic granular to foamy material. The cytoplasms 
of infected cells appear bright red with the Macc stain and their nuclei are commonly 
eccentric. A modified Koster’s modified acid-fast (MAF) staining of fresh placenta smears is 
considered a good screening test but confirmation by immunohistochemical techniques 
remains necessary (Bildfell et al., 2000). In endocarditis lesions, C. burnetii are visible as a 
voluminous intra-cytoplasmic mass within infected mononuclear cells (Brouqui et al., 1994).  
9. CONTROL METHODS AND VACCINATION 
In the case of a Q fever outbreak, sanitary and prophylactic measures should be applied at 
herd and human level, in order to limit disease transmission. Human and animal infections 
must be diagnosed early and treated immediately to prevent the development of chronic 
infections and secondary complications. Q fever being a zoonosis, prophylaxis at herd level is 
fundamental.  
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Control methods 
In the Netherlands, spread of manure from infected herds is forbidden for at least 90 days 
after suspicion of infection (Schimmer et al., 2008). The effectiveness of this measure must be 
evaluated and modified if necessary. This measure, or its modified equivalent, should be 
applied worldwide if its effectiveness is proven. Transport of animals in and from infected 
areas are strictly controlled and restricted to days without wind.  
In France, when Q fever has been diagnosed in a herd on a cheese producing farm, milk of the 
aborted females must be discarded. Indeed, sale, transformation and treatment of this milk are 
strictly forbidden (AFSSA, 2007). Milk of the remainder of the flock can be used for 
transformation, unless it is highly suspected that dairy products originating from these animals 
are dangerous for human consumption. In the latter case, the milk must be pasteurized at 72°C 
during 15 minutes or by an equivalent thermal treatment (Cerf and Condron, 2006; AFSSA, 
2007). If Q fever is diagnosed on a farm producing raw milk for direct human consumption, 
sale of milk is forbidden during one year after the initial diagnosis of Q fever in an animal 
(AFSSA, 2007).  
In the United Kingdom, Health Protection Agency guidelines suggest the use of 2% 
formaldehyde, 1% Lysol, 5% hydrogen peroxide, 70% ethanol, or 5% chloroform for 
decontamination of surfaces, and spills of contaminated material should be dealt with 
immediately using hypochlorite, 5% peroxide or phenol-based solutions (Health Protection 
Agency, 2010 at www.hpa.org.uk/deliberate_accidental_releases/biological). However, the 
guidelines note than decontaminating a large surface area is impossible. Moreover, Scott and 
Williams (1990) found that formaldehyde vapour was ineffective in the absence of a high 
relative humidity. High risk material (contaminated bedding, placenta, aborted fetuses) should 
be buried with lime or incinerated. Treatment of manure with lime or calcium cyanide is also 
recommended before spreading and spreading must be performed on a calm day. 
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At human level, prevention of exposure to animals or wearing gloves and masks during 
manipulation of animals or their litter is advised (AFSSA, 2004; Whitney et al., 2009). Post 
exposure prophylaxis guidelines for the general population have been established in the USA 
(United States Army Medical Research Institute for Infectious Diseases, 2004; Moodie et al., 
2008). Doxycycline at a dose of 100 mg a day or 500 mg of tetracycline twice daily started 8-
12 days post exposure is advised. No recommendation is available for pregnant women 
although cotrimoxazole has been suggested (United States Army Medical Research Institute 
for Infectious Diseases 2004; Moodie et al., 2008).   
Pasteurization of all milk products should be performed if ingestion is proven an effective 
route of infection and after determination of the minimal infecting dose of bacteria. Awaiting 
further scientific research, caution is recommended especially for individuals at high risk of 
chronic infection. 
Currently, antibiotic treatment of animals does not stop shedding (Astobiza et al., 2010). 
Vaccination 
Rodokalis et al. (2007) suggested a follow up of bovine and caprine herds by BTM analysis. 
In herds presenting a PCR-positive BTM result, pools of 10 individual milk samples should 
be tested by PCR to identify the shedding animals. If shedders are not very numerous, they 
can be eliminated, and the other animals should be vaccinated. Rodokalis et al. (2007) also 
suggested vaccination of herds in the proximity of infected herds or flocks.  
In animals, vaccines considered the most effective are composed of inactivated whole phase 1 
bacteria (OIE, 2005). Indeed, in goats, the inactivated phase I vaccine (Coxevac®, CEVA-
Santé animale, Libourne, France) protects efficiently against abortion and has been shown to 
prevent bacterial shedding in vaginal mucus, feces and particularly in milk. However, 
vaccination proved more effective in nulliparous animals than in parous animals. 
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Furthermore, vaccination didn’t clear infection in previously infected goats (Arricau-Bouvery 
et al., 2005; Rousset et al., 2009b; Hogerwerf et al., 2011). 
The study by Guatteo et al. (2008) on dairy cattle reported that the probability of becoming a 
shedder for vaccinated naïve non-pregnant bovids was 5-fold inferior to the probability for 
naïve bovids receiving a placebo. However, vaccination had no effect on the bacterial load 
shed. Vaccination of previously infected animals and of naïve animals during pregnancy 
proved ineffective. Guatteo et al. (2008) hypothesized that the immunodepression induced by 
pregnancy was responsible for the lack of effective immune response after vaccination. This 
explanation seems plausible but a second study is necessary to reach confirmation of this 
hypothesis. No adverse effect was observed at the site of injection in this study. One abortion 
was reported in a vaccinated infected cow but no further investigations were performed on 
this animal except for a PCR on vaginal mucus at the time of abortion that gave a negative 
result.  
The major problem associated to vaccination with inactivated phase 1 vaccine is the 
impossibility of distinguishing vaccinated and naturally infected animals. At herd level, the 
effectiveness of a vaccination program could be evaluated by monitoring bacterial shedding in 
BTM. Currently, prophylaxis includes vaccination with the non-fully licensed inactivated 
phase I vaccine, Coxevac® (CEVA-Santé animale, Libourne, France), when a focus of Q 
fever is declared. This vaccine contains formalin-inactivated C. burnetii strain RSA 493/Nine 
Mile phase I (CEVA, 2010 at www.ceva.com/en/Products/Cattle/Vaccines). A recent study by 
New vaccines, such as recombinant vaccines, have been developed (Zhang and Samuel, 
2003). Several of these vaccines have proven to be antigenic but non protective. Others still 
require an investigation of their effectiveness in field conditions (Waag, 2007). An inactivated 
phase II vaccine, Chlamyvax FQ® has also been tested on animals but has failed to be 
effective (Arricau-Bouvery et al., 2005). In France, Chlamyvax FQ® was used in 2004-2005.  
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Vaccination of humans against Q fever could be effective in certain areas. Several different 
vaccines have been developed since the discovery of C. burnetii. In the Soviet Union in the 
1960s, a live attenuated strain M-44 obtained after repeated passage through guinea pigs and 
mice was used extensively for vaccination. Because of the long-term persistence of the 
attenuated bacteria in animals and vaccinated human, this vaccine was never used in the West 
(Marmion, 1967). The Americans developed a chloroform-methanol residue vaccine based on 
the phase I Henzerling strain of C. burnetii (Fries et al., 1993). Despite being effective in 
protecting animals against aerosol challenges, humans were found to develop severe reactions 
to vaccination (Fries et al., 1993). A trichloroacetic acid extract of phase I Nine Mile strain 
which comprised proteins and LPS was also used for vaccination. However, Kazar et al. 
(1982) reported severe reactions in response to vaccination in humans. Vaccinating with 
phase I Nine Mile extracts treated with chloroform-methanol prevented severe reactions but 
the loss of protective immunogenicity rendered these vaccines ineffective (Williams and 
Cantrell 1982; Brooks et al., 1986; Kazar et al., 1987; Schmeer et al., 1987). Currently, a 
formalin-killed whole cell vaccine prepared from phase I Henzerling strain of C. burnetii 
(Qvax®, CSL Limited, Parkville, Victoria, Australia) is licensed in Australia (OIE, 2005). 
This vaccine proved effective in several studies (Ackland et al., 1994) but vaccination is only 
possible for individuals that haven’t previously been in contact with C. burnetii to prevent 
serious reactions (Bell et al., 1964; OIE, 2005; Rousset et al., 2007a). Screening is thus 
required before vaccination (Ascher et al., 1983; Marmion et al., 1990), making this 
preventive measure time-consuming and costly. Gefenaite et al. (2011) performed a meta-
analysis of previous studies on the effectiveness of Qvax® vaccine. All the studies included in 
their analysis reported a protective effect of vaccination (average effectiveness after pooling 
raw data: 97%, CI: 94-99%). However several biases were present in the latter studies. 
Gefenaite et al. (2011) concluded that generalization of the results to the general population or 
to a specific risk group was not possible. The authors advised more blinded, randomized and 
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unbiased research on Qvax®’s effectiveness. Development of recombinant protein subunit 
vaccines has proven disappointing (Zhang et al., 1994; Zhang and Samuel, 2003; Li et al., 
2005; Tyczka et al., 2005). Before initiating a vaccination program, epidemiological 
knowledge of the area is necessary. Indeed, in endemic regions vaccination is impossible for 
practical reasons (screening) and non effective as a preventive measure. However, vaccination 
could be beneficial for at risk individuals such as pregnant or immunocompromised 
individuals, farmers, veterinarians, abattoir workers, and research and reference laboratory 
personnel in contact with C. burnetii (OIE, 2005). Availability of vaccines causes a real 
problem in most countries and vaccination is currently not performed in Europe.  
10.  OUTBREAK IN THE NETHERLANDS 
The Netherlands has been confronted with a Q fever outbreak since 2007. In 2009, infected 
goats were at the origin of 2,361 human cases of Q fever (including six deaths) diagnosed in 
the Netherlands (Enserink, 2010). Most cases were diagnosed in the Noorth Brabant Province. 
A recent increase in high intensity dairy goat farming has lead to development of very large 
densily populated farms: from 100,000 goats in 2000 to 230,000 goats on approximately 350 
farms in 2009 (Roest et al., 2011b). Transport of animals, manure spreading and wind have 
been reported as influential factors for humans infections. In a study by Karagiannis et al. 
(2009) on the outbreak in 2007 in the Netherlands, living east of the area in which a positive 
goat farm, cattle or small ruminants were situated, smoking and contact with agriculture 
products were found to be associated with recent infection. Scientists suspected the 
emergence of a more virulent subtype of C. burnetii than the initial subtype of bacterium 
identified in 2007 in the Netherlands (Klassen et al., 2009; Enserink, 2010). Genomic studies 
reported that multiple genotypes were involved in the Q fever outbreak. However, an identical 
subtype was identified in a dairy goat herd suffering from multiple abortions and in several 
human patients (Klassen et al., 2009). This particular subtype could thus have a survival and 
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propagation advantage compared to other bacterial subtypes (Klassen et al. 2009; Enserink, 
2010). Roest et al. (2011a) performed multiple locus variable tandem repeat analyses on a 
large number of Q fever positive samples originating from domestic ruminants and associated 
with the outbreak. Their study found that one genotype predominated on all dairy farms in the 
southern part of the Netherlands. Indeed, on 12 out of 14 dairy goat farms, this genotype was 
found in 91% of samples, varying from 33% to 100%. Nine other genotypes occurred once, 
each representing only 0.8% of all found genotypes on the farms. The predominant genotype 
was found on 11 farms in the southern Netherlands and on a farm in the eastern part of the 
country. This suggests a clonal spread of C. burnetii with this predominant genotype. 
However, another study by Huijmans et al. (2011) found five distinct genotypes (3 in humans 
and 4 in livestock) implicated in the outbreak and concluded that environmental factors such 
as animal and human density and climate, rather than one particularly virulent strain favored 
the Dutch outbreak and its spread. Control measures were put in place following the 2007 
outbreak. Vaccination of goats with Coxevac® vaccine on voluntary grounds began in 2008. 
Vaccination was exclusively performed in areas of the human outbreak. In 2009, vaccination 
of all dairy sheep and goats on farms with more than 50 animals became mandatory and area 
of vaccination was enlarged (Noorth-Brabant province and parts of adjacent provinces). 
Moreover, BTM testing was performed. A farm was considered infected when 2 consecutive 
BTM samples were positive by PCR. However, Hermans et al. (2011) reported the presence 
of bacterial DNA originating from the Coxevax® vaccine in goat milk after inoculation. C. 
burnetii DNA was detectable until 9 days post vaccination in quantities estimated by PCR up 
to approximately 100 genome equivalents per ml. The quantity of DNA detected in their study 
was around detection level. After the booster, the duration of vaccine-derived DNA excretion 
was shorter, quantitatively lower and detectable in fewer animals than after the first 
inoculation. This finding induced the modification of the Dutch control strategy. After this 
study, a two week interval between vaccination and BTM testing was imposed (Hermans et 
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al., 2011). In addition to these control methods, movement and breeding were banned for 
dairy goats and sheep on infected farms (Hogerwerf et al., 2011). Culling of all pregnant goats 
and sheep on these farms was also in application until May 2010.  
11.   PERSPECTIVES FOR THE FUTURE 
A better knowledge of Q fever would allow better control and prevention of the disease in the 
future.  
A better understanding of the bacterium and of its pathogenesis (entry into the cell, 
“sporulation-like” phenomenon, metabolism, mechanism of resistance to acidic conditions, 
infectivity of the bacterium, etc.) is essential. The immune response of the infected host must 
also be investigated further. The risk factors for illness must be determined (infectious dose, 
potential danger linked to pets or not, etc.). Moreover, studies are required to define more 
precisely the incidence, clinical spectrum, treatment, morbidity, and mortality associated with 
Q fever in children. Further studies on risk factors could confirm or contradict results of 
previous studies, such as the studies by Whitney et al. (2009) and Mc Caughey et al. (2008). 
Oral transmission of Q fever remains a controversial subject to this day. Further research is 
essential for the establishment of guidelines in case of an epidemic. Importantly, a high 
standard of laboratory diagnostic methods should be available in all accredited laboratories 
and a systematic search for C. burnetii should be performed when clinical signs render the 
individual or animal suspected of Q fever. New guidelines for general practitioners and 
gynecologists should be established to increase the rapidity of diagnosis of clinical Q fever. 
Moreover, guidelines for prevention of infection of the medical staff and for prevention of 
transmission from one patient to another are necessary. The veterinary aspects of Q fever also 
necessitate further investigations. Indeed, the effect of antibiotic treatment on shedding of 
bacteria in ruminants has been insufficiently studied. Identification of an antibiotic capable of 
severely diminishing or completely stopping shedding would radically modify the 
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management of Coxiella infection at a herd level. It could also prove useful to prevent 
infection of pregnant women by inhibiting shedding of bacteria by domestic cats and dogs. 
The prevalence and potential clinical consequences of Q fever in pets and equids must also be 
investigated. Veterinarians must include Q fever in their differential diagnoses of clinical 
cases whenever it cannot systematically be rejected as a potential diagnosis. Inactive whole 
cell phase I vaccines have proved to be effective but present several defects. Further research 
in this field and the development of new recombinant vaccines would permit a better 
management of foci of infection at a herd level but also in human populations in the future. 
Animal vaccination and vaccination of individuals at high risk of exposure or/and of severe 
clinical disease would diminish significantly the zoonotic risk.  
12. CONCLUSIONS  
Q fever is an underestimated disease that remains poorly understood to this day. The lack of 
awareness of this disease leads to underdiagnosing and underreporting of Q fever cases. Q 
fever is ubiquitous and the potential hosts for the infectious bacteria are extremely numerous. 
Q fever infections can have a significant economical impact on animal reproduction, animal 
trade and on the production and commercialization of animal products. In small ruminant 
flocks, the consequences of Q fever can be disastrous. Its zoonotic potential renders Q fever 
even more important. Human infections can lead to death. Furthermore with the advances in 
human medicine, the number of immunosuppressed, premature, elderly and chronically ill 
individuals has greatly increased compared to several years ago. Thus the population 
predisposed to infection, and especially to chronic infection, has also greatly increased. 
Chronic infections can lead to severe consequences that necessitate intense medical treatment 
increasing the patients’ suffering and public health costs. An early diagnosis and early 
initiation of treatment are essential to improve prognosis by preventing the development of a 
chronic infection or other potential complications associated to coxiellosis.  
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2. Introduction to epidemiological tools 
 2.1. Retrospective study 
 
A retrospective study, also called case-control study, consists in an analytical comparative 
study of two groups of individuals: a case group and a control group. The case group consists 
in individuals that are affected by the disease of interest, whereas the control group consists in 
individuals free from the disease. Definitive diagnosis (presence or absence of the disease) 
must be proven by diagnostic methods to ensure statistical and epidemiological accuracy of 
the study. Through an analysis of past exposures of the two groups, risk or/and protection 
factors are determined.  
Retrospective studies were performed in the three studies. 
2.2. Scoring of clinical signs and modified blood parameters 
 
The scoring system permits the transformation of qualitative categorical data into quantitative 
analyzable data. Scoring of clinical signs and modified parameters consists in giving a value 
of 1 to the presence and a value of 0 to the absence of a clinical sign or modified parameter. 
The score of an animal is equal to the sum of the individual values (“1” and “0”) for all the 
clinical signs and modified parameters considered in the study. In more elaborate situations, 
different scores can be attributed depending on the level of gravity of the clinical signs or 
modified parameter observed.  
A two-grade (presence or absence) scoring system was used in the three studies. 
 2.3. Receiver Operating Characteristic curve 
 
Test performance for different cut-off values for a variable can be depicted graphically by 
plotting a Receiver Operating Characteristic (ROC) curve, which compares the true-positive 
rate, or Sensitivity, on the vertical axis with the false-positive rate (1 – Specificity) on the 
horizontal axis (Figure 8). The diagonal line reflects test values that are uninformative, e.g., 
where the true-positive rate equals the false-positive rate. A good test is one which has a high 
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 The false-positive rate is represented on the abscissa axis.  
The different cut-off values are depicted graphically and represented by the points [1], [2] and [3].  
The distances between the left superior corner and each cut-off point are compared.  
The cut-off point [2] is the closest to the left superior corner in this graph (y<x<z). 
 Cut-off value [2] is the cut-off value of choice. 
 
1.4. Classification and regression trees (CART) 
 
Classification and regression trees (CART) analysis is described by Lewis (2000) as a 
powerful technique with significant potential and clinical utility. CART analysis is used to 
predict continuous or categorical variables from a set of continuous and/or categorical 
variables. The predicted variable is called the dependent variable whereas the other variables 
are called predictor or independent variables. A CART analysis is a non-linear and parametric 
model that is fitted by binary recursive partitioning of multidimensional covariate space 
determining in this way “if-then” logical conditions (StatSoft, 2011). At each binary division, 
or node, CART analysis chooses the predictor variable, or splitter, that generates the greatest 
improvement in homogeneity of the two subsequent subsets or child nodes. This potential of 
each independent variable to improve the homogeneity, also called purity, and in this way the 
predictive accuracy of the entire tree is called discriminating power (Lewis, 2000; StataSoft, 
2011). Using CART 6.0 software (Salford Systems, San Diego, CA, USA), the analysis 
successively splits the dataset into increasingly homogeneous subsets until it is stratified to 
meet specified criteria (Saegerman et al., 2004; Thang et al., 2008) (Figure 9). When a 
primary splitting variable is missing for an individual observation, it is not discarded but, 
instead, a surrogate splitting variable is sought (vanEngelsdorp et al., 2010). A surrogate 
splitter is a variable whose pattern within the dataset, relative to the outcome variable, is 
similar to the primary splitter. Thus, the program uses the best available information in the 
face of missing values. In datasets of reasonable quality, this allows all observations to be 
used (vanEngelsdorp et al., 2010). This is a significant advantage of this methodology over 
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more traditional multivariate regression modeling, in which missing observations are often 
discarded. Furthermore, a significant advantage of CART analysis, compared to linear and 
regression models, is the simplicity of interpretation of the results (StatSoft, 2011). The best 
CART is the prediction model that has the least misclassified cases, also expressed as with 
minimum costs (proportion of misclassified cases). The “cost” notion gives a weight to each 
misclassification, some erroneous classifications having a more catastrophic impact than 
others (StataSoft, 2011).  
The Gini index was used as the splitting method, and 10-fold cross-validation was used to test 
the predictive capacity of the obtained trees. CART performs cross-validation by growing 
maximal trees on subsets of data then calculating error rates based on unused portions of the 
dataset. To accomplish this, CART divides the dataset into 10 randomly selected and roughly 
equal parts, with each “part” containing a similar distribution of data from the populations of 
interest. CART then uses the first 9 parts of the data, constructs the largest possible tree, and 
uses the remaining 1/10 of the data to obtain initial estimates of the error rate of the selected 
subtree. The process is repeated using different combinations of the remaining 9 subsets of 
data and a different 1/10 data subset to test the resulting tree. This process is repeated until 
each 1/10 subset of data has been used. The results of the 10 mini-tests are then combined to 
calculate error rates for trees of each possible size; these error rates are applied to prune the 
tree grown using the entire dataset (vanEngelsdorp et al., 2010). The consequence of this 
complex process is a set of fairly reliable estimates of the independent predictive accuracy of 
the tree, even when some of the data for independent variables are incomplete and/or specific 
events are either rare or overwhelmingly frequent (vanEngelsdorp et al., 2010) (Figure 10). 
 
CART analysis was used in the study on equine West Nile Fever. 
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Figure 9. An example of classification and regression tree 
Legend:  
dark cow = cow with clinical sign or modified parameter (clinical score =1) 
light cow = cow without clinical sign or modified parameter (clinical score=0)  
E- and W- Flanders = eastern- and western-Flanders (northern Belgium) 
Firstly, the cow herds are divided depending on their localization (eastern- or western-Flanders versus 
Limburg).  
Localization is the primary predictor variable or splitter. 
Two child nodes are obtained: one pure (100% homogeneity) on the left and one impure on the right. 
The impure child node is analyzed by CART once more. 
The herds of the latter impure node are divided depending on their size (number of bovids superior or 
inferior to 39). 
Size is the second predictor variable or splitter. 
Two final nodes are obtained. 
The final node containing herds with more than 39 bovids per herd (on the right) is pure. All cows are 
positive for the clinical sign or modified parameter.  
In the final node containing herds with less than 39 bovids per herd (on the left), one cow is 
misclassified. 
 
 
Misclassification 
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                                              (Niko Speybroek, 2007) 
Figure 10. Graph for selection of the best classification and regression tree 
Legend:  
abscissa: complexity of the tree (number of nodes) 
ordinate: average decision cost (number of misclassifications or impurity of nodes)   
Each dot on the graph represents a classification and regression tree (CART). Each tree has a fixed 
number of nodes. The number of nodes of a CART increases with the number of binary recursive 
partitionings (or divisions). Thus, each binary recursive partitioning leads to a new tree. As the number 
of binary recursive partitionings increases, the trees grow in size and complexity.  
As mentioned here above, in this study, the Gini index is used as the splitting method. This signifies 
that the dataset available for analysis is divided into 10 subsets of data by CART 6.0 software. An 
initial CART is obtained based on 9 of the 10 subsets of data. These 9 subsets of data are called 
learning data. The remaining tenth subset is used to test the accuracy of the tree obtained based on the 
9 subsets of data and is called test data. 
When based exclusively on learning data, as the number of nodes (complexity) increases, the impurity 
of the nodes (number of misclassifications) decreases. When the trees obtained by the initial CART 
analyses based on learning data are tested with the test data, as the number of nodes (complexity) 
increases, the impurity of the nodes (number of misclassifications) decreases until a certain point. 
Beyond this point (complexity of 8 nodes in this case), the impurity increases. This signifies that an 
overly complex tree whose elaboration is too faithful to the learning data is not adequate for 
application on other subsets of similar data. The optimal CART is situated at the intersection of the 
two curves (curve of CART based on learning data and curve of CART based on test data). 
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The aim of this work was to develop epidemiological methods to facilitate the diagnosis of 
diseases poorly understood and/or poorly investigated by general practitioners. For many 
veterinarians, epidemiology is considered a theoretical science with no direct impact on 
individual clinical diagnosis. This study demonstrates the usefulness epidemiological methods 
can have in on the field situations. Emerging diseases as well as newly diagnosed diseases are 
a current scientific phenomenon. Our knowledge and clinical experience of such diseases are 
limited. Thus the development of methods emphasizing key points to reach a rapid diagnosis 
is of major interest.  
In this study, several epidemiological methods have been developed to facilitate diagnosis by 
clinicians.  However clinical epidemiology has its limitations and laboratory analyses or 
complementary examinations with more sophisticated equipment are sometimes unavoidable.   
The aim of this work was: 
‐ Firstly, to develop epidemiological methods based on a rare disease used as a model, 
equine vegetative endocarditis, to help veterinarians reach an early diagnosis when 
confronted with an emerging clinical disease at the beginning of its emergence  
‐  Secondly, to apply the latter epidemiological methods to a current emerging disease, 
West Nile fever, and introduce the ongoing problem of asymptomatic infections, 
rendering laboratory analyses necessary to reach definitive diagnosis.  
‐ Thirdly, to apply clinical epidemiological methods and laboratory skills introduced by 
the two earlier points, by investigating the prevalence of an emerging and seemingly 
asymptomatic disease, Q fever in horses, felines, pigs and wild boars, four species 
with an unknown and uninvestigated infection status in western Europe, and to assess 
the risk of human infection from these animals.  
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Equine vegetative endocarditis 
 
 
Preface 
 
The first epidemiological study of this thesis was performed on equine vegetative 
endocarditis. Emerging diseases being initially rare in a population, their detection is difficult. 
The development of epidemiological methods facilitating detection of an “endemic” rare 
disease could lead to the adaptation of such methods to emerging diseases. 
A retrospective study on a total of 153 equids admitted to the Veterinary Teaching Hospital of 
Liège University between 1994 and 2006 was performed. The purpose of this study was to 
determine the physical data, clinical signs, associations of clinical signs, and the abnormal 
blood parameters, which should lead the practitioner to consider a potential diagnosis of 
infective endocarditis. Previously epidemiological studies on infective endocarditis in equids 
have been performed but large scale studies remain rare. Many hypotheses on predisposition 
factors have been proposed but remain insufficiently proven.  
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Vegetat ive Endocardit is in Equids (1994 –2006)
S.R. Porter, C. Saegerman, G. van Galen, C. Sandersen, C. Delguste, H. Guyot, and H. Amory
Background: Endocarditis is a rare heart condition with variable clinical expressions in equids. Risk factors for this disease
are incompletely understood.
Objective: Describe risk factors for endocarditis in equids.
Animals: One hundred and ﬁfty-three equids admitted to Lie`ge University, 9 diagnosed with endocarditis and 144 free from
endocarditis but admitted to the hospital with a differential diagnosis including this disease.
Methods: Retrospective case-control study.
Results: Equids with endocarditis were signiﬁcantly younger (mean age 5 4.84  5.74 years) than control equids (mean
age 5 10.8  7.73 years) (P 5 .01). No sex or breed predisposition was observed. Animals with hyperthermia (odds ratio
[OR] 5 24.4; conﬁdence interval [CI] 5 1.40–428), synovial distension (OR 5 13.4; CI 5 3.00–59.8), lameness (OR 5 6.52;
CI 5 1.63–26.1), hyperglobulinemia (OR 5 26.4; CI 5 3.03–229), hypoalbuminemia (OR 5 11.4; CI 5 1.34–96.8), hype-
rﬁbrinogenemia (OR5 9.81; CI5 1.16–82.7), or leukocytosis (OR5 7.12; CI5 1.40–36.4) presented a signiﬁcantly higher risk
of having endocarditis than control horses. The presence of two of the clinical signs mentioned above signiﬁcantly increased the
probability of a diagnosis of endocarditis (P  .05).
Conclusions and Clinical Importance: Age is associated with equine endocarditis. The diagnostic value of certain clinical
signs and abnormalities in blood parameters in this disease are described.
Key words: Case-control study; Clinical study; Equine; Exploratory factors; Valvulitis.
Bacterial endocarditis, also called vegetative or infec-tive endocarditis, is a rare cardiac disease in equids.1–5
Two different forms of vegetative endocarditis can be
distinguished: an acute form and a subacute or chronic
form.1,6,7 Signs characterizing the acute form are pyrexia,
depression, reluctance to move due to thoracic discomfort
or lameness, and the rapid development of signs of cardiac
insufﬁciency including edema and increased jugular ﬁll-
ing.1 In the subacute or chronic form, which is much more
common, equids might have intermittent pyrexia, weight
loss, shifting lameness, poor performance, lethargy/depres-
sion, a heart murmur, or a combination of these signs
lasting for weeks or months.1 Signs of cardiac failure usu-
ally occur only as a terminal event.1 Although endocarditis
is frequently associated with the presence of a heart
murmur, this is not always the case.2,4–6,8 Vegetative endo-
carditis can also be associated with cardiac arrhythmias
including atrial ﬁbrillation and ventricular premature
beats.4,5,9 Atrial premature beats and ventricular tachycar-
dia10–13 also occur, but less frequently.
Vegetative endocarditis2,8 can be suspected on the
basis of history and physical examination but comple-
mentary examinations are required for deﬁnitive
diagnosis. Echocardiography and electrocardiography
can be useful in diagnosis, prognosis, and serial assess-
ment of endocarditis by identifying anatomic lesions
and characterizing arrhythmias.3,4,7,9 Echocardiography
remains the most speciﬁc, but not highly sensitive,
modality in diagnosis of endocarditis.1,6,9,14 Other com-
plementary examinations can be useful in equids with
manifestations of metastatic disease. Once established,
the endocarditis lesion can release bacteria and emboli
into the circulation, causing bacteremia, infarctions, and
metastatic infections leading to secondary organ dys-
function.1,2,6–8,15 The infection stimulates the immune
system causing the formation of immune complexes and
secondary immune-mediated complications.1,2,4–7,15
Vegetative endocarditis being an infection of the valvu-
lar endothelium by a speciﬁc microorganism, treatment
logically consists of a high dose of bactericidal antibiotic,
ideally based on the results of the blood culture and
antibiogram1,4–7,9,16,17,, for a minimum period of 4–6
weeks.1,2,4–8,10,11,18 Resolution of clinical signs, improve-
ment of echocardiographic ﬁndings, and reduction in
leukocytosis and hyperﬁbrinogenemia should be used
to evaluate the response and determine the duration
of therapy.4,17 The prognosis is poor1,4–6,8 in all cases of
infective endocarditis. Valvular insufﬁciency caused by
vegetative endocarditis can remain despite reduction of
the size and sterilization of the lesion.2,6 In addition, in-
farctions, metastatic infections, and ﬁnancial limitations
can also complicate treatment and affect prognosis.1,2,6
Because of the nonspeciﬁc signs associated with endo-
carditis, early detection of the disease is often difﬁcult.2
However, early initiation of aggressive therapy has been
shown to greatly affect the ﬁnal outcome.4,5,7 An early
diagnosis is thus essential to succeed in treating a
patient.4,5,7 A predisposition to infective endocarditis in
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young2,7,12,17, male1,2,7,12 or both equids has been sug-
gested by previous studies but contradictions between
studies remain.17 No breed predisposition was obvious in
a study of 10 cases.17
The purpose of this study was to determine the phys-
ical data, the clinical signs, the associations of the clinical
signs, and the abnormal blood parameters, which should
lead the practitioner to consider a potential diagnosis of
infective endocarditis.
Materials and Methods
Case Deﬁnition
Each animal was identiﬁed by its physical description, its name, its
microchip number if present, and name and address of owner. Each
animal admitted to the Veterinary Teaching Hospital of Lie`ge Uni-
versity was always registered under a speciﬁc unique ﬁle with a record
number identifying the animal throughout its stay at the hospital.
The diagnosis of vegetative endocarditis was made by echocardi-
ography or by postmortem examination for the animals included in
the case group.
For the control group, animals were selected from the ﬁles of equids
admitted to the Veterinary Teaching Hospital during the period from
1994 to 2006. Vegetative endocarditis had to be included in their initial
differential diagnosis, based on history and physical examination, but
its diagnosis was thereafter excluded on the basis of echocardiography
and/or postmortem examination. The clinical signs on which was
based the choice of including vegetative endocarditis in the differential
diagnosis were the presence of one or more of the following signs:
hyperthermia, tachycardia, heart murmur, tachypnea/dyspnea, de-
pression, weight loss, lameness, neurological symptoms, synovial
distension, poor body condition, intensity variation of peripheral
pulse, recurrent/persistent anorexia or inappetence, and arrhythmia.
These clinical signs were the most frequently reported signs in the
cases of endocarditis admitted to Lie`ge University and in cases of
endocarditis in the scientiﬁc literature.1,6,9,10,11,16–33
Animals
A total of 153 equids including horses, ponies, or donkeys were
studied and consisted of 2 groups: a group of animals with endocardi-
tis (case group, n5 9), and a group of control animals (control group,
n5 144).
The case group included 9 cases (7 horses, 1 donkey, and 1 pony)
suffering from vegetative endocarditis and admitted to the Veteri-
nary Teaching Hospital of Lie`ge University between 1994 and 2006.
The control group consisted of 144 cases (horses, ponies, or don-
keys) that were admitted to the Veterinary Teaching Hospital of Lie`ge
University between 1994 and 2006.
Clinical Findings and Laboratory Analyses
For each animal included in this study, the description (breed,
age, sex), the date of admission to the Veterinary TeachingHospital,
and all clinical signs reported in the history and physical examina-
tion at initial examination were abstracted from the medical record.
The values of evaluated blood parameters were recorded. The blood
parameters included CBC, serum protein proﬁle, serum alkaline
phosphatase activity, and serum haptoglobin and ﬁbrinogen con-
tent. The reference values used for each blood parameter were the
reference values used by Lie`ge University’s Biochemistry Labora-
tory. For the control group, the ﬁnal diagnosis was recorded.
In addition, for clinical data, including physical abnormalities
and abnormal clinical chemistry, on CBC, a value of 1 was attrib-
uted for each observed clinical sign, and the score of an individual
animal is deﬁned as the sum of all clinical signs present.
Statistical Analyses
The prevalence of infection among the equids included in the
study, the sensitivity, the speciﬁcity, and the accuracy of each clin-
ical sign were estimated with 95% conﬁdence intervals (95% CI)
assuming a binomial exact distribution. The mean ages and the
mean values for each blood parameter in the 2 respective groups of
animals, with unequal variance and considering nonnormal data,
were compared with a Wilcoxon’s rank-sum test.34 The limit of sta-
tistical signiﬁcance of the tests performed was deﬁned as P  .05.
The potential inﬂuence of age, sex, and breed was assessed. Statis-
tical analysis of these data was performed using a w2-test and the
tendency of each parameter to become a risk factor was evaluated
by an odds ratio (OR) calculation with 95% CI (logarithmic ap-
proximation); a P value  .05 was considered signiﬁcant.35
A receiver operating characteristic (ROC) curve is a graph of the
relationship between the sensitivity (the true-positive rate) against 1
minus the speciﬁcity (the false-positive rate) for different cut-off
values. A good test is 1 which has a high true-positive rate and a low
false-positive rate and whose value, therefore, lies close to the top
left-hand corner of the graph. The ROC curve is typically used to
evaluate accuracy of different cut-off values for 1 variable and this
variable can be the number of clinical signs (score of combination of
clinical signs). In the present study, the determination of the best
score of combination of clinical signs was made using the ROC
curve. Epidemiological software for veterinary medicine was used.36
Results
Animals
Nine of the 153 equids in which vegetative endocarditis
was included in the initial differential diagnosis had a ﬁnal
diagnosis of vegetative endocarditis (5.9% with 95% CI:
2.7–10.9%).
The mean age of the equids was 4.84  5.74 and 10.8 
7.73 years in the case and in the control groups, respectively
(P5 .01).
Sex and breed were not risk factors to developing
endocarditis in equids in this study. With geldings as the
referent group, OR for stallions and females were 5.18
(95% CI: 0.885–30.3) and 1.32 (95% CI: 0.212–8.15),
respectively.
Clinical Signs
The clinical signs presented by the 9 cases with endo-
carditis were hyperthermia (n 5 9), tachycardia (n 5 7),
heart murmur (n 5 7), tachypnea/dyspnea (n 5 7), de-
pression (n 5 7), lameness (n 5 5), recurrent/persistent
anorexia or lack of appetite (n 5 5), weight loss (n 5 4),
synovial distension (n 5 4), neurological symptoms
(n 5 3), poor body condition (n 5 3), intensity variation
of peripheral pulse (n5 1), and arrhythmia (n 5 1).
The 3 clinical signs associated with a signiﬁcant higher
risk of the presence of endocarditis were hyperthermia,
synovial distension, and lameness (Table 1).
Blood Parameters
The abnormal blood parameters most frequently
reported were hyperﬁbrinogenemia (n 5 8), leukocytosis
1412 Porter et al
(n5 7), hypoalbuminemia (n5 7), hyperglobulinemia (n
5 7), neutrophilia (n56), anemia (n55), increased serum
haptoglobin content (n55), increased serum alkaline
phosphatase activity (n54), and hyperproteinemia
(n52). The mean values for the 9 blood parameters in
the case group and in the control group were signiﬁcantly
different for 5 parameters: ﬁbrinogen, white blood
cell count, albumin, total protein, and globulins (Table
2). The 4 abnormal blood parameters associated with a
signiﬁcant higher risk of the presence of vegetative endo-
carditis were hyperglobulinemia, hypoalbuminemia,
hyperﬁbrinogenemia, and leukocytosis (Table 1).
Combination of the Signiﬁcant Clinical Signs
AROC curve shows that the association of 2 of the 3 of
hyperthermia, synovial distension, and lameness gives the
best test performance for a diagnosis of vegetative endo-
carditis (Fig 1). This result was not signiﬁcantly different
when a 2nd clinical pattern study was performed that
considered lameness and synovial distension as being
linked clinical signs. In the 1st pattern study, the speciﬁc-
ity was higher than the sensitivity. Whereas in the 2nd
pattern study, it was the contrary (Table 3).
Discussion
For the case-control study concerning the risk factors
of vegetative endocarditis, age was identiﬁed as a signiﬁ-
cant risk factor. Animals with endocarditis were
signiﬁcantly younger than animals free from endocardi-
tis. This supports previous suggestions on the
subject.12,17 The greater risk in young equids could be
due to a more frequent occurrence of bacteremia in
young animals than in adults, bacteremia being neces-
sary for valve infection. Lower immune function, more
frequent occurrence of severe worm infestation, or both
could predispose young animals to infective endocarditis.
No sex predisposition was found in the current study,
which is consistent with some, but not all other studies.12
In addition, because of the small sample size (n 5 9) the
ability to evaluate sex as an exploratory variable was
Table 1. Odds ratio (OR), sensitivity, speciﬁcity, and accuracy calculated for the 13 clinical signs and the 9 blood
parameters in equids with conﬁrmed endocarditis and in equids with suspected endocarditis but free from the disease.
Parametera
Number of Observations
OR (95% CI)b
Sensitivity
(95% CI)
Specificity
(95% CI)
Accuracy
(95% CI)
Cases Controls
Presence Absence Presence Absence
Clinical signs
Hyperthermia 9 0 63 81 24.4 (1.40–428) 100 (71.7–100) 56.3 (47.7–64.5) 58.8 (50.6–66.7)
Tachycardia 7 2 94 49 1.82 (0.365–9.12) 77.8 (40.0–97.2) 34.3 (26.5–42.7) 43.6(31.6–39.6)
Heart murmur 7 2 83 61 2.57 (0.516–12.8) 77.8 (40.0–97.2) 42.4 (34.2–50.9) 44.4 (36.4–52.7)
Tachypnea/dyspnea 7 2 88 55 2.19 (0.438–10.9) 77.8 (40.0–97.2) 38.5 (30.5–47.0) 40.8 (32.9–49.0)
Depression 7 2 64 79 4.32 (0.867–21.5) 77.8 (40.1–97.3) 55.2(46.7–63.6) 44.7(36.7–53.0)
Lameness 5 4 23 120 6.52 (1.63–26.1) 55.6 (21.2–86.3) 83.9 (76.9–89.5) 82.2 (75.2–88.0)
Recurrent/
persistent anorexia or
inappetence
5 4 48 96 2.5 (0.642–9.74) 56.6 (21.2–86.3) 66.7 (58.3–74.3) 66.0 (57.9–73.5)
Weight loss 4 5 81 62 0.612 (0.158–2.38) 44.4 (13.7–78.8) 43.4 (35.1–51.9) 43.4 (35.4–51.7)
Synovial distension 4 5 8 134 13.4 (3.00–59.8) 44.4 (13.7–78.8) 94.4 (89.2–97.5) 90.7 (84.9–94.8)
Neurological symptoms 3 6 36 107 1.49 (0.353–6.25) 33.3 (7.49–70.1) 74.8 (66.9–81.7) 72.4 (64.5–79.3)
Poor body condition 3 6 53 90 0.849 (0.204–3.54) 33.3 (7.49–70.1) 62.9 (54.5–70.9) 61.2 (52.9–69.0)
Intensity variation
of peripheral pulse
1 8 24 119 0.62 (0.0740–5.19) 11.1 (0.280–48.2) 83.2 (76.1–88.9) 79.0 (71.5–85.1)
Arrhythmia 1 8 36 107 0.372 (0.0449–3.07) 11.1 (0.280–48.2) 74.8 (66.9–81.7) 71.0 (63.2–78.1)
Blood parameters
Fibrinogen 8 1 32 38 9.81 (1.16–82.7) 88.9 (51.8–99.7) 54.3 (41.9–66.3) 58.2 (46.6–69.2)
Leukocytes 7 2 31 60 7.12 (1.40–36.4) 77.8 (40.0–97.2) 65.9 (55.3–75.5) 67.0 (56.9–76.1)
Albumin 7 1 33 52 11.4 (1.34–96.8) 87.5 (47.3–99.7) 61.2 (50.0–71.6) 63.4 (52.8–73.1)
Globulins 7 1 18 64 26.4 (3.03–229) 87.5 (47.3–99.7) 78.0 (67.5–86.4) 78.9 (69.0–86.8)
Neutrophils 6 2 55 38 2.19 (0.419–11.5) 75.0 (34.9–96.8) 40.9 (30.8–51.5) 45.5 (35.6–55.8)
Hematocrit 5 4 35 60 2.18 (0.549–8.65) 55.6 (21.2–86.3) 63.2 (52.6–72.8) 62.5 (52.5–71.8)
Haptoglobin 5 1 23 12 2.86 (0.298–27.4) 83.3 (35.9–99.6) 34.3 (19.1–52.2) 41.5 (26.3–57.9)
Alkaline phosphatase 4 1 21 21 3.81 (0.391–37.1) 80.0 (28.4–99.5) 50.0 (34.2–65.8) 53.2 (38.1–67.9)
Total protein 2 6 23 69 2.19 (0.396–12.2) 25.0 (3.19–65.1) 71.0 (61.1–79.6) 71.0 (61.1–79.6)
aThresholds for parameters: hyperthermia when temperature 438.5 1C, tachycardia when heart rate 444 beats/min, tachypnea when
respiratory rate416 respirations/min, anemia when hematocrito33%, hyperﬁbrinogenemia when concentration ([ ])43 g/L, leukocytosis
when [ ]412109/L, neutrophilia when [ ]46109/L, hyperproteinemia when [ ]475 g/L, hyperglobulinemia when [ ]4 45 g/L, increased
haptoglobin content when [ ]4500mg/L, hypoalbuminemia when [ ]o 25 g/L, increased alkaline phosphatase when4400U/L.
bThe 95% conﬁdence interval (CI) (binomial exact).
Values statistically signiﬁcant at P 5 .05.
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limited. No breed predisposition was observed in the
study. This could be attributable to the large variety of
breeds present in the control and case groups and to an
insufﬁciently large case group. Seasonal effect is impos-
sible to identify in infective endocarditis because
endocarditis can have initially vague clinical signs and
usually following a chronic evolution in time, the date
of diagnosis of the disease can differ greatly from the date
of the initial infection.2,4,5,7
This study shows that the clinical signs signiﬁcantly
increasing the probability of diagnosis of vegetative
endocarditis are hyperthermia, synovial distension,
and lameness. It is interesting to notice that none of
the cardiac clinical signs (tachycardia, heart murmur,
arrhythmia, and intensity variation of peripheral pulse)
was signiﬁcant. These results suggest that endocarditis
should not be considered merely a localized infection,
but, rather, a systemic problem via associated bacter-
emia, or the circulation of antibody-antigen complexes,
or both. The abnormal blood parameters whose presence
signiﬁcantly increases the probability of the diagnosis of
vegetative endocarditis were hyperglobulinemia, hypo-
albuminemia, hyperﬁbrinogenemia, and leukocytosis.
Vegetative endocarditis following more frequently a
subacute or chronic evolution, these blood abnormalities
were likely as they occur in most cases of chronic inﬂam-
mation.8,37 It is however important to underline that in the
present study, haptoglobin concentration and alkaline
phosphatase activity were measured on a small number
of animals. Thus, their importance could be increased or
diminished in further studies with more clinical values.
The result of the statistical clinical pattern study of
the present study shows that a way forward to an early
diagnosis of vegetative endocarditis is the study of asso-
ciations of clinical signs. Because infective endocarditis
produces systemic effects on the organism, this is not
surprising.2,5–7 A statistical clinical pattern study of a
larger number of clinical signs and animals could
increase our knowledge on the clinical expression of
vegetative endocarditis and could help to determine the
multiple associations of clinical signs occurring most fre-
quently in animals affected by the disease.
It must be noted that the only clinical signs and labo-
ratory ﬁndings evaluated in this study were those
reported frequently enough to ensure that the statistical
analysis was valid. Moreover, it was assumed that all
veterinary surgeons from Lie`ge University proceeded in
the same way while taking a history, conducting a phys-
ical examination, and a complementary examination.
Their diagnoses were not reviewed.
Conclusion
This study is aimed in priority at the equine practitioner
with a limited number of complementary examinations
available. The determination of the risk factors, signiﬁcant
clinical signs, and abnormal blood parameters through the
case-control study should increase the practitioners’
awareness of equine endocarditis and its clinical expres-
sion, leading to an earlier diagnosis of endocarditis. An
Fig 1. Receiver operating characteristic (ROC) curve of the score
of the 3 most relevant clinical signs of vegetative endocarditis (hype-
rthermia, synovial distension, and lameness). Se, sensitivity; Sp,
speciﬁcity; [1], [2], and [3]: endocarditis clinical signs score. Score
[1] 5 hyperthermia or synovial distension or lameness. Score [2] 5
hyperthermia and synovial distension simultaneously present, or
hyperthermia and lameness simultaneously present, or synovial dis-
tension and lameness simultaneously present. Score [3] 5
hyperthermia and synovial distension and lameness present. The
test performance (clinical diagnostic) can be depicted graphically by
plotting a ROC curve, which compares the true-positive rate, or Se,
on the vertical axis with the false-positive rate (1Sp) on the
horizontal axis. The diagonal series of dashes reﬂect test values
that are uninformative, eg, where the true-positive rate equals the
false-positive rate. The dot on the continuous line that is the closest
to the left superior corner of the ﬁgure represents the optimal num-
ber of clinical signs to reach a diagnosis of vegetative endocarditis in
the horse.
Table 2. Values for the 9 most frequently observed
abnormal blood parameters in 9 equids suffering from
endocarditis and in 144 equids with clinical signs sugges-
tive of endocarditis but not suffering from endocarditis.
Blood Parameter
Mean Value  SD
P ValueCase Group Control Group
Hematocrit (%) 33.4  10.6 35.0  7.96 .36
Fibrinogen (g/L) 4.26  1.07 3.09  1.55 .01a
WBC (cells  109/L) 17.9  9.73 11.2  6.81 .03a
Neutrophils
(cells  109/L)
13.7  8.67 9.24  7.06 .11
Albumin (g/L) 20.9  3.45 25.3  7.90 .01a
Total protein (g/L) 74.2  14.6 61.8  12.5 .01a
Globulins (g/L) 51.9  19.4 37.7  12.8 .005a
Alkaline
phosphatase (U/L)
554  138 530  414 .33
Haptoglobin (mg/L) 2023  1210 1014  1005 .052
aBlood parameters with mean values signiﬁcantly different in the
case group and in the control group.
WBC, white blood cell count.
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early diagnosis being a major factor for the success of the
medical treatment, it is therefore an essential aspect of this
study. An increased success rate for the treatment of veg-
etative endocarditis would also diminish the ﬁnancial
losses associated with the numerous treatment failures.
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Preface 
The second epidemiological study was performed on equine West Nile Fever (WNF). WNF is 
an emerging viral disease in Europe. The study consisted firstly in a retrospective study, 
secondly in a comparative study, and thirdly, in the creation of classification and regression 
trees based on French data originating from the Camargue area.  
The purpose of the retrospective study was to determine physical data, clinical signs, and 
associations of clinical signs which should lead the practitioner to consider a potential 
diagnosis of WNF. Moreover, WNF is a vector-borne zoonosis highly influenced by climate 
and environmental changes. Thus, location and type of vegetation present in the area 
considered were taken into account to determine the potential risk of circulation of WNV. 
Comparison of the clinical presentation of WNF in France (cases from 2004 and 2008), Italy 
(2008) and Hungary (2008) was performed. Finally, classification and regression trees could 
increase veterinarian diagnostic effectiveness (Breiman, 1984; Grenier, 1990a; Clarck and 
Pregibon, 1992; Saegerman, 2005). The lack of clinical specificity and the high rates of 
asymptomatic infections of WNF limit the usefulness of exclusive clinical detection. Indeed, 
laboratory analyses are indispensable to reach definitive diagnosis and to determine the time 
of infection (recent or not). Increasing awareness and communication between countries on a 
European scale is essential (Brown, 2001; AFSSA, 2004).  
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Clinical Diagnosis of West Nile Fever in Equids by
Classification and Regression Tree (CART) Analysis and
Comparative Study of Clinical Appearance in Three
European Countries
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Introduction
West Nile fever (WNF) is a worldwide viral zoonotic
infection caused by a mosquito-borne Flavivirus of the
Flaviviridae family (Petersen and Roehrig, 2001; Autorino
et al., 2002). The West Nile Fever virus (WNV) was ini-
tially isolated from the blood of a mildly febrile woman
in the West Nile district of Uganda in 1937 (Smithburn
et al., 1940). Recently has WNF become a major public
health and veterinarian concern (Dauphin et al., 2004;
Zeller and Schuffenecker, 2004). Indeed, in the last dec-
ades (mainly since the mid 1990s), WNV has emerged as
an important pathogen for humans and horses (Autorino
et al., 2002; Weese et al., 2003; Leblond et al., 2007a,b;
Blitvich, 2008). In addition, the increased number of
severe human cases, accompanied by an increase in the
severity of the neurological disease observed in infected
horses and the appearance of high bird mortality during
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Summary
This retrospective study describes risk/protection factors for the development
of clinical West Nile Fever (WNF) in equids, compares clinical presentation in
three European countries, France, Italy and Hungary, and creates classification
and regression trees (CART) to facilitate clinical diagnosis. The peak of WNF
occurrence was observed in September whatever the country. A significant
difference between Italy and France was observed in the delay between initial
clinical signs and veterinary consultation. No clinical sign was significantly
associated with WNF. Despite similar clinical presentations in the three
countries, occurrence of hyperthermia was more frequently reported in France.
Classification and regression tree demonstrated the major importance of geo-
graphical locality and month to reach a diagnosis and emphasized differences
in predominant clinical signs depending on the period of detection of the
suspected case (epizootic or not). However, definite diagnosis requires specific
serological tests. Centralized reporting system and time-space risk mapping
should be promoted in every country.
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the outbreaks in the USA since 1999, has given a whole
new importance to this disease previously considered of
minor consequences (Castillo-Olivares and Wood, 2004;
Dauphin et al., 2004; Blitvich, 2008).
In horses, WNF is usually asymptomatic (Blitvich,
2008; Cantile et al., 2000; Castillo-Olivares and Wood,
2004; Zeller and Schuffenecker, 2004; Dauphin and
Zientara 2007; Epp et al., 2007b; Sebastain et al., 2008). If
clinical signs occur, they are non-specific (Weese et al.,
2003; Dauphin and Zientara, 2007). Except for fever, clin-
ical signs are almost exclusively of a neurological nature
and reflect the pathogenicity for the central and periph-
eral nervous system (Ostlund et al., 2000; Murgue et al.,
2001; Castillo-Olivares and Wood, 2004; Zeller and
Schuffenecker, 2004; Blitvich, 2008). Occasionally, a tran-
sitory febrile phase can be observed before the onset of
neurological clinical signs, but this is not always the case
(Murgue et al., 2001; Castillo-Olivares and Wood, 2004;
Zeller and Schuffenecker, 2004).
The neurological signs most commonly observed are
ataxia, paresis, limb paralysis of which can affect one or
two limbs (usually the hind limbs) or all four, the latter
usually progressing into recumbency (Cantile et al., 2000;
Ostlund et al., 2000; Murgue et al., 2001; Castillo-Olivares
and Wood, 2004; Zeller and Schuffenecker, 2004; Dau-
phin and Zientara, 2007; Leblond et al., 2007a). Other
clinical signs reported are skin fasciculations, muscle
tremors (Murgue et al., 2001), muscle rigidity (Cantile et
al., 2000; Ostlund et al., 2000; Castillo-Olivares and
Wood, 2004; Dauphin and Zientara, 2007). A proportion
of horses never recover from infection and die naturally
or are euthanized humanly (Cantile et al., 2000; Ostlund
et al., 2000; Murgue et al., 2001; Weese et al., 2003;
Castillo-Olivares and Wood, 2004; Leblond et al., 2007a).
The severity of initial clinical signs does not necessarily
hinder the ability to recover if appropriate supportive
care is provided (Ostlund et al., 2000). Horses are partic-
ularly sensitive to WNV with approximately 10% of
infected animals presenting neurological disorders, when
compared to 1% of humans (Petersen and Roehrig, 2001;
Leblond et al., 2007a), rendering its detection in equids
highly pertinent in a public health perspective. The differ-
ential diagnosis in equids mainly includes arboviral
encephalitis (e.g., Venezuelan, Eastern, and Western
encephalomyelitis), equine protozoa myeloencephalitis
(Sarcosystis neurona or Neospora hughesi), the neurological
form of rhinopneumonia Equine Herpes Virus 1, Borna
disease, and rabies.
The present retrospective comparative study investi-
gates clinical presentation of WNF in three different
European countries. To our knowledge, this is the first
European comparative study. The purpose of the study
was to determine the physical data, clinical signs, geo-
graphical and temporal information that could assist
practitioners in considering a potential diagnosis of WNF.
With this original approach, clinical impressions were
rendered objective. The aim of the classification and
regression tree (CART) analysis, never used until now for
WNF, was to facilitate clinical diagnosis of the disease by
veterinarians worldwide (e.g., Breiman et al., 1984; Sae-
german et al., 2004).
Materials and Methods
Case definition
Data on the neurological syndromes were collected
through the passive surveillance system of each country
constituted by the veterinary practitioners and health
authorities. In the area of study, every neurological syn-
drome observed in a horse was suspected of West Nile
infection and was mandatorily to be declared to the
health authorities by the attending veterinarian. Indeed,
a suspicion of WNF was made after veterinary observa-
tion of neurological clinical signs with or without fever.
Hereafter, the definitive diagnosis of WNF was reached
exclusively by laboratory analyses. Horses presenting
neurological clinical signs were classified as confirmed
WNF cases when they tested positive to the ELISA IgM
assay as performed by certified national laboratories.
The cases were classified as probable WNF cases when
the ELISA tests were positive for IgG and negative for
IgM (Leblond et al., 2007b). Control animals used in
the retrospective study were French equids suspected of
WNF but later proven free from infection by laboratory
analyses.
The antigens used for the detection of WNV antibodies
were either recombinant prM/E antigens, used in indi-
rect and competition ELISA or whole inactivated
antigens, used in indirect or capture IgM ELISA. For
WNV laboratory confirmation, a battery of tests was sys-
tematically used (confirmation never relied on a single
test but on a combination of ELISA tests, for the detec-
tion of IgG and IgM antibodies, virus neutralization test,
at least for the confirmation of the first recorded case
and PCR tests, when central nervous system samples
were available). As the proposed study is a retrospective
one (with some samples that are no more available), the
tests used differed over time, and for example, competi-
tion ELISA was used only recently for the confirmation of
WNV outbreaks (Hungarian 2008 outbreak, for example).
However, IgG ELISA tests (indirect with whole inactivated
antigens, recombinant antigens or competition) gave
comparable results, in terms of sensitivity, specificity and
repeatability, on a panel of reference equine sera, sampled
during French WNV outbreaks, while the IgM ELISA
protocol did not change.
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For French equids, to improve the passive surveillance,
in 2004 an experimental integrated electronic system was
developed based on the department’s existing infrastruc-
ture for secure web-based and standardized electronic
health information interchange with sentinel veterinary
practitioners. This original system was called ‘Equine Dis-
eases Information System’ and 2 years after was included
in a computerized veterinary system allowing practitio-
ners to report all neurological syndromes throughout the
country (called ‘Re´seau d’e´pide´miosurveillance en pathologie
equine (RESPE)’; http://www.respe.net/). Suspicions of
WNF were retained after evaluation by a college of
experts in equine neurology of the RESPE. Physical
description, horse name, microchip number, name and
address of owner, geographical location and environment
in which the equid lived were retained.
Animals
Clinical presentation of WNF in European countries: To
compare the clinical presentation of WNF in three Euro-
pean countries, three previously published datasets were
used, which included raw clinical data of 14 Italian con-
firmed cases from 1998 (Cantile et al., 2000), 39 French
confirmed or probable cases from 2004 (Leblond et al.,
2007a) and 20 Hungarian confirmed cases from 2007 to
2008.1
French retrospective study: For the retrospective study,
equine data from the French epizootic of 2004 were col-
lected (39 cases and 61 controls). Data from suspected but
infirmed cases from 2008 (i.e., 1 year after a phase test of
the national network RESPE) were also included (39 other
controls) to investigate the possible differences in the
recruitment of suspected cases in a non-epizootic period.
Classification and regression tree analysis: Similarly to
the retrospective study, the French data were analysed
with CART. The first analyses were performed on all the
French data available (2004 and 2008; N = 139). A CART
analysis was further performed on data from the epizootic
of 2004 exclusively (N = 100).
Clinical findings and laboratory analyses
The description (breed, age, sex), date of observation of
initial clinical signs, and all clinical signs reported in the
history and during physical examination were retained
(Table 1). In addition, for clinical data, a value of 1 was
attributed for each observed clinical sign, and the score of
an individual animal is defined as the sum of all clinical
signs present. The results were coming from certified
Table 1. Frequency of clinical signs in cases of West Nile fever in three different European countries (N = 73)
Clinical characteristic
Frequency of occurrence of clinical findings
France (2004)a Italy (1998)b
Hungary
(2008)c Total
Nd % N % N % N %
Ataxia or incoordination 25 64 12 86* 10 50 47 64*
Muscular tremor, myoclonia and/or tetany 13 33 8 57 11 55 32 44
Paresis 12 31 9 64 6 30 27 37
Hyperthermia 15 38 2 14 2 10 19 26
Behaviour disorders 10 26 1 7 7 35 18 25
Prostration 9 23 3 21 6 30 18 25
Weakness 2 5 9 64* 5 25 16 22*
Paralysis 5 13 7 50* 2 10 14 19*
Cranial nerves deficit 6 15 1 7 5 25 12 16
Recumbency 1 3 3 21 8 40 12 16
Hyperaesthesia 7 18 1 7 1 5 9 12
Anorexia 3 8 1 7 1 5 5 7
Hypermetria 0 0 0 0 2 10 2 3
a39 clinical cases of West Nile Fever (WNF).
b14 clinical cases of WNF.
c20 clinical cases of WNF.
dNumber of cases showing the clinical sign.
*Significant difference between Italy and Hungary.
Significant difference between France and Italy.
Significant difference between France and Hungary.
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national laboratories and were recorded in a unique file
for each equid.
Comparative statistical analyses
The statistical data analysis was conducted using chi-
square tests, and the tendency of each parameter to
become a risk/protector factor was evaluated by odds
ratios (OR) with 95% confidence interval (CI). The fre-
quency of occurrence of each clinical sign and the month
of occurrence of WNF were compared in pairs with a
Fisher’s exact test. Comparisons of clinical scores between
countries were performed using a two-sample Wilcoxon
rank sum (Mann-Whitney) test assuming an unequal var-
iance and non-normal data distribution. The clinical
score of each animal was also compared with its level of
WNV-IgM and WNV-IgG antibodies using Spearman’s
rank correlation, noted ‘rs’ in the text. The statistical sig-
nificance of the tests was set at a level of P £ 0.05 (Petrie
and Watson, 2006).
Classification and regression tree analysis
A CART analysis was conducted on the data set, where
the presence or absence of West Nile infection deter-
mined by laboratory analyses was used as the dependent
variable and the animal description (breed, age, sex),
and clinical (n = 13; Table 1), as well as spatio-tempo-
ral (month of occurrence and geographical location),
data were used as independent or predictor variables. A
CART analysis is a non-linear and non-parametric
model that is fitted by binary recursive partitioning of
multidimensional covariate space (Breiman et al., 1984;
Saegerman et al., 2004; Speybroeck et al., 2004). Using
cart 6.0 software (Salford Systems, San Diego, CA,
USA), the analysis successively splits the dataset into
increasingly homogeneous subsets until it is stratified
and meets the specified criteria. The Gini index was
used as the splitting method, and 10-fold cross-valida-
tion was used to test the predictive capacity of the
obtained trees. Classification and regression tree per-
forms cross-validation by growing maximal trees on
subsets of data and then calculating error rates based
on unused portions of the data set. To accomplish this,
CART divides the data set into 10 randomly selected
and roughly equal parts, with each ‘part’ containing a
similar distribution of data from the populations of
interest (i.e., confirmed versus infirmed WNF suspects).
Classification and regression tree then uses the first nine
parts of the data, constructs the largest possible tree
and uses the remaining 1/10 of the data to obtain ini-
tial estimates of the error rate of the selected subtree.
The process is repeated using different combinations of
the remaining nine subsets of data and a different 1/10
data subset to test the resulting tree. This process is
repeated until each 1/10 subset of the data has been
used as to test a tree that was grown using a 9/10 data
sub set. The results of the 10 mini-tests are then com-
bined to calculate error rates for trees of each possible
size; these error rates are applied to prune the tree
grown using the entire data set. The consequence of
this complex process is a set of fairly reliable estimates
of the independent predictive accuracy of the tree, even
when some of the data for independent variables are
incomplete and/or comparatively small. For each node
in a CART generated tree, the ‘primary splitter’ is the
variable that best splits the node, maximizing the purity
of the resulting nodes. When the primary splitting vari-
able is missing for an individual observation, that
observation is not discarded but, instead, a surrogate
splitting variable is sought. A surrogate splitter is a var-
iable which pattern within the dataset, relative to the
outcome variable and is similar to the primary splitter.
Thus, the program uses the best available information
in the face of missing values. In datasets of reasonable
quality, this allows all observations to be used. This
is a significant advantage of this methodology over
more traditional multivariate regression modelling, in
which observations which are missing any of the pre-
dictor variables are often discarded. Further details
about CART are presented in previously published arti-
cles (e.g., Saegerman et al., 2004; Speybroeck et al.,
2004).
In this study, four different analyses were performed.
The first (I) and third (III) analyses were performed on
all the French data available without distinguishing the
year of occurrence of the suspected cases. The second (II)
and fourth (IV) analyses only took the French data from
2004 into account. Analyses I and II only used the clinical
signs for their tests, whereas analyses III and IV included
all independent variables.
Results
Clinical presentation of WNF in European countries
French, Italian and Hungarian WNF case data were sum-
marized and studied to determine the most frequently
presented clinical signs for each subdataset (Table 1). The
occurrence of paresis, weakness and paralysis was more
frequently observed in Italian WNF cases than in French
cases (Fisher’s exact test; P < 0.03). The occurrence of
hyperthermia was more frequently reported in France
(Fisher’s exact test; P = 0.02), whereas weakness and
recumbency were more frequently reported in Hungary
(Fisher’s exact test; P < 0.04). Finally, ataxia, weakness
and paralysis were significantly more frequently reported
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in Italian cases than in Hungarian cases (Fisher’s exact
test; P < 0.04).
The score of clinical signs was significantly higher in
Italy than in France (Wilcoxon rank sum test; P = 0.03)
but non-significantly different between Italy and Hungary
or between France and Hungary, respectively (Wilcoxon
rank sum test; P > 0.30) (Fig. 1). Considering equine data
from the French epizootic of 2004 for which quantitative
serological data were available, the clinical score seems to
be inversely proportional to the level of WNV-IgM anti-
bodies (rs = )0.38; P = 0.04) but not to the level of
WNV-IgG (rs = 0.26; P = 0.18).
In addition, the delay between observation of initial
clinical signs and veterinary consultation was significantly
longer for Italian cases in comparison with French cases
(Wilcoxon rank sum test; P = 0.006) (Fig. 2). The month
of occurrence of WNF was comparable in the three coun-
tries (Fisher’s exact; P = 0.83). In each country, the peak
of occurrence of WNF was observed during the month of
September (Fig. 3). Hungary was the only country pre-
senting a WNF case in November.
Of the 14 Italian horses, two died of a natural death
and four were euthanized humanly. The eight other
horses recovered. Among the Hungarian WNF cases,
seven died, 10 recovered and three were lost for follow-
up. Finally, seven horses died out of the French WNF
cases, 31 survived and two were lost for follow-up. How-
ever, the mortality rate (including natural death and
euthanized on human grounds) was not significantly dif-
ferent between France (82%), Italy (63%) and Hungary
(53%) (Fisher’s exact; P = 0.09).
Retrospective French study
Considering equine data from the French epizootic of
2004, no clinical sign was found to be significantly associ-
ated with WNF. However, living in the location ‘Saintes
Maries de la Mer’ with postal code 13 460 significantly
increased the risk of WNF (v2 = 14.85 with P < 0.001;
OR = 10.67 with 95% CI: 2.76–41.17). In addition, dur-
ing the non-epizootic period, the presence of cranial
nerve deficit was found to significantly decrease the prob-
ability of the horses having WNF (v2 = 4.55 with
P = 0.03; OR = 0.34 with 95% CI: 0.12–0.94). No breed,
age or gender effects were observed.
Classification and regression tree analyses
In CART analysis I (only clinical signs without distin-
guishing the year of occurrence of the suspected cases)
(Data S1), paresis, weakness and recumbency were the
Fig. 1. Comparison of the clinical score for each country respectively.
The graph shows the clinical score distribution; vertical line in the rect-
angle is the median score; right and left limits of the rectangle were
the first and third quartiles; right and left limits of the Boxplot were
the minimum and the maximum values; abscissa: clinical score (=sum
of each presented clinical sign, each individual clinical sign presented
having a value of 1); ordinate: each individual country.
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Fig. 2. Delay between observation of initial clinical signs and veteri-
nary consultation in France and Italy. Abscissa: days; ordinate:
percentage of confirmed West Nile Fever cases; vertical line: 7 days.
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Fig. 3. Month of West Nile fever clinical appearance in France,
Hungary and Italy. Abscissa: month; ordinate: number of West Nile
Fever confirmed cases; data from France in white; data from Hungary
in grey; data from Italy in black.
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three most important predictors (or splitters). The sensi-
tivity and the specificity of this tree were of 82.1% and
78%, respectively. However, in analysis II (only clinical
signs in 2004 for the suspected cases) (Data S2), hyperes-
thesia, recumbency and anorexia were the most impor-
tant. The sensitivity and the specificity of this tree were of
74.4% and 88.5%, respectively. Moreover, analysis III (all
independent variables without distinguishing the year of
occurrence of the suspected cases) reported an increase in
specific anti-WNV IgM, postal code and month as major
splitters. Analysis IV (all independent variables in 2004
for the suspected cases) reported positive anti-WNV IgM
and anti-WNV-IgG serology assays and then postal code
and month as major splitters. The importance of each
splitter in their respective CART is reported in Table 2
for analyses I and II. The first splitter for CART III and
CART IV confirms the case definition of WNF (circular
process), but the second and the third splitters are of
main interest in time-space risk mapping.
Discussion
Clinical detection of WNF cases in horses is interesting as
a public health perspective because of their higher suscep-
tibility to develop neurological clinical signs compared to
humans. For this reason, every neurological syndrome
observed in a horse was suspected of West Nile infection
and was mandatorily to be declared to the health authori-
ties by the attending veterinarian. However, clinical pre-
sentation of WNF is known to vary from one equid to
another and during the course of illness. Indeed, some
clinical signs are only observed at the initial stages and
disappear as disease progresses, requiring great awareness
of the owner/veterinarian during that period for their
detection. Other clinical signs only appear during the
final stages of the disease.
Hyperthermia potentially appears at different phases
of the disease (3–6 days post-inoculation and second,
in neurological animals, 5–22 days post-inoculation)
(Cantile et al., 2001). However, hyperthermia was only
frequently reported in French WNF cases. This may be
because of a more attentive observation by horse owners
in France than in Italy and Hungary, allowing detection
of the initial hyperthermic phase, and to the shorter delay
between initial clinical signs and veterinary consultation.
In a first step, the countries were compared in pairs.
Paresis, weakness and paralysis were significantly more
frequently observed in Italian WNF cases than in French
cases. Between France and Hungary, hyperthermia was
more frequently reported in France, whereas weakness
and recumbency were more frequently reported in Hun-
gary. These two latter results could be explained by lack
of awareness of Italian and Hungarian horse owners at
the time of this study: unaware of WNF circulation and
of its clinical presentation, the owners/veterinarians could
be less attentive to the more subtle clinical signs; severe
clinical signs being more frequently reported. On the
other hand, French owners living in endemic areas could
be more attentive and seek prodromic clinical signs.
Finally, ataxia, weakness and paralysis were significantly
more frequently reported in Italian than in Hungarian
cases. This could be because of a closer observation and
thus earlier detection in Hungary compared to Italy, as
horses are in closer contact with humans in rural areas
(working horses versus sport and leisure horses). Another
hypothesis is that the differences observed in this compar-
Table 2. Power of the different clinical signs splitters obtained after CART analysis (maximum score = 100)
CART I CART II
Predictor variable Score Predictor variable Score
Paresis 100.00 Hyperesthesia 100.00
Weakness 81.37 Recumbency 93.60
Recumbency 75.45 Anorexia 81.41
Hyperthermia 63.59 Prostration 58.88
Paralysis 61.61 Cranial nerve deficit 57.87
Prostration 60.27 Hyperthermia 52.13
Cranial nerve deficit 46.13 Trembling, tetany, fasciculations 51.05
Trembling, tetany, fasciculations 42.15 Paralysis 49.65
Change in behaviour 40.81 Paresis 39.14
Anorexia 34.64 Change in behaviour 32.60
Hyperesthesia 34.27 Weakness 25.80
Ataxia 13.05 Ataxia 17.76
CART I, Classification and regression tree analysis that takes into account all the French suspected cases from 2004 and 2008 (N = 139;
sensitivity = 82.1%; specificity = 78.0%); CART II, Classification and regression tree analysis that takes into account French suspected cases from
2004 epizootic exclusively (N = 100; sensitivity = 74.4%; specificity = 88.5%).
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ative study are because of differences in viral strains, each
viral strain potentially having a different pathogenicity.
Several scientific studies support the latter hypothesis
(Cecilia and Gould, 1991; Halevy et al., 1994; Chambers
et al., 1998). In a mouse model, Beasley et al. (2002) iso-
lated groups of viruses in lineage 1 and lineage 2 with
variable neuroinvasive potentials. According to the
authors, their neuroinvasive potential was found not to
be influenced by the source of the virus (mosquito, mam-
mal, bird) or by its passage history. Individual factors of
receptivity are also thought to be of major importance for
the evolution and clinical expression of WNF (Joubert et
al., 1971; Beasley et al., 2002). Indeed, several authors
(Glass et al., 2005; Brault et al., 2007; Lim et al., 2009)
demonstrated that variations in certain loci of the host’s
genome influenced susceptibility to and clinical presenta-
tion of WNV infection. Furthermore, the presence of
antibodies against other flaviviruses is thought to play a
role in determining clinical presentation in certain areas
(e.g., Africa or Latin America) (Beasley et al., 2002). Our
results are not in contradiction with literature, ataxia,
recumbency, paresis and paralysis being considered as
‘classic signs’ of WNF (Epp et al., 2007a).
The delay between observation of initial clinical signs
and veterinary consultation was significantly different
between Italian and French cases. This difference is
thought to be because of a lack of awareness of disease
by Italian horse owners and to the absence of a central-
ized epidemiological surveillance system at the time of
the outbreak in 1998. Indeed, an efficient surveillance
system could permit registration of suspected and con-
firmed cases of WNF in a standardized manner. The
peak of occurrence of WNF cases in the three countries
was observed during September. This result is in accor-
dance with previous studies on WNF and vector activity
in temperate climates (Murgue et al., 2001; Zeller and
Schuffenecker, 2004; Ludwig et al., 2010). Indeed, the
study by Ludwig et al. (2010) performed on American
crow populations demonstrated that time of year was a
significant risk factor and that end of summer and
autumn were associated with a higher mortality rate
owing to WNF. Therefore, awareness must be increased
before and during this period to allow early detection of
WNV circulation. Hungary reported a case occurring in
November. It would be interesting in the future, with the
development of a centralized epidemiological surveillance
system increasing the number of reported cases, to
investigate if this isolated case is just a result of late clini-
cal detection or if it is because of persistence of vector
activity in the environment (climate change) or a false
positive.
In the retrospective study, geographical location was
found to be a significant risk factor. This result is in
agreement with the previous studies (Epp et al., 2007a;
Leblond et al., 2007b; Pradier et al., 2008; Soverow et al.,
2009). In accordance with other retrospective studies
(Cantile et al., 2001; Trock et al., 2001; Leblond et al.,
2007a), no breed, age, gender or clinical signs (despite the
fact that only clinical signs most frequently reported in
WNF equine cases were included) were found to be sig-
nificantly associated with WNF. Furthermore, proximity
to host populations could be considered as a potential
risk factor in future studies. In America, proximity of
humans to colonies of white pelicans has been studied
(Johnson et al., 2010). West Nile Fever virus-associated
deaths in pelicans were found to increase by 5-fold the
probability of neurological human WNF cases (Johnson et
al., 2010). In Europe, proximity to large populations of
magpies, crows, sparrows or any other avian species could
be a risk factor (Jourdain et al., 2008; Calistri et al.,
2010). Indeed, magpies were found to be seropositive in a
study by Jourdain et al. (2008) and could thus serve as
amplifying hosts.
The CART I and II analyses reported different clinical
predictors depending on the inclusion (CART I) or not
(CART II) of WNF suspected but not confirmed cases of
2008. Moreover, the sensitivity of the tree was more
important for CART I in comparison with CART II, and
the reverse was observed for the specificity. This observa-
tion could suggest the influence of different recruitment
of suspected cases by owners/veterinarians during epizo-
otic (CART II) or non-epizootic (CART I) periods. This
observation stresses the necessity of regular awareness
campaigns among owners and veterinarians. In accor-
dance with the results of the retrospective study, the
results of the CART analyses demonstrate that in a case
of emergence of WNF, clinical suspicions are the first and
essential step towards diagnosis, but confirmation by
serology remains necessary. Indeed, CART III and IV
emphasized the importance of specific diagnostic serologi-
cal assays (case definition) to confirm a clinical suspicion
and of time and place of occurrence of the suspected
WNF case. This result is in agreement with the retrospec-
tive study, as well as with the study by Leblond et al.
(2007a) and by Ward (2005).
Conclusion
Despite several previous studies on the subject, WNF
remains a challenging disease and an important veterinary
public health issue. Awareness of its potential emergence
must be promoted. A centralized passive animal surveil-
lance system reporting WNF and suspected WNF cases,
in a standardized manner, must be organized in different
countries to permit an early detection of its emergence.
Communication between countries and between veteri-
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nary and public authorities is essential for an efficient
control of WNF in the currently unstable epidemiological
situation. Spatio-temporal modelling could be of signifi-
cant help for assessing risk of emergence and detecting
high risk areas to allow active surveillance.
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Preface 
WNF has demonstrated the limits of clinical diagnosis when confronted with emerging 
diseases that can have an asymptomatic or non specific clinical presentation. Q fever is a 
typical example of an emerging, potentially asymptomatic, disease. The recent awareness and 
the lack of scientific knowledge on the subject make it an ideal choice for our study. After 
presenting the global epidemiological context of Q fever worldwide, the prevalence of 
infection in Belgian and Dutch horses, Belgian and French felines, Belgian pigs and wild 
boars was estimated. The epidemiological and zoonotic role of these species has not been 
investigated previously. Limitations of a purely clinical approach render laboratory analyses 
indispensable. The prevalence of Q fever was estimated by enzyme-linked immunosorbent 
assay (ELISA) and then confirmed by immunofluorescence assay (IFA). Our results are 
presented in the following article. 
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Figure 11. Isolation of C. burnetii by IFA in two different cats from a rescue center 
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Abstract  
Several human Q fever cases associated with infected cats have been reported. Moreover, 
Coxiella burnetii is known to infect numerous hosts. This study investigates Q fever 
seroprevalence in felines, equids, pigs and wild boars, and then compares enzyme-linked 
immunosorbent assay (ELISA) protein G, ELISA protein A/G and immunofluorescent assay 
(IFA) phase II. Sera from domestic, stray, and rescue center cats (N=318), horses (N=344), 
pigs (N=264) and wild boars (N=272) were tested by ELISA Prot G and IFA. Moreover, 
feline sera (N=247) were tested by ELISA ProtA/G. The seroprevalence in the feline 
subgroups were compared by Chi2 test. Distributions of S/P ratio were compared between 
species by a two-sample Mann-Whitney test. A Bonferroni correction was applied for 
multiple comparisons. Statistical significance was defined as P < 0.05/k, with k being the 
number of comparisons made. All animals were negative by ELISA Prot G. Several cats were 
IFA positive at dilution 1:40, whereas, only one horse was positive. No pig or wild boar was 
IFA positive. A significant difference in IFA seroprevalence was observed between domestic 
and stray cats (P=0.007). In conclusion, felines, especially strays, represent a potential 
zoonotic risk. Reasons for the difference in seroprevalence between species and felines 
remains to be elucidated.  
Keywords: Q fever; Coxiella burnetii; Diagnostic; Seroprevalence; Uninvestigated species 
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Introduction  
Q fever is a ubiquitous neglected zoonosis caused by a resistant intracellular bacterium, 
Coxiella burnetii (Derrick, 1937; Mitscherlich and Marth, 1984; Babudieri, 1959; Ormsbee et 
al., 1978). Domestic ruminants are considered the main reservoir for the pathogen (Lang, 
1990; Guatteo et al., 2007; Vaidya et al., 2010). However Q fever is known to infect a large 
variety of hosts (Marmion and Stoker, 1950; Davoli and Signorini, 1951; Slavin, 1952; 
Marmion, 1954; Stocker and Marmion, 1955; Blanc and Bruneau, 1956; Evans, 1956; 
Syrucek and Raska, 1956; Fiset, 1957; Hirai and To, 1998). Inhalation is the main route of 
animal and human infection (Welsh et al., 1957; Tissot-Dupont et al., 1999; Russell-Lodrigue 
et al., 2006). Epidemiological studies on Q fever in animals have found that cats can be 
infected by C. burnetii (Marrie et al., 1985; Higgins & Marrie, 1990; Pinsky et al., 1991; 
Mattewman et al., 1997). Moreover, in 1952, Gillepsie and Baker performed successful feline 
experimental infections by subcutaneous inoculation, feeding infected yolk sacs and by 
contact with infected cats. Despite the presence of pathogen in blood, urine and a serological 
response, clinical signs were not observed in all infected cats. In felines, Q fever is, 
seemingly, frequently asymptomatic and remains undiagnosed. However, infected cats 
excrete C. burnetii in the environment and are a potential source of human infections. Indeed, 
human Q fever cases associated to infected cats have been reported previously (Marrie et al., 
1989; Langley et al., 1988; Marrie et al., 1988). In Europe, the role played by cats in Q fever 
transmission remains poorly investigated. Moreover, Q fever has rarely been investigated in 
equids, pigs and wild boars despite some contacts with infected domestic ruminants.  
The aim of this study was to investigate Q fever-seroprevalence in western European cats, 
equids, pigs and wild boars, allowing, in this way, an estimation of their zoonotic importance.  
Finally, the authors suggest cut-off values for the enzyme-linked immunosorbent assay 
(ELISA) kits used in this study.  
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Materials and Methods 
Animals 
A total of 30 bovine, 344 equine, 318 feline, 264 swine and 272 wild boar sera were analyzed. 
The bovine sera were used as a reference to gain the laboratory skills. 
Bovines: The bovine sera were obtained from southern Belgian and Luxemburgish cattle 
between February and October 2010, which had a history of abortion associated or not with a 
proven Coxiella infection. 
Felines: The French feline sera (n=130) originated from domestic cats from the Rennes area, 
France. The cats were sampled between January and November 2004 at two different 
veterinary clinics; one at Vern sur Seiche, mainly with an urban and suburban feline 
population and, one at Chateaugiron with a predominant suburban and rural feline population. 
Belgium feline samples were provided by two different sources. 62 samples were obtained 
through an eradication of stray cats program started in March 2010, in Ciney. Serological tests 
were performed to evaluate the feline immunodeficiency virus (FIV) and feline leukemia 
virus (FeLV) status of each animal. Euthanasia was decided based on the latter results or on 
general condition. Other feline samples (n=126) were provided by animal rescue centers 
localized in southern Belgium. 
Horses: 163 sera originated from horses admitted in private clinic in the Netherlands for 
arthroscopy from 2007 to 2009. 
181 sera originated from Belgian Sport horses admitted to the Veterinary Teaching Hospital 
of Liège University, Belgium, from 2007 to 2009 for a pre-purchase examination, 
arthroscopy, or for a complete standard examination before registration in the Belgian Sport 
Horse Stud Book. 
Pigs and wild boars: The wild boar sera were obtained during a previous study performed by 
Association Régionale de Santé et d’Identification Animales (ARSIA) on classical swine 
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fever in 2007 (n=272). The wild boars sampled originated from the free roaming southern 
Belgium population. The pigs were sampled in 2010 and were housed in various farms in 
southern (n=232) and northern Belgium (n=32).  
Conservation of the serum samples 
The blood obtained was centrifuged and the serum conditioned in aliquots, identified and 
frozen. All samples were stored at a temperature of –20 degrees C° before analyses and were 
thawed the least times possible to prevent any modification of sera quality.  
Data retained for each sample 
Age, breed, sex, environmental habitat, date of sampling, vaccination status and motif of 
consultation were retained for each French feline sera. For the Belgian felines from Ciney, 
age, breed, sex, weight, general condition, environmental habitat (stray or domestic), date of 
sampling, FIV and FeLV status, necessity of euthanasia or not and its motif were included in 
the sample data. The data concerning the Belgian blood samples from animal rescues included 
date of sampling and localization only. 
Age, breed, sex, weight, motif of consultation, and date of sampling were retained for every 
equine sample included in the study. 
A large panel of data was available for pig and wild boar sera including identification, herd 
number, geographical localization and results of previous analyses. 
Laboratory analyses 
All the laboratory analyses were performed at ARSIA, Loncin, Belgium.  
Firstly, an ELISA using a recombinant protein G conjugate (ELISA Prot G) was performed, 
followed by an ELISA using a recombinant protein A/G conjugate (ELISA ProtA/G). The 
differences between recombinant proteins A, G, and A/G are summarized in Table 1. 
LSIVET Ruminant Milk/Serum Q fever ELISA kits, licensed by “Institut National de 
Recherche Agronomique” (INRA), provided by LSI (France), were used.  
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In ELISA test, the ratio optical density of the sample / optical density of the positive control 
(S/P) expressed in percent was calculated using the following formula: 
100x
ODncODpc
ODncODs ⎟⎟⎠
⎞
⎜⎜⎝
⎛
−
−  
with “OD” for optical density values measured at 450 nm, “s” for sample; “nc” for negative 
control and “pc” for the positive control supplied by the manufacturer.  
Secondly, immunofluorescent assays (IFA) were performed on approximately 30 randomly 
selected samples from each group. The VMRD* IFA kit and VIRCELL** Coxiella burnetii 
slides were used.  Each slide contains 10 wells coated with grown in MRC-5 cells, with C. 
burnetii phase II, Nine Mile strain (ATCC 616-VR), formaldehyde inactivated and acetone 
fixed. Dilutions from 1:40 to 1:160 were obtained successively by two-fold dilutions. Tests 
were carried out according to standard procedures and slides were read using a fluorescent 
light microscope at * 400 magnification. Titers of 1:40 or more were considered positive. This 
cut-off value was determined following a previous study by Matthewans et al. (1997) on Q 
fever seroprevalence in felines. 
Sera selection for analyses 
All samples were tested by ELISA Prot G. Feline samples only (n=247) and 9 bovine sera, as 
controls, were tested by ELISA ProtA/G. For IFA, due to lack of time and cost of analyses, 
samples to be tested were selected randomly. The number of samples tested by ELISA and 
IFA per species is summarized in Table 2.  
Statistical analyses 
The Chi 2 or Fisher’s exact test was used to compare seroprevalences in the different feline 
subgroups. The relation between distributions of the S/P ratio in function of groups was 
evaluated by pair using two-sample Wilcoxon rank-sum (Mann-Whitney) test. A Bonferroni 
correction for multiple comparisons was applied. Statistical significance was defined as P < 
0.05/k , with k is the number of comparisons made (Petrie and Watson, 2006).  
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As the true infectious status of the animals was unknown, a theoretical cut-off value was 
proposed based on the distribution of the S/P ratio values of IFA negative sera for each 
species. The latter distributions were considered normal and the cut-off value was determined 
as follows: mean + 3 * standard deviation (SD).  
 
Results 
The results obtained by ELISA Prot G and ELISA ProtA/G and by IFA are summarized in 
Table 2.  
IFA: Only four French felines (17.4%) out of the 24 tested were found to be positive for C. 
burnetii at dilution 1:40. Two and none remained positive at dilution 1:80 and 1:160, 
respectively. The two feline subgroups from Belgium presented a higher seroprevalence at 
dilution 1:40: 41.2% (14/34) for the group from rescue centers and 51.4% (18/35) for the 
group of stray cats. The difference between the two latter subgroups was not significant 
(Chi2=0.73; 1ddl; P=0.39).  After pooling both subgroups, 11 and 6 animals remained 
positive at dilution 1:80 and 1:160, respectively. In addition, a non significant difference 
occurs between domestic cats and cats originating from rescue centers (Chi2=3.95; 1 ddl; 
P=0.05). However, a significant difference was observed between domestic cats and stray cats 
(Chi2=7.36; 1 ddl; P=0.007) after Bonferroni adjustment.  
Exclusively one horse was positive at dilution 1:40 only. No pig or wild boar was positive. 
ELISA: The distribution of the S/P ratio for IFA negative sera, in function of ELISA tests and 
species is presented in Figure 1. For ELISA Prot G, except for pigs and wild boars, each 
species has a significantly different distribution (Wilcoxon rank-sum test; P<0.008). 
Distribution of feline S/P ratio was very different depending on the ELISA test used (Prot G 
versus ProtA/G) (Wilcoxon rank-sum test P<0.0001). The theoretical cut-off values per 
species are summarized in Table 3. For cats, the theoretical cut-off value for ELISA Prot G 
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was lower in comparison with other species. Moreover, the theoretical cut-off value was 
higher for ELISA ProtA/G than for ELISA Prot G.  
Considering each value of S/P ratio above the theoretical cut-off value, the number of positive 
sera was determined for each group (species) (Table 2). Except for abortive bovines (as 
reference sub-population) and wild boars (only one positive serum with S/P ratio close to the 
cut-off value), other species were negative for ELISA Prot G. For felines, the use of ELISA 
ProtA/G permitted to identify 4 and 2 positive sera for rescue and stray cats, respectively. The 
proportion of positive sera between the two subgroups was not significantly different 
(Fischer’s exact test; P=0.56).  
 
Discussion 
This study on Q fever suggests that horses, pigs and wild boars don’t represent an important 
zoonotic hazard for human infections in Western Europe. Felines, however, especially strays, 
could be a source of human infections.  
Currently, farming has become more specialized leading to bigger farms with a higher density 
of animals of one unique species. Horses and pigs are frequently housed separately from 
ruminants, in studs, yards or riding clubs and in specialized pig farms. Furthermore, the 
horses included in this study are predominantly sport horses with generally very little contact, 
if any, with domestic ruminants.  
Wild boars, however, can have indirect contact with ruminants’ environment and are 
frequently infested by ticks. In Northern Spain, C. burnetii was detected by PCR in 4.3% of 
wild boars (Astobiza et al., 2011). The absence of seropositive wild boars in this study could 
be related to the absence or low rate of infection in ticks. Indeed, in Germany, only 3% of 
Dermacentor spp. were found to be infected despite the study area being endemic for Q fever 
(Pluta et al., 2010). Further studies on a larger number of Belgian wild boars are necessary. 
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Among the felines sampled in this study, the subgroup of strays presented a significantly 
higher seropositivity rate. Free roaming cats can have direct or indirect (contaminated litter) 
contact with environment, milk, feces, urine, vaginal mucus and birth products of infected 
ruminants. Thus, greater proximity to the main source of C. burnetii could explain their higher 
seroprevalence compared to horses, pigs and wild boars. Moreover, free roaming cats are 
more likely to be infected by FIV and FeLV, predisposing those to secondary viral and 
bacterial infections (Hosie et al., 1989; Fuchs et al., 1994; Bandecchi et al., 2006; Gleich et 
al., 2009; Skykes, 2010). In this study, in the subgroup of 11 stray cats with IFA positive 
results, 8 were positive for FIV and/or FeLV (73%). In the subgroup of 23 stray cats with IFA 
negative results, 11 were positive for FIV and/or FeLV (48%) (data not shown). Strays are 
more likely to be under fed, unvaccinated, flea, tick and worm ridden, leading to an 
immunodepressed state. Furthermore, ticks are known reservoirs and vectors of C. burnetii 
and are suspected of having a role in environmental maintenance of Q fever. Ixodes ricinus, 
the main species of tick present in Europe, has low host specificity and readily feeds on small 
mammals such as cats, dogs and rodents (Parola and Raoult, 2001). Stray animals in the 
absence of preventive anti-parasitic treatments have an increased likelihood of tick infestation 
and consequently, of arthropod-borne infection. Furthermore, rodents are preferential hosts 
for I. ricinus larva and occasional hosts for nymphs and adults. A closer and more frequent 
contact with rodents and rodents’ environment could increase the risk of tick bites. However, 
as mentioned previously, prevalence of Q fever in ticks is apparently low in Western Europe, 
rendering the true contribution of tick-borne infections to feline seroprevalence minimal. In 
the United Kingdom, Webster et al. (1995) found that wild brown rats were frequently 
infected by C. burnetii (seroprevalence: 7 to 53%). The authors hypothesized that rats could 
represent a major reservoir of the organism from which domestic animals may become 
contaminated. Strays are more likely to have hunted for survival. Thus infection by oral route 
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must not be discarded, especially as this route was proven effective by Gillepsie and Baker 
(1952) in their experimental infection. However, currently, controversy on this subject 
remains. The study by Komiya et al. (2003) reported a higher seroprevalence of Q fever in 
stray than in domestic cats in Japan. A previous study on dogs also reported a higher 
seroprevalence in stray than in domestic dogs (Willeberg et al., 1980). These two studies 
reinforce the hypothesis of increased vulnerability of stray animals due to immunodepression 
and/or exposure.  
In our study one horse only proved to be positive at dilution 1:40. The seropositive horse 
originated from Mont Saint Aubert, in the province of Hainaut, in southern Belgium. This 
could be explained by contact or proximity with infected ruminants or by aerosols transported 
by wind. Testing the other horses on the yard and local farm animals by IFA, as well as 
meteorological studies to evaluate the main direction of the wind, would allow confirmation 
of direct or indirect exposure to C. burnetii. In previous studies, horses have been found to be 
seropositive toward Q fever (Willeberg et al., 1980). The difference in seroprevalence 
observed between studies could be due to a difference in level of exposure to ruminants or to 
another reservoir of C. burnetii (Enright et al., 1971; Riemann et al., 1978). 
The results of studies based exclusively on IFA for Q fever diagnosis must be interpreted with 
care as cross-reactions are known to occur between C. burnetii, Legionella micdadei and 
Bartonella spp. (La Scola and Raoult, 1996; Musso and Raoult, 1997).  
In the study by Chomel et al. (1995), cats from shelters and former strays had a significant 
higher Bartonella-seropositivity rate than the group of pet cats (92% versus 71.40%). Several 
studies have obtained similar results (Childs et al., 1994; Gurfield et al., 2001; Juvet et al., 
2010). However, a study on Danish felines reported no significant difference in 
seroprevalence between rescue center and stray cats compared to pet cats (46.9% versus 
44.2%). In their study, 45.6% of the cats sampled were seropositive (Chomel et al., 2002). In 
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the Netherlands, stray and pet cats were also found to have the same risk of being seropositive 
to Bartonella henselae (Bergmans et al., 1997). If cross-reactions between C. burnetii and 
Bartonella spp. occurred in our study, the Bartonella-seroprevalence observed in the domestic 
cat group would be abnormally low in comparison to previous studies (Chomel et al., 1995; 
Bergmans et al., 1997; Chomel et al., 2002). However, to confirm our results cross-absorption 
followed by Western blot analysis is advised. However, this additional analysis was not 
performed due to insufficient sera volumes. 
The study by Collins et al. (1982) demonstrated that horses are frequently seropositive for L. 
pneumophila and related organisms. In the study by Barth et al. (1983), 83% of horses 
included in this study were seropositive towards L. micdadei at dilution 1:16. Among these 
seropositive horses, 52% had an antibody titer of 1/64 or more. This high seroprevalence of 
antibodies against L. micdadei indicates that if cross-reactions occurred during our IFA 
testing, many horses should have been seropositive at dilution 1:40. In our study, only one 
horse was seropositive at dilution 1/40. Considering the number of horses tested by IFA 
(n=83), the likelihood of the presence of only one horse seropositive to L. micdadei is small. 
Furthermore, Barth et al. (1983) reported a L. micdadei-seropositivity rate of 72% in pigs. In 
our study no pig was found to be seropositive. We can thus conclude that the likelihood that 
the equine positive IFA reaction represents the presence of antibodies towards C. burnetii is 
high. 
 
This study confirms that IFA is currently the diagnostic method of choice for sero-diagnosis 
of Q fever. However, the ELISA cut-off value for bovids might not be adequate for other 
species. In this study, ELISA Prot A/G seems to be a better assay than ELISA Prot G for Q 
fever diagnosis in cats. The latter result could be expected as Prot A/G has a greater affinity 
for feline immunoglobulins than Prot G (http://www.piercenet.com). This test needs further 
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research on conjugate calibration to improve properties of detectability, specificity and 
sensitivity. 
 
Conclusion and perspectives 
This original study investigates neglected aspects of the Q fever such as uninvestigated 
potential hosts and laboratory diagnostic methods for these species. This study demonstrates 
that felines can be infected by Q fever and thus could represent a reservoir for zoonotic 
transmission. Limiting human contacts, especially of at risk individuals, with pregnant and 
parturient cats is advised. If these cats have to be manipulated, protective clothing, masks, and 
gloves should be worn. Birth products should be destroyed as soon as possible. Separating 
pregnant and parturient cats from other animals would limit propagation of bacteria. In 
breeding catteries, euthanasia of infected cats could be considered.   
Further investigations are necessary to explain the differences in seroprevalence observed. 
IFA on indoor domestic cats could confirm or infirm the hypothesis on the importance of 
exposure. Detection of FIV, FeLV, and evaluation of general physical condition, would allow 
a study on the correlation between the presence of viral infections, immunodepression and 
infection by C.burnetii. The role of other pets in transmission of Q fever to humans should be 
investigated. 
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Tables and Figures 
 
Table 1. General characteristics of immunoglobulin binding proteins produced by E. coli 
 
 
 
 
 
 
Legend: * Ig: Immunoglobulin 
 
 
 
 
 
 
 
 
 
 
 
Recombinant Molecular 
weight 
Number of binding 
sites for Ig  
(binding target = Fc)
Optimal 
binding pH 
Protein A 44.6 4 8.2 
Protein G 21.6 2 5 
Protein A and G 50.46 6 5 to 8.2 
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Table 2. The number of samples tested and positive by test and per species 
 
Legend: Nb.: Number; *: according to the determination of a theoretical cut-off value for ELISA Prot G and 
ELISA Prot A/G (see section of results); #: borderline value. 
 
 
 
 
 
 
 
 
 
 
 
 
Samples Nb. of animals tested Nb. of positive animals*  
Species Country Period 
ELISA 
Prot G 
ELISA 
ProtA/G
IFA 
1/40 
ELISA 
Prot G
ELISA 
ProtA/G 
IFA 
1/40 
IFA 
1/80 
IFA 
1/160 
Horses The Netherlands 2007 to 2009 163 - 68 0 - 0 - - 
 
Belgium 2007 to 2009 181 - 15 0 - 1 0 - 
Cats (rescue centers) Belgium 2008-2009 126 72 34 0 4 11 6 3 
Cats (strays) Belgium 2010 62 47 35 0 2 17 5 3 
Cats (domestic) France 2004 130 126 24 0 0 4 2 0 
Pigs Belgium 2010 264 - 15 0 - 0 - - 
Wild boars Belgium 2007 272 - 24 1# - 0 - - 
Cows (as reference) Belgium 2010 30 9 30 17 4 19 18 18 
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Table 3. Main statistical characteristics of the S/P ratio in the ELISA Prot G and ELISA Prot 
A/G, for IFA negative sera, in function of species 
Species 
S/P ELISA Prot G S/P ELISA ProtA/G 
Number Mean SD Cut-off* Number Mean SD Cut-off* 
Horses 77 2.89 8.93 29.67 - - - - 
Cats 56 -6.20 2.56 1.49 47 3.01 6.00 20.99 
Pigs 15 6.36 5.81 23.79 - - - - 
Wild boars 24 4.83 5.08 20.08 - - - - 
Bovines 11 0.12 5.37 16.23 - - - - 
 
Legend: SD, Standard Deviation; * Theoretical cut-off as the mean of the S/P ratio plus 3 standard deviations. 
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New challenges, new opportunities 
According to Rhyan and Spraker (2010), any significant change occurring in the ecosystem 
may imbalance the host/agent/environment equilibrium, allowing a newly introduced agent or 
subclinical infection to manifest as an emerging disease. Among emerging infectious diseases 
(EID), zoonoses are considered to represent between 60 to 75% (Taylor et al., 2001; Kuiken 
et al., 2005; Woolhouse and Gowtage-Sequeria, 2005; Jones et al., 2008). Domestic animals 
and, especially, wildlife’s importance for emerging diseases must not be underestimated. In 
fact, involvement of wildlife in livestock and human diseases is considered to have increased 
in recent decades (Rhyan and Spraker, 2010). In the close future, surveillance of diseases of 
wildlife, domestic animals, and vectors must become a priority to prevent major outbreaks of 
zoonoses. For many zoonotic agents, the potential to cause infection in accidental hosts, such 
as humans, exist, but often this represents a dead-end host (Cutler et al., 2010). 
The reasons for the major recent emergence of zoonotic infections are numerous. This 
increase is essentially due to anthropogenic factors. 
Firstly, increase in human population has cause encroachment of humans and their domestic 
animals into wildlife habitat, which is becoming more and more fragmented (Rhyan and 
Spraker, 2010). Wildlife can serve as vectors for non-zoonotic diseases of livestock, leading 
to potentially devastating economical and dietary consequences, and also as reservoirs for 
zoonotic diseases (Rhyan and Spraker, 2010). The interface between wildlife, other free-
living or captive wildlife, domestic animals and humans has increased. Moreover, fragmented 
landscapes are known to provide more habitats for edge species and a greater diversity of 
resources. For example, high tick densities are generally found between forests and open 
areas, leading to a higher rate of tick-borne infections (Daniel et al., 1998; Kantso et al., 
2010). Increasing interest in and popularity of wildlife has led to more human contact with 
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wild animals. Wildlife associated and captive wildlife industries have developed with 
sometimes intensive management of selected species. Management actions, such as 
supplementary feeding, lead to an unnatural increase in animal density. Increase in animal 
density result in behavioral changes (concentration of animals around feeding areas) and thus, 
increase exposure to infectious animals and discharges (Rhyan and Spraker, 2010). 
Furthermore, deliberate or accidental introduction of non-native animals into areas already 
containing high population densities can cause emergence of disease (Cutler et al., 2010; 
Rhyan and Spraker, 2010). In addition, Cutler et al. (2010) in their article on emerging and 
neglected zoonoses, reported that hunting and eating wildlife are currently risk factors of 
increasing global concern. Indeed, tracking, capturing, handling, butchering in the field and 
transport of carcasses are associated with a high risk of zoonotic infection. Transport of live 
wildlife and of wildlife products can also lead to emerging diseases (Rhyan and Spraker, 
2010). Intensification of agricultural practices with associated deforestation can have 
unexpected effects (Cutler et al., 2010; Rhyan and Spraker, 2010). In Malaysia in 1998-1999, 
an outbreak of Nipah virus occurred due to an intensification of domestic pig farming and 
plantation and cultivation of fruit trees. The fruit trees attracted subclinically infected 
shedding fruit bats. The pigs’ proximity to the attractive trees led to their infection. The high 
density of pigs and trade allowed a rapid transmission within the pig population and next, to 
an outbreak of human infections (Daszak et al., 2001). Loss of biodiversity caused by increase 
in human populations has been associated with increase in pathogen transmission and disease 
incidence (Keesing et al., 2010). Indeed, several case studies have reported that species most 
likely to be lost from ecosystems as diversity declines are those most likely to reduce 
pathogen transmission (Kosoy et al., 1997; LoGuidice et al., 2008; Allan et al., 2009; Keesing 
et al., 2009; Suzan et al., 2009). 
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Secondly, many zoonotic infections are transmitted by vectors. If host availability is reduced, 
vectors seek alternative hosts, such as domestic animals or humans, increasing in this way, 
opportunities for zoonotic transmission (Cutler et al., 2010). In recent decades, vector 
distribution has expanded due to climate change, leading to introduction of new pathogens 
into naïve populations (Cutler et al., 2010). Furthermore, according to Lambin et al. (2010), 
human behavior is a crucial controlling factor of vector-human contacts, and of infection.  
Thirdly, collapse of public health programs during political upheavals has been associated 
with reemergence of zoonotic pathogens (Cutler et al., 2010). Concentration of humans in 
refugee camps with lack of hygiene and medical care are known to be preferential sites for 
disease emergence (plague, typhoid, cholera, dengue hemorrhagic fever, etc.) (Elias et al., 
1990). Moreover, economic crisis’s sometimes modify people’s livelihood strategies (e.g., 
fruit/mushroom picking, collecting wood in forests), exposing them to a new zoonotic risk. 
Education and awareness are influential risk/protection factors (Sumilo et al., 2008).  
Fourthly, increased globalization and international transport of humans and animals have 
created great opportunities for rapid geographical spread of pathogens. Tourism, with an 
increased interest in exotic destinations and adventure holidays, has been associated with an 
increase in imported zoonotic infections. Human activities such as water sports, wilderness 
camping, contact with companion animals (cats, dogs, pet rats, psittacine birds) and exotic 
pets (reptiles, prairie dogs, etc.) have also been found to be risk factors for zoonotic infections 
(Cutler et al., 2010). 
Fifthly, factors such as increased longevity and aging of the population, therapies for sick 
people, Human Immunodeficiency Virus (HIV), and organ transplants, have modified the 
susceptibility of the human host, facilitating infection by pathogens (Cutler et al., 2010).  
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Finally, at the pathogen level, variants with altered pathogenic, persistence and spreading 
potential can arise and cause major disease outbreaks (Cutler et al., 2010).  
Surveillance as a major tool in preventing emerging infectious diseases 
High density clustering of human population paves the way for potential outbreaks on an 
immense scale, rendering a better surveillance a fundamental priority for the future (Cutler et 
al., 2010). As reported previously by Koplan (2001) and Sosin (2003) in their respective 
report and manuscript, good surveillance is the first major tool in preventing EID that arise 
naturally or through terrorist activities. Surveillance is defined by the Last and International 
Epidemiological Association (2001) as a systematic ongoing collection, collation and analysis 
of data with the timely dissemination of information to responsible decision-makers. Brillant 
(2008) advanced the idea of “being ahead of the curve”, in other words, identifying risky 
situations before the first cluster of hospital cases are identified. Regarding the high 
proportion of zoonoses among EID, Kruse et al. (2004) proposed surveillance systems based 
on animal health information for early warning purposes. The number of human-only 
surveillance systems in the literature increased in 1998, leveled off then increased again in 
2003-2005; animal-only surveillance systems were relatively steady with a marked jump in 
2006; and systems including both showed a steady rate with a jump in 2000 followed by a 
leveling off (Vrbova et al., 2010). The majority of surveillance systems (70%) are designed 
for known diseases (Vrbova et al., 2010). In Canada, the Canadian Field Epidemiology 
Program (CFEP) in the Public Health Agency of Canada evaluated surveillance systems 
between 1999 and 2007. The reports often used multiple evaluation criteria depending on the 
system attributes, data availability and the specific objectives of each evaluation. The most 
common evaluation criteria were timeliness, acceptability, utility or relevance, flexibility, 
sensitivity, specificity or positive predictive value, data quality, simplicity, and sustainability 
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(Vrbova et al., 2010). Recently the “one world one health” trend aims at centralizing animal 
and human data in one global and unique surveillance system. Unfortunately, surveillance of 
animal and zoonotic diseases in animals is often not legally mandated to the same extent as in 
humans, particularly in wildlife (Vrbova et al., 2010).  
Surveillance of zoonoses is necessarily a multi-disciplinary endeavor. Domestic animals, 
wildlife, humans and environment are interconnected in a complex manner, rendering 
effective surveillance extremely challenging. For surveillance and management of wildlife 
diseases, for example, public affairs specialists must be involved and have thorough 
understanding of the disease situation and needed management actions. Communication and 
education of the public are essential in the complex context of emerging diseases in wildlife 
(Rhyan and Spraker, 2010). Passive surveillance of wildlife consists in observation of 
clinically ill or dead animals and on the opportunistic collection of specimens. The general 
public and hunters can be involved in this type of surveillance. The difficulties of passive 
surveillance of wildlife include lack of any baseline data on the disease and population in 
question. Indeed, basic knowledge such as susceptibility, carrier status, and transmission 
potential are unavailable for many diseases in wildlife. Furthermore, survival behavior often 
masks clinical signs, and predation and scavenging hinder observation of dead animals and 
diagnostic processes (Rhyan and Spraker, 2010). To this day, surveillance and management of 
diseases in wildlife remains a challenge rendering further wider and more intense 
interdisciplinary collaboration essential (Rhyan and Spraker, 2010).  
Improving surveillance, a challenging task for scientists worldwide 
Temporal and spatial, also called landscape, epidemiology are fundamental for development 
of effective surveillance. Temporal epidemiology consists in the study of variation of disease 
incidence in relation to time. Disease incidence can vary depending on season and year. 
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Knowledge of this temporal variation of disease incidence allows detection of a sudden 
increase above the natural variation of incidence, and thus, early detection of emergence. 
Moreover, temporal epidemiology allows detection of clusters of cases and thus, detection of 
high risk periods. Detection of high risk periods is useful to permit concentration of 
surveillance means at specific times. Spatial epidemiology is defined as the study of spatial 
variation in disease risk or incidence (Lambin et al., 2010). Landscape and meteorological 
factors control not just emergence, but also spatial concentration and spatial diffusion of 
infection risk. Factors influencing people-vector contacts include the relative population 
densities, as well as spatial and temporal distributions of both vectors and people, and their 
movements and behaviors. Landscape, connectivity of habitats for vectors and hosts, and 
vector-host ratio are the main influential factors. Proximity of vector and host habitats may 
not necessarily result in a high level of risk if these critical habitats are not connected spatially 
by landscape features favorable to the circulation of vectors and hosts (Lambin et al., 2010).  
Improved surveillance and disease detection may be achieved through use of a syndromic 
approach rather than searching for specific diagnoses (Cutler et al., 2010). In 2005, Leblond et 
al. suggested that horses could be considered as good sentinels for the WNV circulation in the 
Camargue area, France. Later, in 2007, Leblond et al. (2007a) developed an equine syndromic 
surveillance system based on the 2004 WNV epizootic in Camargue. This system proved to 
provide a warning 4 weeks before the epidemic period. In the same study, by comparison, the 
laboratory-case confirmation in horses could only provide a warning less than one week 
before the epizootic. However, the stability of such surveillance depends on voluntary or 
mandatory reporting, generally without compensation. In the future, more emphasis should be 
focused on regular feedback as motivating practitioners to provide timely input is essential 
(Leblond et al., 2007a). Moreover, further evaluation of syndromic surveillance in horses for 
WNF should be undertaken. Effectiveness must be evaluated depending on the area 
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concerned. Indeed, in the USA in 1999 and 2000, equine WN cases did not precede detection 
of the virus in mosquitoes and wild birds, nor did it predict human case occurrences (Leblond 
et al., 2007a). In the study by Nielsen et al. (2008), however, immunologically naïve horses in 
California were found to be more sensitive for detection of WNV transmission than mosquito 
sampling alone, and were thus considered a sensitive indicator of WNV activity. Vaccination 
programs and naturally acquired immunity can hinder the effectiveness of equine passive 
surveillance (Nielsen et al., 2008).  
Novel contribution to improve surveillance 
Animal surveillance and using animal data for precocious clinical detection of emerging 
zoonoses before their emergence in human populations are the basis of this work. This 
original work emphasizes the need for collaboration between countries, as well as for a 
multidisciplinary approach with involvement of clinical and laboratory skills. The 
epidemiological methods developed in this study are methods that can be applied to a large 
panel of diseases, emerging or not. It is not limited by the species affected or by the necessity 
of having a good knowledge of the illness diagnosed. Clinical epidemiology does not require 
special equipment to be put into place and is relatively easy and fast to develop. Furthermore, 
the great originality of this work is its acknowledgement of the fact that emerging zoonotic 
diseases can potentially be asymptomatic in animal reservoirs. This study goes from a 
methodological approach of a rare clinical disease used as a model of an emerging disease 
(equine endocarditis), to a more complex situation where the emerging zoonotic disease is 
occasionally symptomatic (equine WNF) or considered asymptomatic (Q fever in felines, 
equids, pigs and wild boars). The aim of this work was to develop epidemiological methods to 
facilitate the diagnosis of diseases poorly understood and/or poorly investigated by general 
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practitioners in western Europe. It is an important step forward towards a better surveillance 
of zoonotic diseases; improved surveillance allowing earlier detection of emergence. 
The study on equine vegetative endocarditis demonstrates that epidemiological methodologies 
can easily be applied to clinical diseases. Being a rare disease, equine endocarditis permits the 
development of a methodology that can be applied to any emerging disease. Determination of 
significant risk factors can facilitate diagnosis for the field practitioner, leading to an earlier 
treatment and a better prevention of spread of infection. Earlier diagnosis and improved 
management of infectious diseases would have local financial advantages; national and 
international commercial advantages, by preventing spread of infection by fast control of the 
identified focus of infection and by escaping any sanctions for international trade. The 
epidemiological methodologies used in this study can be applied at individual or herd level. 
Large scale studies on risk factors increase awareness but also improve surveillance of a 
specific proportion of the population, of a period of the year or of an area, identified as being 
at high risk of emergence. This study also emphasizes the major importance of association of 
different risk factors.  
The second study on WNF is a more sophisticated application of the methodology developed 
for equine endocarditis. This study contributes to improvement of surveillance by 
emphasizing the importance of standardized centralization of data, and of focusing on 
geographical areas at high risk of emergence. Standardization is facilitated by the fact that 
clinical signs and risk factors seem constant in Europe. Communication with veterinarians and 
the public was found to be lacking in certain countries and must be promoted in the future for 
a more effective surveillance. Development of classification and regression trees emphasized 
the importance of major risk factors for WNF emergence and is a methodology that can be 
applied to a great variety of situations.  
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This study demonstrates the need for increased awareness among clinicians and veterinarians 
about the possibility of WNF cases of encephalitis and meningoencephalitis during periods of 
potential transmission (Zeller and Schuffenecker, 2004). Among many other unanswered 
questions, the mechanism of WNV (re)introduction in Europe and the cycle of maintenance in 
infected areas remain to be elucidated (AFSSA, 2004; Zeller and Schuffenecker, 2004). The 
major difficulty with WNV circulation and infections is the fact that most infections are 
asymptomatic and that the etiology of a large number of encephalitis and/or 
meningoencephalitis cases (both human and equine cases) remain unknown (AFSSA, 2004). 
It is essential to continue studying the evolution of the epidemiological situation of WNV to 
prevent its harmful effect on human and animal populations in the future (Toma et al., 2001; 
AFSSA, 2004). Moreover, a better knowledge of the epidemiology of WNV, that is complex 
and deeply influenced by environmental factors and hosts (Leblond et al., 2007b), as well as 
by climatic conditions (Sardelis et al., 2001; Khasnis and Nettleman, 2005; Haines et al., 
2006) and vector biology (Cantile et al., 2000), in each country or area would justify the use 
or not of equine vaccination (AFSSA, 2004; Morse, 2004). Extensive studies to identify both 
the invertebrate vector and the vertebrate reservoir species of WNV seem necessary (Cantile 
et al., 2000). 
The third original study is a major contribution to a better understanding of the epidemiology 
of Q fever in western Europe. Q fever can have disastrous consequences (e.g., in the 
Netherlands (Karagiannis et al., 2009; Enserink, 2010)) and is currently of major concern; 
improving its surveillance is fundamental. This study investigates neglected aspects of Q 
fever: potential domestic animal reservoirs, diagnostic methods and their application to 
different species. Importantly, this work increases our awareness of pet associated zoonotic 
risk. To our knowledge, Q fever seroprevalence has not previously been investigated in 
western European equids, felines, pigs and wild boars. This study found that several cats and 
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one horse were seropositive for Q fever. The presence of seropositive animals signifies that 
these species could potentially represent a zoonotic threat and a source of bacteria for 
environmental contamination. Risk and protection factors for seropositivity were determined 
within each species and subgroup. Stray cats were the most likely to be seropositive for Q 
fever. This signifies that cats could be a sentinel for circulation of Q fever in areas where 
ruminants are scarce. Cats are easier to catch than wild rodents (Webster et al. (1995) 
suggested wild brown rats with a seroprevalence of 7 to 53% as sentinel in the United 
Kingdom) and sampling could be performed at the same time as eradication or sterilization 
programs. According to this study, usefulness of equids as sentinel animals seems minor in 
western Europe. However, equine sentinels could prove effective in other areas (e.g., 
California (Willeberg et al., 1980)). In the future, a closer observation and follow-up of 
felines and equids could potentially allow detection of clinical signs associated to Q fever 
infection, which were previously unnoticed, or, erroneously, defined as being the consequence 
of another independent condition. Indeed, in the USA, in 1952, Gillespie and Baker infected 
farm cats experimentally by subcutaneous inoculation with infected yolk sac (n=3) or guinea 
pig spleen (n=1) suspensions, by feeding infected yolk sacs (n=3) or guinea pig spleens (n=1), 
or by exposure (n=4) to subcutaneously infected cats. In their study, 3 out of the 4 cats 
infected subcutaneously developed fever, lethargy and lack of appetite two days after 
inoculation and for a period of 3 days. The only subcutaneously infected cat that didn’t 
develop clinical signs was the cat infected with a guinea pig spleen suspension of bacteria. 
None of the cats infected orally or by exposure developed clinical signs. C. burnetii were 
isolated from blood or urine of all subcutaneously infected cats (n=4), all cats fed infected 
yolk sacs (n=3) and of one cat out of 4 exposed cats. All these cats became seropositive 
between 4 and 8 weeks post-infection. Thus, according to this study, subclinical infections are 
frequent in cats (only 3 out of 8 infected cats developed clinical signs). However, no long 
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term clinical follow-up is available in this experimental study. Moreover, no postmortem 
examinations or blood tests evaluating organ functions (kidneys, liver, etc.) are available. This 
study demonstrates that cats can be infected by C. burnetii, can develop clinical signs 
associated to infection, and can be a source of environmental contamination by excreting 
bacteria in urine (Gillespie and Baker, 1952). Most reports of cat associated human outbreaks 
do not describe clinical signs in the cat (Marrie et al., 1988a; Marrie et al., 1989; Pinsky et al., 
1991). However, a case report from Marrie et al. (1988b) reported the presence of vaginal 
bleeding in an infected cat before parturition and the birth of stillborn kittens. In conclusion, a 
better understanding of Q fever infection in felines could contribute to clinical veterinary 
medicine. In our study, no pig or wild boar was found to be positive for C. burnetii. However, 
the number of animals tested by IFA, the gold standard for definite diagnosis, was small. 
Further IFA on a larger number of pigs and wild boars are necessary to confirm our results 
and hypotheses. ELISA ProtG, ELISA ProtA/G, and IFA were compared in this study. ELISA 
kits and cut-off values adequate for diagnosis in bovids are not adequate for Q fever diagnosis 
in felines or equids. This study emphasizes the need for improvement of ELISA testing and 
proposes new cut-off values after distribution analyses.  
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Human disease surveillance must be associated with enhanced longitudinal veterinary 
surveillance in food-producing animals, pets, and wildlife (Cutler et al., 2010). Indeed, control 
of zoonotic infections in reservoir hosts is known to have a protective effect in human 
populations (Cutler et al., 2010). Spatial and temporal surveillance of vectors, and potential 
vectors, is essential, as vector distribution is expanding and in continual evolution. A more 
intense interdisciplinary approach and international collaboration must be promoted. 
Surveillance networks must be organized involving specialists in each domain (doctors, 
veterinarians, epidemiologists, entomologist, etc.). The role of each specialist must be defined 
precisely for the best effectiveness of the network. Prioritization of emerging, and potentially 
emerging, diseases must be performed depending on risk and consequences of emergence. 
Standardized classification and regression trees are a great help for prioritization and also for 
rapid decision making in case of emergence. Worldwide standardization of data collecting is 
fundamental and must be developed further.   
Future studies on wildlife are necessary to identify potential hosts, reservoirs, vectors and 
sentinels. Follow-up of wildlife migration and movements is necessary as they can lead to 
infection of new areas by asymptomatic pathogen shedding, leading to outbreaks in naïve 
populations. 
Adequate animal sentinels should be placed (domestic animals) or selected (wildlife) in at risk 
areas. As mentioned previously, sentinel species must be chosen depending on the 
epidemiological context to permit disease detection before human cases occur.  
A syndromic approach would allow fast and cheap detection of disease circulation and 
prevent major outbreaks in human populations. Early detection of major risk factors would 
permit to focus controls on key points or areas. Thus, syndromic approach and risk factors 
must be emphasized more in the future. Classification and regression trees could be used to 
standardize the diagnostic approach for a large variety of diseases. 
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Medical and laboratory staff, people involved in public health and food-processing, farmers, 
breeders and traders must received regular training sessions concerning emerging diseases. 
Communication with the public must be promoted to increase awareness and emphasize the 
importance of preventive measures. At risk individuals (elderly, HIV, transplant patients, etc.) 
must be informed of the risk of exotic destinations, animal contact, petting farms, outdoor 
activities (e.g., mushroom picking), and food-borne zoonoses.  
Concerning diagnosis of emerging diseases, further development of laboratory assays is 
necessary in veterinary medicine, as well as in human medicine. Cut-off values must be 
adapted depending on the species concerned and on the area (variability in strains). ROC 
analyses are a fast and easy method to orientate the choice of an accurate cut-off value (best 
compromise between sensitivity and specificity) but require testing of samples with “gold 
standard” test beforehand. Sensitivity of the ELISA kits for emerging zoonoses must be 
improved. Using a more sensitive conjugate (e.g., for C. burnetii, ProtA/G versus ProtG), 
prolonging incubation period with the conjugate/substrate, increasing temperature or 
developing more sensitive techniques could lead to a better detection of seropositive animals. 
Laboratories must be aware of the need for collaboration and be ready for rapid diagnosis of 
new pathogens. They should be equipped with diagnostic tests for diseases at high risk of 
emergence in their area. Communication and their capacity of helping one another in case of a 
crisis are important to permit early diagnosis. Development of laboratory assays allowing 
distinction of different emerging strains (e.g., WNV, C. burnetii) would be useful as 
pathogenicity can vary greatly between strains. Detection of a particularly virulent strain early 
after its emergence would prevent disastrous consequences for veterinary and public health. 
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In conclusion, this work is a direct application of epidemiology to clinical situations. Through 
its original and broad approach, it emphasizes aspects that must be improved for a better 
surveillance of emerging diseases in the future. 
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Introduction 
Les maladies émergentes, zoonotiques dans 60 à 75% des cas (Taylor et al., 2001), sont actuellement 
un sujet de grand intérêt pour les scientifiques du monde entier. Les changements climatiques et socio-
économiques, le transport international, les modifications environnementales, le développement et la 
commercialisation de méthodes diagnostiques ont mené à la découverte de nouveaux pathogènes et de 
nouvelles maladies. 
L’épidémiologie clinique des maladies émergentes est définie comme l’application du raisonnement 
épidémiologique à l’étude des maladies nouvellement apparues dans une population ou qui ont existé 
précédemment mais qui augmentent en incidence ou s’étendent géographiquement de manière 
importante (Morse, 1995), en vue d’en améliorer le diagnostic, la prévention ou le traitement (Toma et 
al., 1991). La détection précoce des maladies émergentes est un point clé pour la prévention de 
conséquences désastreuses au niveau de la santé publique et animale. Les maladies émergentes sont 
souvent très peu connues dans les régions concernées, rendant le diagnostic clinique problématique. 
Dans ce contexte, la communication entre pays et la centralisation d’informations sont essentielles.  
Ce travail est basé sur l’étude de trois maladies différentes. La première consiste en une étude 
rétrospective de l’endocardite végétante équine, maladie considérée comme étant symptomatique dans 
tous les cas (tant que le cheval ne meurt pas d’une autre pathologie avant le développement des signes 
cliniques). L’endocardite végétante équine est une maladie rare, infectieuse, non contagieuse, non 
émergente mais connue (Patteson, 1996). Elle est utilisée comme « modèle » d’une maladie émergente 
qui est rare au début de son introduction dans un territoire donné. Développer des méthodes 
épidémiologiques sur l’endocardite végétante équine à partir de données rétrospectives permet, par la 
suite, de transférer ces méthodes aux maladies réellement émergentes. La deuxième étude porte sur la 
Fièvre de la vallée du Nil Occidental (FNO) chez les chevaux, maladie émergente et symptomatique 
dans 10% des cas (Petersen et Roehrig, 2001). Les méthodes épidémiologiques développées dans la 
première étude ont été adaptées dans ce nouveau contexte et ont permis l’identification de facteurs de 
risque significatifs. En outre, des arbres de classification et de régression ont été mis au point afin 
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d’aider au diagnostic clinique de terrain (Lewis, 2000). Une étude comparative a été réalisée à partir 
de données françaises, italiennes et hongroises permettant la détection de différences fondamentales 
entre la présentation clinique et l’épidémio-vigilance dans les trois pays. La troisième étude investigue 
la prévalence de la fièvre Q chez les chevaux, chats, porcs et sangliers. La fièvre Q est une zoonose 
émergente en Europe de l’ouest. En l’absence de signes cliniques rapportés dans ces espèces, la 
séropositivité indiquerait une circulation du pathogène et un risque zoonotique. Face à une maladie 
d’allure asymptomatique, l’approche de l’épidémiologie clinique est limitée. Dès lors, des analyses de 
laboratoire ont été nécessaires pour évaluer la prévalence de la fièvre Q chez les 4 espèces. Ensuite, les 
facteurs de risque pour la séropositivité ont été déterminés. De même, une étude comparative des 
différentes analyses de laboratoire et la détermination d’une valeur seuil idéale pour un diagnostic par 
espèce a été réalisée.   
Résultats 
Etude sur l’endocardite végétante équine 
Cette étude a permis de déterminer les signes cliniques et paramètres sanguins modifiés qui 
doivent pousser le vétérinaire à une investigation cardiologique des équidés présentés en 
consultation. L’identification des facteurs de risque a pour avantage de faciliter le diagnostic 
menant ainsi à un traitement plus précoce. Appliquer la méthodologie développée dans cette 
étude aux maladies infectieuses permettrait un diagnostic plus précoce et une meilleure 
gestion de l’infection grâce à un contrôle rapide du foyer infectieux identifié. De plus, les 
méthodes épidémiologiques utilisées dans cette étude peuvent être appliquées au niveau 
individuel ou de troupeau. Des études à large échelle sur les facteurs de risque amélioreraient 
la surveillance ciblée d’une proportion spécifique de la population, à une période déterminée 
de l’année et/ou d’une zone géographique donnée, identifiée comme étant à haut risque 
d’émergence. Les résultats de l’analyse faisant usage d’une courbe ROC (Receiver Operating 
Characteristic) (Toma et al., 1991) mettent en évidence l’importance majeure de l’association 
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de différents facteurs de risque, en proposant un seuil de score clinique (somme des signes 
cliniques présents) pour permettre un diagnostic clinique plus précoce.  
Etude sur la fièvre du Nil occidentale (FNO) chez les équidés 
La deuxième étude porte sur la FNO et est un développement plus sophistiqué de la 
méthodologie mise au point pour l’endocardite équine. Cette étude contribue à l’amélioration 
de la surveillance de la FNO en mettant en avant l’importance de la communication et de la 
centralisation de données standardisées. L’étude sur les facteurs de risque associés à la FNO a 
démontré l’importance de focaliser l’effort de surveillance sur des périodes et régions 
géographiques à haut risque d’émergence. L’étude comparative des cas cliniques de FNO de 
France, Italie et Hongrie a permis la mise en évidence d’un manque de communication au 
sujet de la maladie envers les vétérinaires et les propriétaires de chevaux. Les effets néfastes 
d’un manque de sensibilisation concernant le risque d’émergence de FNO sont rendus 
explicites dans cette étude. En effet, dans le pays le moins informé, le délai de diagnostic 
clinique était significativement prolongé. La communication doit être améliorée à l’avenir 
afin d’effectuer une meilleure surveillance. Le développement d’arbres de classification et de 
régression dans cette étude a permis de mettre en évidence l’importance des facteurs de risque 
géographique et saisonnier dans l’émergence de la FNO. Cette méthodologie novatrice peut 
être appliquée à une grande variété de situations et mérite davantage d’intérêt (Lewis, 2000). 
Etude sur la fièvre Q chez les chevaux, chats, porcs et sangliers 
La troisième étude est une contribution originale permettant une meilleure compréhension de 
l’épidémiologie de la fièvre Q en Europe de l’ouest. La fièvre Q peut avoir des conséquences 
désastreuses (par ex. aux Pays-Bas (Karagiannis et al., 2009 ; Enserink, 2010)) et est 
actuellement un sujet d’intérêt majeur. Améliorer sa surveillance est crucial. Cette étude 
explore des aspects négligés de la fièvre Q: réservoirs potentiels non explorés parmi les 
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animaux domestiques, méthodes de diagnostic actuelles et leur application à ces espèces. Ce 
travail augmente de manière importante la connaissance du risque zoonotique associé aux 
animaux domestiques. De plus, cette étude propose un nouvel animal « sentinelle » (Toma et 
al., 1991), le chat, qui pourrait se montrer utile dans de futurs programmes de surveillance. 
Finalement, cette étude met en évidence le besoin d’amélioration des tests Enzyme Linked 
Immunosorbent Assay (ELISA) et propose de nouvelles valeurs seuils par espèce en recourant 
à l’usage de courbes ROC. 
Conclusions et Perspectives  
Ces trois études mettent en évidence des points clés pour améliorer la surveillance des maladies 
émergentes à l’avenir et propose une méthodologie pour augmenter son efficacité. Elles se basent sur 
l’utilisation de données animales pour une détection clinique plus précoce des zoonoses avant leur 
émergence dans la population humaine. Ce travail original met en évidence la nécessité d’une 
collaboration internationale, d’une approche interdisciplinaire et d’une standardisation des données. 
Les méthodes épidémiologiques développées dans les trois études sont des méthodes qui peuvent être 
appliquées à une grande variété de maladies, émergentes ou non. Leur application n’est pas limitée ni 
par l’espèce affectée ni par la nécessité d’avoir une connaissance approfondie de la maladie (ce qui ne 
sera pas toujours possible immédiatement face à une maladie nouvelle). De plus, l’épidémiologie 
clinique ne requière pas d’infrastructure spécialisée et est relativement facile et rapide à mettre en 
place. L’originalité de ce travail est la reconnaissance du fait que les zoonoses émergentes peuvent 
potentiellement être asymptomatiques chez les animaux réservoirs. Ce travail commence par une 
approche méthodologique d’une maladie rare (l’endocardite équine), utilisée comme « modèle » d’une 
maladie émergente (première étude), puis évolue vers des situations plus complexes où la zoonose est 
occasionnellement symptomatique (FNO chez les chevaux) ou considérée comme asymptomatique 
(fièvre Q chez les chevaux, chats, porcs, sangliers) (deuxième et troisième études).  
L’objectif de ce travail était de développer des méthodes épidémiologiques pour faciliter le diagnostic 
précoce de maladies émergentes, peu comprises et/ou peu investiguées par les vétérinaires de terrain 
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en Europe de l’ouest. Ce travail démontre que la surveillance des maladies humaines doit être associée 
à une surveillance vétérinaire accrue des animaux de production, domestiques et de la faune sauvage. 
En effet, le contrôle des zoonoses dans les hôtes réservoirs a été reconnu comme ayant un effet 
protecteur pour les humains (Cutler et al., 2010). Ce travail est une contribution significative à 
l’amélioration de la surveillance des maladies zoonotiques. Cette amélioration de la surveillance 
permettra une détection précoce de l’émergence.  
A l’avenir, une approche interdisciplinaire plus intense et une collaboration internationale doivent être 
davantage développées. Des réseaux de surveillance doivent être organisés impliquant des spécialistes 
de domaines variés (médecins, vétérinaires, épidémiologistes, entomologistes, etc.). Le rôle de chaque 
spécialiste doit être défini précisément pour une efficacité optimale du réseau. La priorisation des 
maladies émergentes et potentiellement émergentes doit être réalisée après une étude approfondie des 
risques et conséquences d’émergence. Les arbres de classification et de régression sont une aide pour 
la priorisation mais aussi pour la prise de décision rapide en cas d’émergence. La standardisation 
internationale de la récolte de données est fondamentale et doit être stigmatisée et rendue accessible 
par tous. Des études approfondies sur la faune de sauvage sont nécessaires pour identifier les hôtes 
potentiels, les réservoirs, vecteurs et animaux « sentinelles » (Rhyan and Spraker, 2010). Un suivi des 
migrations et mouvements de la faune sauvage est nécessaire puisqu’ils peuvent mener à l’infection de 
nouveaux territoires par excrétion asymptomatique de pathogènes, provoquant ainsi une épidémie dans 
des populations naïves. La surveillance spatio-temporelle des vecteurs et vecteurs potentiels est 
essentielle étant donné que leur distribution est en expansion et en évolution (Lambin et al., 2010). 
Des animaux « sentinelles » adéquats doivent être placés (animaux domestiques) ou sélectionnés 
(faune sauvage) dans les zones à risque (Toma et al., 1991). Ils doivent être choisis en fonction du 
contexte épidémiologique local pour permettre la détection précoce de l’émergence avant l’émergence 
de cas humains (Leblond et al., 2007; Nielsen et al., 2008). Une approche syndromique permettrait 
une détection rapide et peu coûteuse de la circulation de maladies et préviendrait des épidémies 
majeures dans les populations humaines (Leblond et al., 2007; Cutler et al., 2010). La détection 
précoce des facteurs de risques permettrait une focalisation de la surveillance et des contrôles sur des 
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points ou endroits clés. L’importance de l’approche syndromique et des facteurs de risque ne doit donc 
pas être sous-estimée et doit être valorisée à l’avenir. Les arbres de classification et régression 
pourraient être utilisés pour standardiser l’approche diagnostique d’une grande variété de maladies. 
Les personnels médicaux et de laboratoire, le personnel impliqué dans la santé publique et la chaîne 
alimentaire, les agriculteurs, éleveurs et marchands d’animaux doivent recevoir des formations 
concernant les maladies émergentes. De même, la communication avec le public doit être développée 
pour augmenter la vigilance et sensibiliser à l’importance des mesures préventives. Les individus à 
risque (jeunes enfants, personnes âgées, femmes enceintes, immunodéprimés, malades chroniques) 
doivent être informés des risques associés aux voyages exotiques, aux contacts avec des animaux de 
rente et domestiques, aux fermes pédagogiques, aux activités extérieures et aux zoonoses alimentaires.  
Concernant le diagnostic des maladies émergentes, le développement des tests de laboratoire est 
nécessaire en médecine vétérinaire aussi bien qu’en médecine humaine. Les valeurs seuils des 
analyses doivent être adaptées en fonction de l’espèce concernée. L’analyse de courbes ROC est une 
méthode facile et rapide pour orienter le choix de la valeur seuil la plus appropriée (meilleur 
compromis entre sensibilité et spécificité) mais nécessite l’existence préalable d’un test de référence 
(Toma et al., 1991). Actuellement, la sensibilité des kits ELISA pour les zoonoses émergentes doit 
être améliorée. Utiliser un conjugué plus sensible (protéine A/G versus protéine G), prolonger la 
période d’incubation avec le conjugué/substrat, augmenter la température ou développer des nouvelles 
analyses plus sensibles permettraient une meilleure détection des animaux séropositifs. Les 
laboratoires doivent être conscients de la nécessité de collaboration et être prêts pour le diagnostic 
pour de nouveaux pathogènes. Ils doivent être équipés avec des tests diagnostiques pour les maladies à 
haut risque d’émergence dans leur secteur. La communication et leur capacité d’entre-aide en cas de 
crise sont importantes pour permettre un diagnostic précoce. Le développement d’analyses de 
laboratoire permettant la distinction entre différentes souches émergentes (par ex. pour FNO ou C. 
burnetti) pourrait être utile puisque la pathogénicité peut varier de manière importante en fonction des 
souches (Klaassen et al., 2009 ; Vazquez et al., 2010). La détection précoce d’une souche émergente 
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particulièrement virulente préviendrait des conséquences désastreuses pour la santé publique et 
vétérinaire.  
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